

Curriculum Vitae

**Theoharis C. Theoharides,
BA, MS, MPhil, PhD, MD, FAAAAI
(Hon. Doctor of Medicine, Hon. Doctor of Science)
Professor of Pharmacology and Internal Medicine
Director
Molecular Immunopharmacology and Drug Discovery**

<http://sackler.tufts.edu/Faculty-and-Research/Faculty-Profiles/Theoharis-Theoharides-Profile>

<http://sackler.tufts.edu/Academics/Degree-Programs/PhD-Programs/Faculty-Research-Pages/Theoharis-Theoharides.aspx>

www.mastcellmaster.com

Department of Immunology
Tufts University School of Medicine
Tufts Medical Center
136 Harrison Avenue, Suite J304
Boston, Massachusetts 02111, U.S.A.

**Clinical Pharmacologist, Massachusetts
Drug Formulary Commission (1986-2022)**

Phones: (617) 636-6866 (Office – J304)
(617) 636-6898 (Lab –J304)

Fax: (617) 636-2456

Email: theoharis.theoharides@tufts.edu

January 21, 2021

<u>Content</u>	<u>Page</u>
Personal information	3
Education	3
Other training	3
Academic appointments	3
Awards and Honors	4
Executive Health Experience and fund raising	5
Pharmaceutical industry experience	5
Pharmaceutical regulatory experience	6
Corporate business experience	6
Certifications	7
Other appointments	7
Teaching	7
University Committee assignments	7
Other Committee assignments	8
Bibliographical listings	8
Editorial reviews	9
Grant review study sections	9-10
Membership to professional societies	10-11
Office and committee assignments in professional societies	11
Research interests	11-12
Clinical studies	13
Research fellowships and grants	14-18
Patents	19-22
TradeMarks	21
Training of postdoctoral fellows	22-24
Training of graduate students	25-26
Graduate student rotations	27
Medical and dental student training	27
Masters in Biomedical Sciences training	28
College student research training	28
High school student summer research training	28-29
Graduate Student Doctoral Committee Chair	29-30
Courses taught	30
Trainee distinctions	31
Summary of publications and citations	32
Theses	33
Books	33
Live presentations	33
Full peer-review papers	34-49
Review/Chapters/Editorials	50-63
Commentaries	64-65
Case reports	66
Abstracts/ Proceedings	67-80
Non-print publications	81
Invited lectures	82-95

- 2006-13 **Special Advisor** Allergy Clinical Research Center, Allergy Section, Attikon Hospital,
Athens Univ. Med. School, Athens, Greece
- 2018-22 **Director of Health Science Programs and Research** Americal Colege in Greece-Deree (part time), Athens, Greece

Awards and Honors

- 1971 **Connecticut Commission for Undergraduate Research Award**
- 1971 **Yale College Dean's Research Award**
- 1972 **Yale College Cum Laude & Divisional Honors** for joint Bachelor of Arts
- 1972 **Yale University Cuyler Award** "for outstanding Yale College Graduates"
- 1975-77 **Advisory Committee to the Dean**, Graduate School, Yale University
- 1979 **Academic Award**, Hellenic Medical Society of New York
- 1980 **Travel Award**, American Society for Cell Biology
- 1980 **Yale University Winternitz Prize** "for the best work in Pathology"
- 1981,82 **Research Fellowship**, Intl. Institute of Cellular and Molecular Pathology, Brussels
- 1982 **Volunteer Award**, Veterans Administration Medical Center, West Haven, CT
- 1983 **Medical Award**, Hellenic Medical Society of New York
- 1983 **Chairman - Immunopharmacology**, 9th International Congress of Pharmacology, London
- 1984 **Travel Award**, American Society for Pharmacology and Experimental Therapeutics
- 1986 **Chairman - Neuroimmunology**, 2nd World Conference of Inflammation, Monte Carlo
- 1986 **Distinguished Service Citation** for faculty excellence, Tufts University
- 1987 **Special Faculty Recognition Award**, Tufts University School of Medicine
- 1987 **Honorary Member**, Alpha Omega Alpha Honor Medical Society
- 1988 **Special Faculty Recognition Award**, Tufts University School of Medicine
- 1989 **Chairman - Neuroimmune Modulation**, 3rd World Conf. on Inflammation, Monte Carlo
- 1989 **Citation for Excellence in Teaching**, Tufts University School of Medicine
- 1990 **Citation for Excellence in Teaching**, Tufts University School of Medicine
- 1991 **Advisory Committee**, 4th World Conference on Inflammation, Geneva
- 1991 **Citation for Excellence in Teaching**, Tufts University School of Medicine
- 1991 **Interstitial Cystitis Association Recognition Award**
- 1992 **Citation for Excellence in Teaching**, Tufts University School of Medicine
- 1993 **Advisory Committee**, 5th World Conference on Inflammation, Geneva
- 1993 **Citation for Excellence in Teaching**, Tufts University School of Medicine
- 1993 **Medical Awareness and Patient Support Award**, Interstitial Cystitis Association
- 1994 **Chairman, Inflammatory Mechanisms**, 6th Intl. Conference on Immunopharm., Prague
- 1994 **Citation for Excellence in Teaching**, Tufts University School of Medicine
- 1994 **Great Cross**, Greek Orthodox Diocese of Boston for humanitarian health care
- 1995,97 **Advisory Committee**, 6th and 7th World Conferences on Inflammation, Geneva
- 1995 **Chairman**, International Committee to Upgrade Medical Education in Greece
- 1996 **Citation for Excellence in Teaching**, Tufts University School of Medicine
- 1997-00 **Supreme Scientific Health Council to Secretary of Health**, Hellenic Republic
- 1998 **Community Service Award** for humanitarian healthcare, Mayor T. Menino, Boston
- 1999-02 **Supreme Healthcare Board**, Social Welfare Organization, Ministry of Labor and Human Resources, Hellenic Republic
- 1999 **Oliver Smith Award**, Recognizing Excellence, Compassion and Service, New Engl. Med. Center
- 1999 **Certificate in Global Leadership and Management**, The Fletcher School of Law and Diplomacy, Tufts University
- 2000 **Archon of the Ecumenical Patriarchate** of Constantinople, for humanitarian healthcare
- 2001 **Plenary Speaker**, National Minority Research Symposium, Cancun, Mexico
- 2002 **Dr. George Papanicolaou Gold Medal** for contributions in humanism and medicine
- 2003 **J.F. Kennedy Fellow**, Harvard University, J.F. Kennedy School of Government
- 2003-08 **National Public Health Council**, Secretary of Health, Hellenic Republic
- 2006 **Science and Medicine Award**, Federation HASNE, Boston, MA
- 2006 **Hygeia Award**, New England Hellenic Medical and Dental Society, Boston, MA
- 2007- **Fellow**, European Academy of Allergology and Clinical Immunology
- 2007- **Fellow**, American Academy of Allergy, Asthma and Immunology
- 2013 **Inductee**, Rare Diseases Hall of Fame
- 2010 **Honorary Doctor of Medicine**, Athens University (Greece), conferred on January 25, 2011
- 2014 **Honorary Doctor of Science**, Hellenic American U (conferred Nov. 11, 2014)

- 2018 **Albert Nelson Marquis Lifetime Achievement Award** (Marquis Who is Who)
- 2018 **Albert Nelson Distinguished Humanitarian Award** (Marquis Who is Who)
- 2020 **Inductee, World Academy** (https://en.wikipedia.org/wiki/The_World_Academy_of_Sciences)

Executive Health Experience and fund raising

1. *Clinical Pharmacologist*, Massachusetts Drug Formulary Commission (1985-2022).
2. Member, *Board of Directors, Institute of Pharmaceutical Research and Technology (IFET)* and *Special Advisor* for the establishment of the *Laboratory for Drug Bioequivalence* (1994-1999).
3. *Chairman, International Committee to upgrade BioMedical Education* in Greece, Hellenic Ministries of Education and Health (1995).
4. Member, *Supreme Scientific Advisory Health Council*, Hellenic Ministry of Health (1997-2001).
5. Member, *Supreme HealthCare Board*, Institute of Social Welfare (IKA), Hellenic Ministry of Labor and Social Insurance (1999-2002).
6. *Consultant* for the establishment of graduate biomedical studies, Jeddah University, Saudi Arabia (2001-02)
7. Member, *National Public Health Council*, Hellenic Ministry of Health (2003-2008).
8. *Scientific Advisor for the establishment of the Allergy Clinical Research Center* at Attikon Hospital, Athens University, Greece (2005-2012).
9. Visiting Professor at Athens University Medical School (2005, 2007).
10. Member, *Committee for Research Evaluation*, Italian Ministry of Universities and Research (2005).
11. Continuously funded by NIH since 1986.
12. Received over \$5 million from private donors.
13. Helped Tufts raise over \$20 million from private donors.

Pharmaceutical Industry Experience

- 1984-1988 Consultant, *Hoechst Pharmaceuticals*, Frankfurt, Germany
- 1988-1989 Consultant, UpJohn, Kalamazoo, MI (helped identify and develop ibuprofen, Motrin)
- 1988-2003 Consultant, *Kos Pharmaceuticals*, Miami, FL (helped develop slow release niacin, Niaspan)
- 2002-2003 Consultant, Abbott Labs (helped develop non-flushing slow release niacin, Niaspan-Plus)
- 2000-2002 Consultant, UCB, Belgium (helped identify and develop Cetirizine, Zyrtec)
- 1990-1998 Consultant, *Muro Pharmaceuticals*, Tewksbury, MA
- 1994-1999 Consultant, *Galenica*, Athens, Greece

2011-2015 Consultant, Thorne research (ID)

Pharmaceutical Regulatory Experience

1986-2022 Clinical Pharmacologist, *Massachusetts Drug Formulary Commission*
1994-97 Special Advisor, *Hellenic National Drug Organization*, Athens, Greece
1994-00 Member, Board of Directors, *Institute of Pharmaceutical Research and Technology*, Athens, Greece
1998-08 Member, *Supreme Special Scientific Health Council*, Ministry of Health, Hellenic Republic
1999-01 Member, *Supreme Healthcare Board*, Institute of Social Welfare, Ministry of Labor and Human Resources, Hellenic Republic

Corporate Business Experience

1986- President and CEO, *Theta Biomedical Consulting and Development Co., Inc.* (Brookline, MA)
1999-2004 Scientific Advisor International Pain Center, Hygeia Hospital (Athens, Greece)
2001- Scientific Director, Algonot, LLC. (Sarasota, FL)
2000-03 Executive Committee, Board of Trustees, Hellenic College (Brookline, MA)
2003-09 Board of Directors, Brookline Education Foundation, MA
2003-10 Board of Overseers, Brookline Education Foundation, MA
2013- CEO, AutismFreeBrain.org
2014- CEO, Brain-Gate.org
2014 President, BiomedAdvice, LLC
2018- Scientific Director and Manager, Algonot, LLC

Certifications

1983 National Board of Medical Examiners, USA
1984 Hellenic Ministry of Health and Social Services, Greece
1984- License to practice medicine, Republic of Greece and European Union (#34542)
1986-93 License to practice medicine, Commonwealth of Massachusetts (NEMC #92-3418)
2016- License to practice medicine, Republic of Cyprus (#5933)

Other Appointments

1964-68 Instructor of Braille, Anatolia College, Thessaloniki, Greece
1974-77 Instructor of Modern Greek, Yale University, New Haven, CT

Teaching

1984-89 Dental Pharmacology: 3 hours and one 1-hour review
1984-92 Veterinary Pharmacology: 5 hours and one 1-hour review
1984-89 Pre-matriculation program - Pharmacology: **Director**, 12 hours (summer)
1984- National Board of Medical Examiners, Part I (NBME-I): one 7 hour review
1985-93 Medical Pharmacology: **Director**, 25 hours and five 1 hour reviews
Created a unified pharmacology course for the first time with a syllabus which became a textbook, now in its second edition.
1993- Medical Pharmacology: 5 hours and four 1 hour reviews
1993-97 Graduate Pharmacology: **Director**, 30 hours; Created the graduate program in pharmacology for the first time which was granted independent status.
1998- Translational pharmacology: 4 hours
1994- Pharm 218-Immunopharmacology: Advances and Failures in Drug Discovery **Director**, 20 hours
2004-09 Bio 195-Pharmacology of Multiorgan Diseases (Tufts undergraduate course). **Director**, 50 hrs

University Committee Assignments

1984-86 **Curriculum Planning Committees:** Tufts University School of Medicine
1985-86 **Self-study Committee on Educational Methods:** Tufts University
1984-91 **Advisor, Progressive Minority Student Alliance:** Tufts University School of Medicine
1984-91 **Advisor, Medical Student Advisory Program:** Tufts University
1987-91 **Curriculum Committee:** Tufts University School of Medicine
1987-91 **Admissions Interviewing Committee:** Tufts University School of Medicine
1987-93 **Promotions Committee:** Tufts University School of Medicine
1987-91 **Ad Hoc Advisor:** Tufts Amnesty International Chapter
1987-91 **Ad Hoc Advisor:** Tufts Literary Club
1988-91 **Chairman:** Committee for Graduate Studies in Pharmacology, Sackler School of Graduate Biomedical Sciences, Tufts University
1992- **Member:** Committee for Graduate Studies in Pharmacology, Sackler School of Graduate Biomedical Sciences, Tufts University
1992- **Phase II Curriculum Committee:** Tufts University School of Medicine
1992- **Research Development Group:** Arthritis, autoimmunity, and immunologic diseases, Tufts
1992, 98 **Accreditation Review Committee on Educational Programs**
2000-03 **Basic Sciences Promotion and Tenure Committee,** Tufts University School of Medicine
2001-04 **Program and Faculty Committee,** Tufts University School of Medicine
2009 **Strategic Implementation Committee,** Tufts University School of Medicine
2011- **Committee on Committees,** Tufts University School of Medicine
2013-16 **Grievance Committee,** Tufts University School of Medicine
2017- **Basic Sciences Promotion and Tenure Committee,** Tufts University School of Medicine

Other Committee Assignments

- 1974-78 **Senator:** Graduate and Professional Student Senate, Yale University
1977-78 **Executive Secretary:** Graduate and Professional Student Senate, Yale University
1980 **U.S.A. Representative:** for the IXth Congress of the European Association of Poison Control Centers and the European Meeting of the International Association of Forensic Toxicologists
1983 **Peer-Reviewer:** Cellular Biology Section, National Science Foundation
1984 **Co-Chairman:** Ninth International Congress of Pharmacology, London
1985 **Founding member:** Serotonin Club, U.S.A.
1986 **Chairman:** Second Interscience World Conference on Inflammation, Monte Carlo
1986 **Organizing Committee:** Conference on Healing, N.Y.
1986- **Clinical Pharmacologist:** Drug Formulary Commission of Massachusetts
1988- **Honorary Member:** Research Board of Advisors, The American Biographical Institute
1989 **Chairman:** Third Interscience World Conference on Inflammation, Monte Carlo
1989 **Peer-Reviewer:** National Institutes of Health - NIDDKD/Urology *Ad Hoc* study section
1990 **Advisory Committee:** Fourth World Conference on Inflammation, Geneva
1993 **Advisory Committee:** Fifth World Conference on Inflammation, Geneva
1993 **Visiting Consultant:** King Abdul-Aziz University Medical School, Jeddah, SA
1993-94 **Consultant:** Committee to Upgrade the National Health Care System, Athens, Greece
1994 **Chairman:** Inflammatory mechanisms, 6th Intl. Conference on Immunopharm, Prague
1994-99 **Board of Directors:** Institute of Pharmaceutical Research and Technology: responsible for the analytical branch of the Food and Drug Administration, as well as the National Pharmaceutical Industry and National Drug Warehouse, Athens, Greece
1994-99 **Special Advisor:** in charge of establishing a bioequivalence and drug development center for the Greek National Drug Organization, Athens, Greece
1994-95 **Chairman:** International Committee to Upgrade Medical Education, Athens, Greece
1995 **Advisory Committee:** 6th World Conference on Inflammation, Geneva
1997 **Advisory Committee:** 7th World Conference on Inflammation, Geneva
1997 **Chairman:** Postgraduate Medical Education, 3rd European Medical Students' Congress, Crete, Greece
2000 **Chairman:** International Congress on Interstitial Cystitis and Related Neuroinflammatory Conditions, Crete, Greece
1997-00 **Member:** Supreme Scientific Health Council to Secretary of Health, Hellenic Republic
1999-02 **Member:** Supreme Healthcare Board, Institute of Social Services, Hellenic Republic
2000-03 **Member:** School Site Council, Devotion School, Brookline, MA
2003- **Member:** Board of Directors, the Brookline Foundation, MA
2003-08 **Member:** National Public Health Council, Secretary of Health, Hellenic Republic
2015- **Member,** International Advisory Committee, University of Cyprus Medical School

Bibliographical Listings

Marquis Who's Who in America

Marquis Who's Who in the World

Marquis Who's Who in Medicine and Healthcare

Marquis Who's Who in Frontier Science and Technology

Hellenic Who's Who in Business and the Professions

Men of Achievement

Dictionary of International Biography

Editorial Reviews

- 1978- **Ad Hoc Reviewer:** *Archives of Dermatology, Biochemical Pharmacology, Behavioral and Neural Biology, Cancer Research, Clinical and Experimented Allergy, Journal of Allergy & Clinical Immunology, Journal of Cellular Physiology, Journal of Clinical Investigation, Journal of Clinical Psychopharmacology, Journal of Immunology, Journal of Neuroimmunology, Neuropharmacology, Neuroscience, New England Journal of Medicine, Proceedings of the Society for Experimental Biology and Medicine, Trends Immunology, Urology, Journal of Urology.*
- 1986- **Editorial Board:** *Acta Toxicologica et Therapeutica*
- 1988- **Deputy Editor:** *International Journal of Immunopathology and Pharmacology*
- 1992- **Editorial Board:** *Hellenic Allergology & Clinical Immunology*
- 1992- **Editorial Board:** *International Journal of Tissue Reactions*
- 1993- **Deputy Editor:** *International Journal of Immunopathology and Pharmacology*
- 2001- **Editorial Board:** *Allergy and Asthma Proceedings*
- 1994- **Consultant:** *Drug Evaluations, AMA*
- 2002- **Deputy Editor:** *European Journal of Inflammation*
- 2008- **Editorial Board** *Clinical, Cosmetic and Investigational Dermatology*
- 2009- **Deputy Editor** *Journal Biological Regulatory Homeostatic Agents*
- 2009- **Editorial Board** *Expert Opinion in Pharmacotherapy*
- 2009- **Editorial Board** *Autism Insight*
- 2012- **Section Editor** *Clinical Therapeutics*
- 2012- **Deputy Editor** *International Trends in Immunity*

Grant Reviews

- 1992 NIDDK *Ad Hoc* Urology Study Section
- 2000-02 NIH Biobehavioral & Behavioral Processes-SS2
- 2001 MDCN1
- 2002 NINDS ZDK1 GRB-B (J2) Biology of Neuroendocrine Peptides
- 2001-02 NSF Division of Integrative Biology and Neuroscience
- 2002 NIDDK Reparative Medicine, Renal/Urology (SSS-M 05)
- 2002 NIDDK ZDK11 GRB-9 Urology Research Centers Special Urology Emphasis Panel

2003 VA Neurobiology Section A

2011 Italian Ministry of Universities and Research

2007 ZAI1 SV-IS1 Cellular & Inflammation Pathways

2007 NIAID Asthma & Allergic Dis Coop Res Centers

2009 DK ZDK1 GRB-6 Urology Research Centers

2009 SEP, Natl Center Minority Health & Disparities (NCMHD)

2010 Hellenic Ministry of University Review and Accreditation

2010 NIMSD ZRG1 MOSS-D12B SBIR: Dermatology, Rheumatology and Inflammation

2011 ZRG1 CFS-M (80) S-Chronic Fatigue Syndrome

2012 ZRG1 MOSS T12- Small Business: Dermatology, Rheumatology and Inflammation

2012 ZRG1 MOSS-S (04) S-Musculoskeletal, Oral & Skin Sciences

2013 ZRG1 VH-D 02M Molecular and Cellular Hematology

2014 ZRG1 MOSS-V (02) M Special Emphasis Panel

2015 ZRG1 MOSS-C (02) Skin Immunology-CHAIR

2016 ZRG1 MOSS-C (02) Skin Immunology

2017 ZRG1 BBBP-L(40) P: RFA HD-17-009-Autism Centers of Excellence

2017 ZRG1 IFCN-N (U54) Myalgic Encephalopathy/Chronic Fatigue Syndrome CRCs

2017 ZRG1 IFCN-N (R21) Myalgic Encephalopathy/Chronic Fatigue Syndrome-CHAIR

2019 ZRG1 CFS-N (80) S Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

2020 ZRG1 CFS-N (80) S Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Membership to Professional Societies

1972- Hellenic Biochemical and Biophysical Society

1977- New York Academy of Sciences

1978- American Medical Association

1978- American Association of University Professors

1978- American Institute of the History of Pharmacy

1978- American Association for the Advancement of Science

1978- Society for Health and Human Values

1979- American Association for the History of Medicine

1979- American Society for Cell Biology

1980- Sigma Xi: The Scientific Research Society

1980- Society for Neuroscience

1980- International Brain Research Organization

1980- International Society of the History of Medicine

1980- American Federation for Clinical Research
 1980- Connecticut Academy of Arts and Sciences
 1980- American Society for Pharmacology and Experimental Therapeutics
 1981- American Society for Microbiology
 1981- Hellenic Society for Cancer Research
 1981- Hellenic Society for Medicinal Chemistry
 1981- Hellenic Society of Pharmacology
 1981- American Association of Immunologists
 1982- International Society for Immunopharmacology
 1984- Massachusetts Medical Society
 1987- International Association for the Study of Pain
 1987- Harvard Count way Historical Library Associates
 1994- World Stress Society
 1996- Physicians for Human Rights
 2007- European Academy of Allergology and Clinical Immunology
 2007- American Academy of Allergy, Asthma and Immunology
 2008- Royal Academy of Medicine (UK)

Office and Committee Assignments in Professional Societies

1974-79 **Secretary:** Association of Greeks at Yale University
 1978-79 **Board of Directors and Vice President** for Relations with Greece, Krikos, NY
 1982-83 **President:** Association of Greeks at Yale University
 1984-85 **Trustee:** Anatolia College, Boston, Massachusetts
 1984-86 **Secretary:** International Anatolia Alumni Association, Boston, MA
 1984-85 **Secretary:** New England Hellenic Medical Society, Boston, MA
 1985 **Board of Directors:** Hellenic Scientists Association of Boston, Boston, MA
 1985-86 **Vice-President:** New England Hellenic Medical Society, Boston, MA
 1986-87 **President:** New England Hellenic Medical Society, Boston, MA
 1995-97 **Vice-President:** New England Hellenic Medical & Dental Society, Boston, MA
 2000-09 **Trustee,** Hellenic College, Brookline, MA

Research Interests

1. Pathophysiology of mast cells in mastocytosis and in neuroimmunoendocrine disorders. Mast cells are known for their involvement in allergic reactions, but we were the first to show that they are also necessary to initiate inflammation, thus participating in inflammatory diseases that worsen by stress, such as autism, cancer, chronic fatigue syndrome, interstitial cystitis, migraine headaches, psoriasis and multiple sclerosis. We have developed *in vivo* and *in vitro* models for these diseases and we are studying neurohormonal activation of mast cells. The only plausible way to explain how mast cells can participate in so many diverse processes is their ability to secrete distinct chemicals relative for different pathophysiological settings.
2. Molecular events involved in mast cell stimulus-secretion coupling, especially with their ability to release mediators selectively without degranulation. Mast cells are typically activated by immunoglobulin E and antigen, a process that leads to an explosive release of over 20 biologically active molecules (some of which are presorted in some 500 secretory granules, while others are synthesized during activation) through a process called degranulation or exocytosis. However, we were the first to show that mast cells can also respond to non-allergic triggers and release mediators *selectively, without degranulation*. We specifically reported that the inflammatory cytokine IL-1 can induce selective release of the also inflammatory cytokine IL-6, that the stress hormone corticotropin-releasing hormone (CRH) can induce selective release of vascular endothelial growth factor (VEGF), and IL-33 augments substance P(SP)-induced VEGF release. We are currently studying the regulation of CRH receptor expression and function on human cultured mast cells and the effects of their respective activation on allergic stimulation.

3. Mast cells have the ability to superstimulate activated T cells; moreover, the mast cell mediators IL-6 and TGFbeta participate in the maturation of Th17 cells, which are increasingly implicated in autoimmune diseases such as multiple sclerosis and psoriasis. Part of this process requires cell-to-cell contact, but also TNF secretion. We are investigating how IL-33 and SP (see above) could drive mast cells to participate in Th1-type of diseases and how such interactions may be interrupted for therapeutic purposes.
4. Regulation of mast cell secretion by the mitochondrial uncoupling protein 2 (UCP2) and mitochondrial dynamics. We showed for the first time that there is an inverse relationship between UCP2 expression and mast cell secretion. We also showed for the first time that mast cell degranulation, but not selective release of tumor necrosis factor (TNF), is associated with mitochondrial fission and relocation from perinuclear localization to cell-widespread distribution. We further showed that mitochondrial components are secreted outside the cell where they stimulate other cells, including endothelial cells, immune cells and neurons to secrete inflammatory molecules.
5. Antisecretory and antiproliferative function of the 78 kD mast cell phosphoprotein, moesin. We sequenced this protein and showed that, in its phosphorylated state, it inhibits mast cell secretion and tumor growth. We are investigating the regulation of its expression, identification of the phosphorylated sites and molecules that could increase and sustain the phosphorylated state of this protein.
6. Anti-allergic and anti-inflammatory actions of some natural polyphenolic flavonoids. We are investigating the mechanism of action of the select flavonoids luteolin and methoxyluteolin, their formulation in ways that increases their absorption, as well as their blood concentrations in order to achieve maximal effective levels. Such compounds could serve as anti-allergic, anti-inflammatory and anticancer drugs.
7. Role of neonatal mast cell activation in the pathogenesis of autism. We reported that the prevalence of autism spectrum disorder (ASD) is ten times higher (1/10 children) in patients with mastocytosis than the general population (1/100 children). What makes this finding even more impressive is that mastocytosis is a rare disease occurring in 1/2000 children and is characterized by many hypersensitive mast cells in many tissues. We also found that the neuropeptide neurotensin, which is a potent mast cell trigger, and mitochondrial DNA are significantly increased in the serum of patient with ASD. We are investigating the presence of additional biomarkers in the serum, the effect of stress (CRH) and environmental triggers (heavy metals, mycotoxins, Lyme) on the action of on human mast cells and microglia, as well as the benefit of the unique flavonoids luteolin and methoxyluteolin Two open label clinical trials have already shown that a formulation containing luteolin (called NeuroProtek) has significant benefit in over 50% of autistic children in 6 months.
8. Stimulated mast cells undergo fission and translocation of mitochondria with extracellular mitochondrial particle and DNA secretion extracellularly leading to autocrine and paracrine inflammatory actions. These mitochondrial components are misconstrued by the body as “innate pathogens” and could lead to the pathogenesis of inflammatory diseases, such as ASD, atopic dermatitis and psoriasis.
9. The role of brain mast cells in neuropsychiatric diseases such as Alzheimer’s disease, autism spectrum disorder (ASD), myalgic encephalomyelitis/chronic fatigue syndrome, fibromyalgia syndrome, mast cell activation syndrome, chronic inflammatory syndrome, post-Lyme syndrome and pelvic pain syndrome/interstitial cystitis.
10. The inhibitory/protective role of the cytokines IL-37 and IL-38 against inflammatory disorders, especially ASD.

Clinical Studies

1. Double-blind, placebo-controlled, cross-over study for the treatment of remitting-relapsing multiple sclerosis. (Principal Investigator: T.C. Theoharides, Ph.D., M.D, Co-PI: S.L. Hauser, M.D. Site: Massachusetts General Hospital, Boston, MA).
2. Double-blind, placebo-controlled, study for the treatment of interstitial cystitis. (Principal Investigator: T.C. Theoharides, Ph.D., M.D, Co-PI: G.R. Sant, M.D. Site: Clinical Research Center, New England Med. Center).
3. Double-blind, placebo-controlled, study for the prevention of migraine headaches. (Principal Investigator: T.C. Theoharides, Ph.D., M.D; co-PI: E. Spierings, M.D., Ph.D. Site: Boston, Clinical Research Center, Newton, MA-2004).
4. Single-blind, open label study of the effect of a flavonoid formulation on niacin-induced flush. (Principal Investigator: T.C. Theoharides, Ph.D., M.D., Co-I: Dimitris Kalogeromitros, Ph.D., M.D. Site: Attikon Hospital, Athens, Greece-2008).
5. Single-blind, open label study of the effect of a flavonoid formulation, CystoProtek, on interstitial cystitis. (Principal Investigator: T.C. Theoharides, Ph.D., M.D., Co-I: Grannum R. Sant, M.D. Site: Multiple throughout the USA-2008).
6. Single-blind, open label study of the effect of a flavonoid formulation on niacin-induced flush. (Principal Investigator: T.C. Theoharides, Ph.D., M.D., Co-I: Dimitris Kalogeromitros, Ph.D., M.D. Site: Attikon General Hospital, Athens, Greece-2009).
7. Open label study of biomarkers in young children with autism. (Principal Investigator: T.C. Theoharides, Ph.D., M.D., Co-Is: Dimitris Kalogeromitros, Ph.D., M.D., Konstantinos Francis, M.D. Site: Attikon General Hospital, Athens, Greece-2009).
8. Open label study of tolerability and effectiveness of NeuroProtek® in autistic children (Principal Investigator: Prof. L. Lykouras . site: Second Department of Psychiatry, Attikon Hospital Athens, Greece-2011)
9. Double-blind, placebo-controlled, cross-over study of a flavonoid formulation for the treatment of autism. (Principal Investigator: T.C. Theoharides, Ph.D., M.D, Co-PI: Isaac Melamed, M.D. Site:IMMUNOe, Centennial, CO).

Research Fellowships and Grants

- 1980 **Co-Investigator:** *Alternate pathways of tumor immunity.* American Cancer Society
(PI: P.W. Askenase, M.D.).
- 1980 **Co-Investigator:** *T-cell mediated serotonin release from mast cells.* Veterans Administration
(PI: P.W. Askenase, M.D.).
- 1981 **Co-principal Investigator:** *Mast cell and histamine involvement in immunoregulation of patients with chronic renal failure.* Veterans Administration (PI: P.W. Askenase, M.D.).
- 1982 **Collaborator:** *The immunology of cutaneous basophil hypersensitivity.* National Institutes of Health
(PI: P.W. Askenase, M.D.).
- 1983 **Collaborator:** *The role of conjugated amines in modulating cell function.* Veterans Administration
(PI: P.K. Bondy, M.D.).
- 1983 **Charlton Award:** Tufts University School of Medicine. Duration: 5/1/84 - 4/30/86. Budget: \$4,000.
- 1984 **Grasp Center Awards:** Tufts University School of Medicine / New England Medical Center.
Duration: 9/1/85 - 12/31/86. Budget: \$7,000.
- 1985 **Dean's Fund:** Tufts University School of Medicine. Duration: 9/1/85 - 8/31/90. Budget: \$85,000.
- 1985 **Principal Investigator:** *Effect of cromolyn-like drugs on leukotriene secretion.* Fisons Pharmaceuticals, England. Duration: 7/1/86 - 6/31/87. Budget: \$5,000.
- 1986 **Post-Doctoral Stipend:** Muro Pharmaceutical, Tewksbury, MA. Duration: 7/1/86 - 6/31/91.
Budget: \$109,000.
- 1987 **Principal Investigator:** *Central effects of non-opioid analgesics.* Hoechst Pharmaceuticals, Frankfurt, Germany. Duration: 1/1/87 - 12/31/90. Budget: \$240,000.
- 1987 **Charlton Award:** Tufts University School of Medicine. Duration: 5/1/87 - 4/30/88. Budget: \$5,000.
- 1988 **Principal Investigator:** *Involvement of mast cells in demyelinating processes.* Multiple Sclerosis Society, RG-1961-A-1. Duration: 10/1/87 - 9/30/90. Budget: \$118,410.
- 1987 **Principal Investigator:** *Tricyclic effects on mast cell secretion.* Muro Pharmaceutical, Tewksbury, MA. Duration: 7/1/87 - 6/30/89. Budget: \$114,758.
- 1987 **Post-Doctoral stipend:** Gerondelis Foundation, MA. Duration: 9/1/87 - 6/30/89. Budget: \$5,000.
- 1988 **Principal Investigator:** *Functional relationship between brain mast cells and neurons.*
Kos Pharmaceuticals, Miami, FL. Duration: 10/1/88 - 9/30/93.
Budget: \$1,299,400 (plus \$200,000 towards an endowed professorship in pharmacology).
- 1989 **Principal Investigator:** *Secretion of bladder mast cell mediators in interstitial cystitis.*
National Institute of Diabetes and Digestive and Kidney Diseases.
RFA #98-DK-03, Division of Kidney, Urologic and Hematologic Diseases
R01-DK-42409. Duration: 9/30/89 -9/29/92. Budget: \$630,785.

- 1992 **Principal Investigator:** *Neurohormonal and free radical activation of bladder mast cells.* National Institute of Diabetes and Digestive and Kidney Diseases. RFA #DK-9104, Division of Kidney, Urologic and Hematologic Diseases R01-DK 44816. Duration: 3/1/92-2/28/95. Budget: \$468,899.
- 1992 **Co-Principal Investigator:** *Mast cell activation in child migraine patients before and after training in self-regulation.* W.T.Grant Foundation. Duration: 4/1/92-3/31/95. Budget: \$376,168.
- 1994 **Principal Investigator:** *Functional relationship between brain mast cells and neurons.* Kos Pharmaceuticals, Miami, FL. Duration: 7/1/94 - 6/30/97. Direct costs: \$263,446. Entire budget: \$399,504.
- 1995 **Principal Investigator:** *Double blind study of hydroxyzine for the treatment of interstitial cystitis.* ICA. Duration: 6/1/95-5/30/97. Direct costs: \$44,666. Entire budget: \$49,666.
- 1997 **Principal Investigator:** *Characterization of the 78 kD mast cell phosphoprotein which inhibits mast cell secretion.* Muro Pharmaceutical, Tewksbury, MA. Duration: 4/1/97-3/31/00. Direct costs: \$533,406. Budget: \$611,791.
- 1997 **Principal Investigator:** *Effect of acute stress on dura mast cell activation and implications for migraine pathophysiology.* Kos Pharmaceuticals, Miami, FL. Duration: 7/1/97 - 6/30/99. Direct costs: \$269,265. Entire budget: \$323,118.
- 1998 **Principal Investigator:** *Effect of Elmiron on the proliferation and activation of bladder mast cells.* Alza Corporation, Mountain View, CA. Duration: 7/1/98 - 6/30/2000. Direct costs: \$58,369. Entire budget: \$75,879.
- 1999 **Principal Investigator:** *Effect of acute stress on cardiac mast cell activation.* Kos Pharmaceuticals, Miami, FL. Duration: 7/1/99 - 6/30/00. Direct costs: \$140,721. Entire budget: \$168,983.
- 1999 **Principal Investigator:** *Effect of chondroitin sulfate and hyaluronic acid on the activation of bladder mast cells.* Seikagaku Corporation, Japan. Duration: 9/1/99 - 2/28/00. Direct costs: \$50,000. Entire budget: \$50,000.
- 2000 **Principal Investigator:** *Effect of acute stress on cardiac mast cell activation.* Kos Pharmaceuticals, Miami, FL. Duration: 7/1/00 - 6/30/01. Direct costs: \$140,721. Entire budget: \$168,983.
- 2001 **Principal Investigator:** *Effect of acute stress on cardiac mast cell activation.* Kos Pharmaceuticals, Miami, FL. Duration: 7/1/01 - 6/30/02. Direct costs: \$140,721. Entire budget: \$168,983.

1 U01 DK065244-01 NIDDK (PI: Sant; Co-I: Theoharides) Interstitial cystitis clinical trials group	Duration: 7/1/98-6/30/03 Direct Cost/yr: \$140,000	10%
1 R01 NS38326 NINDS (PI: Theoharides) CRH-induced dura mast cell activation	Duration: 7/1/99-6/30/03 Direct Cost/yr: \$153,573	40%
Research Grant (PI: Theoharides) Kos Pharmaceuticals, Inc., Miami, FL Effect of stress on myocardial mast cells	Duration: 7/1/02-6/30/03 Direct Cost/yr: \$108,333	10%
Research Contract (PI: Theoharides) Kos Pharmaceuticals, Inc., Miami, FL Mechanism of niacin-induced flush	Duration: 2/1/02-1/31/03 Direct Cost/yr: \$ 72,500	10%

Research Grant (PI: Theoharides) Estee-Lauder, Inc., LI, NY Keratinocyte effect on mast cells	Duration: 5/1/01-6/30/03 Direct Cost/yr: \$ 45,000	5%
Research Grant (PI: Theoharides) Cantata Pharmaceuticals, Inc. Cambridge, MA)	Duration: 2/5/03-2/4/04 Direct Cost/yr: \$ 50,000	5%
1 U01 DK65244-01 NIDDK (PI: Sant; Co-I: Theoharides) Interstitial cystitis clinical research network	Duration: 9/1/03-2/28/04 Direct Cost/yr: \$140,000	10%
BC024430 DOD- Concept Award (PI: Theoharides) Role of mast cells in mammary gland carcinogenesis	Duration: 7/1/03– 6/30/04 Direct Cost/yr: \$75,000	10%
Research Grant (PI: Theoharides) Estee-Lauder, Inc., LI, NY Keratinocyte effect on mast cells	Duration: 7/1/03-6/30/04 Direct Cost/yr: \$ 45,000	5%
Research Grant (PI: Theoharides) TAIHO Pharmaceutical Co., Japan IPD effect on human mast cells	Duration: 10/15/03-10/15/04 Direct Cost/yr: \$ 60,000	5%
Research Grant (PI: Theoharides) TAIHO Pharmaceutical Co., Japan IPD effect on bladder inflammation in mice	Duration: 11/1/04-05/01/05 Direct Cost/yr: \$ 30,000	5%
William James Foundation (Sarasota, FL) (PI: Theoharides) Research and publication preparation	Duration: 11/1/04– 3/31/05 Direct Cost only: \$55,000	N/A
Research Grant-continuation (PI: Theoharides) TAIHO Pharmaceutical Co., Japan IPD effect on bladder inflammation	Duration: 05/01/05-10/15/05 Direct Cost: \$ 15,000	5%
Research Grant (PI: Theoharides) Nucryst Pharmaceuticals, Wakefield, MA Nanocrystalline silver on bladder inflammation	Duration: 11/1/04-6/30/05 Direct Cost: \$ 27,500	N/A
Research Grant (PI: Theoharides) Nucryst Pharmaceuticals., Wakefield, MA Nanocrystalline silver on bladder inflammation	Duration: 12/1/05-6/30/07 Direct Cost: \$ 47,500	N/A
1 R01 DK062861 (PI: Theoharides) NIDDK Acute restraint stress-induced neurogenic bladder inflammation The major goal of this grant is to investigate the role of CRH and mast cells in stress-, SP- and LPS-induced rodent bladder inflammation as it may relate to the pathogenesis of bladder pain syndrome/interstitial cystitis.	Duration: 5/1/2003-4/30/2007 Direct Cost/yr: \$175,000	
1 R21 NS055681 (PI: Theoharides) NINDS Mast cells, tricyclic antidepressants and chronic fatigue syndrome The major goal of this application is to investigate the ability of human cord blood and cord matrix-derived mast cells to be activated by corticotrophin-releasing hormone and the effect of certain antidepressants.	Duration: 9/1/2006-9/29/2008 Direct cost: \$175,000	

Research Grant-continuation (PI: Theoharides) TAIHO Pharmaceutical Co., Japan IPD effect on bladder neurogenic inflammation	Duration: 03/01/07-02/28/08 Direct Cost: \$ 80,000
Mastocytosis Society (PI: Theoharides) Skin mast cell expression of CRH receptors	Duration: 5/1/09-12/31/09 Direct cost: \$45,000
National Autism Association (PI: Theoharides) Mast cell-related biomarkers in autism	Duration: 5/1/09-12/31/09 Direct cost: \$35,000
Safe Minds (PI: Theoharides) Effect of mercury on human mast cells	Duration: 5/1/09-12/31/09 Duration: 5/1/09-12/31/09
National Autism Association (PI: Theoharides) Serum biomarkers in children with autism	Duration: 5/1/10-12/31/11 Direct cost: \$30,000
Safe Minds (PI: Theoharides) Mercury and neurotensin induce mitochondrial DNA release from human mast cells and contribute to auto-immunity in autism	Duration: 12/30/10-12/29/11 Direct cost: \$75,000
Autism Research Collaborative (PI: Theoharides) Investigation of IL-9, IL-33 and TSLP in serum of autistic children	Duration: 4/19/11-12/31/11 Direct cost: \$8,500
Thorne Research (PI: Theoharides) Comparison of anti-inflammatory anti-flushing effects of six different flavonoid compounds	Duration: 6/13/11-10/31/11 Direct cost/yr: \$50,000
2 R01 AR047652-11 (PI: Theoharides) NIAMSD Stress induces skin mast cell activation and vasodilation The major goal of this grant is to investigate the role of CRH receptors in stress and CRH-induced skin vascular permeability using knockout mice and recombinant techniques, as well as in human skin biopsies from patients with urticaria, psoriasis and mastocytosis, the symptoms of which worsen by stress	Duration: 9/1/2007-3/31/2012 Direct Cost/yr: \$215,000
National Psoriasis Fnd Translational Award (PI: Theoharides) The role of the novel mTOR pathway in psoriasis and the effect of methoxyluteolin	Duration: 6/1/13-5/31/15 Direct costs: \$200,00
The Jane Botsford Johnson Foundation Research Award PI: Theoharides Activation of signaling complex mTOR in mast cells and microglia by environmental triggers increases the risk of autism and is inhibited by the flavonoid methoxyluteolin	Duration: 6/1/13-5/31/15 Direct costs: \$100,00
1R01NS071361-05 (PI: Theoharides) Brain mast cells and chronic fatigue syndrome	Duration: 07/10-6/30/15 Direct cost : \$1,100,000
National Psoriasis Foundation (PI: Theoharides) The role of the novel mTOR pathway in psoriasis and the effect of methoxyluteolin	Duration: 05/15/13 – 05/14/15 Direct costs: \$100,000
Michael S. and Katherine V. Johnson Family Fnd Serum levels of SP, CRH and IL-33 in fibromyalgia patients	Duration: 01/15/14 – 06/30/15 Direct costs: \$50,000

Pfizer #WI194875	Duration 1/1/15-12/31/16
PI: Theoharides	Direct costs: \$230,000
Effect of inflammasome in psoriasis	
National Psoriasis Foundation Translational Award	Duration: 6/1/13-5/31/15
PI: Theoharides	Direct costs: \$200,000
The role of the novel mTOR pathway in psoriasis and the effect of methoxyluteolin	
Autism Research Institute	Duration: 7/1/14-6/30/15
PI: Theoharides	Direct costs: \$30,000
Serum levels of CRH, neurotensin and mitochondrial DNA in children with autism	
1 R01 NS066205-04	Duration: 7/1/10-6/30/15
MPI: Veves and LoGerfo; Role: Subcontract	Direct costs: \$60,000
Role of neuropeptides in diabetic foot problems	
Anonymous donation	Duration 1/1/17-12/31/19
PI: Theoharides	Direct costs: \$150,000
Expression of Neurotensin and its receptors in brains of children with autism	
Anonymous donation	Duration 1/1/17-12/31/19
PI: Theoharides	Direct costs: \$100,000
Identification of exosomes in serum of children with autism and effect on cultured human microglia	
Veritas Grants	Duration 1/1/18-12/31/19
PI: Theoharides	Direct costs: \$25,000
Effect of mycotoxins on human microglia	
Solve ME/CFS Initiative 2018 Ramsay Award	Duration 11/1/18-12/31/19
PI: Theoharides	Direct costs: \$40,000
Role of extracellular vesicles in Myalgic encephalomyelitis/chronic fatigue syndrome	

Patents (in chronological order-no. date=d,m,y)

Methods claims

#5,250,529 (10/05/1993)	Method of alleviating migraine headache with mast cell degranulation blocking agents.
#5,648,350 (07/15/1997)	Method of treatment of endogenous, painful gastrointestinal conditions of non-ulcerative origin.
#5,821,259 (10/13/1998)	Histamine-3 receptor agonists as therapeutic agents.
#5,855,884 (01/05/1999)	Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker.
#5,994,357 (11/30/99)	Method of treatment of interstitial cystitis.
#6,020,305 (02/01/2000)	Treatment of stress-induced skin diseases by CRH antagonists and mast cell inhibitors.
#6,689,748 (02/10/2004)	Method of treating mast cell activation-induced diseases with a proteoglycan.
#7,759,307 (3/30/2004)	A method of treating niacin-induced flush.
#7,923,043 (4/12/2011)	Method for protecting humans against superficial vasodilator flush syndrome
#9,050,275 (06/09/15)	Methods of treating autism spectrum disorders and compositions for same.
#9,176,146 (11/3/15)	Methods of screening for and treating autism spectrum disorders and compositions for same.


Composition claims

#6,624,148 (09/23/03)	Proteoglycan compositions for treatment of cardiovascular inflammatory diseases.
#6,635,625 (10/21/03)	Proteoglycan compositions for treating prostate and bladder inflammatory conditions.
#6,641,806 (11/04/03)	Proteoglycan compositions for treating arthritic inflammation conditions.
#6,645,482 (11/11/03)	Proteoglycan compositions for the treatment of arthritic inflammatory diseases.
#6,984,667 (1/10/06)	Synergistic proteoglycan compositions for treatment of inflammatory diseases.
# 7,155,278 (10/3/06)	Compositions for oral use for treatment of cardiovascular inflammatory diseases.
#7,799,766 (9/21/10)	Composition for treatment of hormone-dependent cancers.
#7,906,153 (3/15/11)	Anti-inflammatory composition for treating multiple sclerosis.
#8,268,365 (9/18/12)	Anti-inflammatory compositions for treating brain inflammation.
#13/112,675 (Filed 5/23/11)	Compositions for protecting against superficial vasodilator flush syndrome. and methods of use

Foreign patents

- EPO # 0618796 (6/5/99) Alleviating or preventing of migraine headache with mast cell degranulation blocking agents.
France, Germany (6922912.5), Ireland, Italy, Netherlands, Spain, United Kingdom
- New Zealand #246748 (13/7/00) Method for alleviating or preventing migraine headache onset with mast cell degranulation blocking agents.
- Australia #672,772 (4/4/97) Method for alleviating or preventing migraine headache onset with mast cell degranulation blocking agents.
- EPO # 0748217 (7/8/02) Compositions comprising a mast cell degranulation-blocking agents for treatment of endogenous, painful, gastrointestinal conditions of non-inflammatory, non-ulcerative origin
France, Germany (69722809.6), Greece, Ireland, Italy, Netherlands, Spain, United Kingdom
- EPO # 0618796 (11/6/03) Treatment of stress-induced skin diseases by corticotropin-releasing hormone antagonists and skin mast cell degranulation blockers.
France, Germany (69722809.6), Ireland, Italy, Spain, United Kingdom
- EPO # 1365777 (4/19/06) Proteoglycan compositions for the treatment of skin inflammatory diseases.
France, Germany, Greece, Ireland, Italy, Spain, United Kingdom
- European Application No. 09743496.3
Based on International Application No. PCT/US09/042888)
Method for protecting humans against superficial vasodilator flush syndrome.
- International Application No. PCT/US09/52577
Methods of treating autism spectrum disorders and compositions for same.

Trade marks

<u>Mark</u>	<u>Regis. No.</u>	<u>Regis. Date US</u>
ALGONOT PLUS	2,520,109	12/18/2001
ARTHROSOFT	2,660,778	12/10/2002
ARTHROSUPREME	3,169,936	11/07/2006
BRAINGAIN	3,518,791	10/21/2008
BRAIN GAIN BOOST	3,593,572	03/24/2009
CARDIOPROTEK	3,373,400	01/22/2008
CARDIONIACIN	8,5119,878	8/31/2010
CYSTOPROTEK	2,840,956	05/11/2004
FIBROSMOOTH	3,051,493	01/24/2006
FIBROPROTEK	4,002,672	7/26/2011
LET NATURE EASE YOUR PAIN	3,464,990	07/15/2008
LET NATURE HEAL YOUR HEART	3,244,349	05/22/2007
MASTOSTAT	3,383,202	02/12/2008
NEUROPROTEK	3,225,924	04/03/2007
NRG-Q	3,822,322	7/20/2010
PROSTAPROTEK	2,849,683	06/01/2004
WHERE SCIENCE AND NATURAL REMEDIES MEET	3,044,013	01/17/2006
SKINPROTEK	3,518,790	10/21/2008
THETA BIOMEDICAL CONSULTING AND DEVELOPMENT CO., INC. and design 	3,574,373	02/17/2009
GENTLEDERM	86,442,451	06/16/2015

Training of Postdoctoral Fellows

<u>Year</u>	<u>Name</u>	<u>Title</u>	<u>Present Position</u>
1979-80	Nikolaos Kokolis, MD	Post-doctoral Fellow	Professor of Biochemistry Vet School, Aristotle University, Thessaloniki, Greece
1979-80	Zaphiroula Kritsi, MD	Post-doctoral Fellow	Professor of Biology, Aristotle University, Thessaloniki, Greece
1981-83	Sandra Kraeuter-Kops, MD	Assoc. Research Scientist	Section of Trauma, Department of Surgery, Yale University School of Medicine, New Haven, CT
1984-85	Katerina Marathias, MD	Research Associate	Attending in Critical Care Medicine, Onasis Memorial Cardiac Center, Athens, Greece
1985-86	Larry G. Miller, MD	Research Fellow	Chief Science Officer, Medi Phase Venture Partners
1986-87	Zenon Protopapas, MD	Research Fellow	Attending in Radiology, St. Elizabeth's Hospital, Yale University, New Haven, CT
1986-88	A. Konstantinidou, MD	Research Fellow	Practicing Neurologist, Thessaloniki, Greece
1987	Nikos Flaris, MD	Research Fellow	Attending in Neuropathology, Hippokratio Hospital, Thessaloniki, Greece
1987-88	Vasilios Blatsios, MD	Research Fellow	Chief, Internal Medicine, 401 Military Hospital, Athens, Greece
1987-88	P. Panagiotacopoulos, MD	Research Fellow	Attending in Cardiology, Rochester University, Rochester, NY
1988-90	Harissis Vliagoftis, MD	Research Associate	Assistant Professor in Internal Medicine, Canada
1989-90	Violetta Dimitriadou, PhD	Research Associate	Chief Science Officer, Biotech Company, Ottawa, Canada
1991	Linda Mak, MD, PhD	Research Fellow	Resident in Pediatrics, Stanford University, CA
1991-92	E. Kotronis, MD	Research Fellow	Attending, Internal Medicine, 401 Military Hospital, Athens
1991-92	V. Agelakas, MD	Research Fellow	Attending, Vascular Surgery, 201 Military Athens, Greece
1989-90	Jan Trnovsky, PhD	Research Associate	Director, Molecular Biology, Gene-Trak, Framingham, MA
1991-92	Panagiotis Bakos, MD	Research Fellow	Attending in Anesthesia, Cleveland, OH

1990-92	Mihalis Alexandrakis, MD	Research Fellow	Associate Professor, Hematology-Oncology, Un. of Crete, Greece
1990-93	Mervat El-Mansoury, MD	Research Fellow	Attending in Anesthesia, Bay State, Boston, MA
1991-94	Efthymios Deliargyris, MD	Research Fellow	Invasive Cardiologist, Medical Center, Athens Greece
1991-94	Miltos Sugiultzoglou, MD	Research Fellow	Attending in Neurosurgery, Cornell Hospital, New York, NY
1990-95	J.J. Rozniecki, MD, PhD	Research Associate	Associate Professor of Neurology, Medical Academy of Lodz, Poland
1992-94	Constantinos Spanos, MD	Research Fellow	Instructor in Surgery, Aristotle University, Thessaloniki, Greece
1993-94	Nasser Hosseini, MD	Research Fellow	Instructor in Dentistry, Kaz Medical School, Jeddah, Saudi Arabia
1992-98	Xinzhu Pang, MD, MSc	Research Associate	Attending in Pathology, Walter Reed Medical Institute Washington D.C.
1993-96	Linghua Wang, MD, MSc	Research Associate	Internist, New York, NY
1996-97	Spiros Manolidis, MD, Dsc	Res Asst Professor	Assistant Professor ENT, Columbia University, NY
1994-99	Leena K. Singh, MD, PhD	Research Fellow	Practicing Endocrinologist, CA
1997-98	Apostolos Filippou, MD	Research Fellow	Instructor in Urology, University of Athens, Greece
1998-00	D. Georghe, M.D.	Research Fellow	Attending in Neurosurgery, Paris, France
1998-99	Phani Patra, PhD	Research Fellow	
1998-02	Subimal Basu, MD, PhD	Research Fellow	Bioinformatics Officer, Boston, MA
1998- 09	D. Kempuraj, PhD	Research Associate	Research Scientist I, Iowa Veterans Administration Medical Center
2001-03	Koreaki Sugimoto, MD	Research Fellow	Assistant Professor of Neurology, Osaka, Japan
2001-04	Spyridon Christodoulou, MD	Research Fellow	Attending Surgeon, London
2002--03	Man Huang, PhD, MD	Research Fellow	Research Associate, Eli Lilly, OH
2002-03	B. Kempuraj, MD	Research Associate	Research Associate, U Iowa

2003-05	N. Papapodoulou, PhD	Research Fellow	Junior Group Leader at IMMH, U Cologne, Germany
2006-07	Vahagn Kotsinyan, MD	Research Fellow	
2007	Margaret Michaelian, MD	Research Fellow	
2008-09	Taxiarchis Kourelis, MD	Research Fellow	Resident in Medicine, U Connecticut
2008-10	Akrivi Manola, MD	Research Fellow	Resident in Medicine, U Connecticut
2009-11	Asimena Angelidou, MD	Research Fellow	Resident in Pediatrics, U Texas Southwestern Med Center, Dallas, TX
2009-11	Konstantinos-Dionysios Alysandratos, MD	Research Fellow	Resident in Medicine, U Texas Southwestern Med Center, Dallas, TX
2009-13	Shahrazad Asadi, Pharm D	Research Fellow	Pharmacist, MGH, Boston
2009-10	Zoi Magga, MS	Research Fellow	
2010-12	Nikos Sismanopoulos, MD	Research Fellow	Resident in Medicine, St. Elizabeth's MC
2010-11	Danae Delivanis, MD	Research Fellow	Resident in Medicine, U Connecticut
2010-12	Alexandra Miniati, MD	Research Fellow	Resident in Medicine, Lahey Clininc, MA
2012-13	Anna Karagkouni, MD	Research Fellow	Resident in Medicine, Jacoby Hospital, Albert Einstein College of Medicine, NY
2012-13	Michail Alevizos, MD	Research Fellow	Resident in Psychiatry, Weschester Hospital, NY
2012-13	Melina Shioni, MD	Research Fellow	Resident in Anesthesiology, BU Med Ctr
2013-	Eirini Tsilioni, PhD	Research Associate	

Collaborators

1987-	Pio Conti, Dsc	Professor	University of Chieti, Italy
2014-	Isaac Melamed, MD	Director	IMMUNOe, Denver, CO

Training of Graduate Students

<u>Year</u>	<u>Name</u>	<u>Degree</u>	<u>Present Position</u>
1978-79	Stewart Greissman, MD	MD, Yale Sch of Medicine	Asst. Professor of Rheumatology, Cornell Medical Center, New York
1980-82	Nikolaos Tsakalos, MD	DSc, Aristotle University Greece (deceased 1/86)	Instructor in Medicine, Aristotle University, Thessaloniki, Greece
1985-90	Mona Lambracht-Hall, BS	PhD, Tufts University	Associate Professor of Biology, Wellesley College, Wellesley, MA
1991	G. Goumenos, BPh, DDS	MS, Tufts University DSc, Athens Univ. Greece	Asst. Professor of Periodontology, Athens Univ. School of Medicine, Greece
1989-93	A. Konstantinidou, MD	DSc, Aristotle University Greece	Practicing Neurologist, Thessaloniki, Greece
1990-93	H. Vliagoftis, MD	DSc, Aristotle University Greece	Assistant Professor in Internal Medicine Canada
1992-93	Eman Haggag, MS	DSc, Cairo University	Research Scientist, National Egypt Research Foundation, Egypt
1989-95	Ivan Correia, MS, MBA	PhD, Tufts University	CEO, Biotech Company, Cambridge, MA
1994-95	Mohammed Alhelal, DDS	MSc, Tufts University	Faculty of Dentistry, Riahd University, Saudia Arabia
1994-98	Leena Singh, MD	PhD, Tufts University	Practicing Endocrinologist, CA
1998-02	Pamela Esposito, BS	PhD, Tufts U.	Researcher, Galena Pharmaceuticals, Cambridge, MA
1999-02	Man Huang, MD	PhD, Tufts U.	Research Associate, Eli Lilly, OH
1999-02	Michael Lytinas, DDS	PhD, U. Athens	Inventor, Boston, MA
1999-03	Kristiana Kandere, BS	PhD, Tufts U.	Post-doctorate Fellow, NorthWestern University, IL
2002- 03	Abdulmohsen Alrohaimi, DDS	MS, PhD Tufts U.	VP, FDA, Saudi Arabia
2002- 05	Jill Donelan, BS	PhD, Tufts U	Scientist II, Millenium Pharmaceuticals, MA
2003-05	Jing Cao, M.D.	PhD, Tufts U	Post-doctorate Fellow, Cancer Inst., NJ
2005-08	Michael Tagen, BS	PhD, Tufts U	Senior Research Investigator, Bristol-Myers Squibb, Princeton, NJ
2007-08	Virginia Karapanou, DMD.	MSc, Tufts University	Associate Professor of Endodontics, Tufts School of Dental Medicine

2008-11	Bodi Zhang, MPH	PhD, Tufts University	Strategy Consultant, Thorne Res
2009-11	Evangelos Papathanasiou, DMD	MS, Tufts University	Asst. Prof. Periodontologist, Tufts University, MA
2008-13	Zuyi Weng, BA	PhD, Tufts University	
2006-10	Magdalini Vasiadi, BA	DSc, Athens University	NYU Law School
2009-13	Magdalini Vasiadi, BA	PhD Tufts University	
2011-	Anilia Taliou, MD	DSc candidate, Athens U	Dept of Pediatrics, Athens U
2011-	Anastasia Therianou, MD	DSc candidate, Athens U	Dermatology, King's College, London
2011-15	Alexandra Miniati, MD	DSc, Athens U	Hospitalist, Lahey Clinic, MA
2014-	Ania Petra, MD	DSc candidate, Athens U	Dermatology, Al. Syggros Hospital, GR
2012-16	Arti Patel, MS	PhD, Tufts U	Postdoc, Novartis, Cambridge, MA
2012-17	Alexandra Taracanova	PhD, Tufts U	
2015-17	Pinelopi Pani, DMD	Masters, Tufts Dental	BU staff
2013-	Iro Palaska, DM, MS	DSc candidate, Athens U	Queens College, London
2014-18	Amanda Gross, BS	PhD candidate, Tufts U	
2015-19	Mona Bawazeer, PharmD, MS	PhD candidate, Tufts U	Asst Prof, Riyad Sch of Pharmacy
2018-19	Khlood Almehmadi. Pharm D	Master's, Tufts U	PhD Oklahoma Stae Univ

Graduate Student Rotations

1984	Charles Vecoli	2002	Abdu Alrohaimi
1985	Karen J. Kotkow	2003	Lu Gan
1986	Jennifer Hartigan	2003	Anna Markowska
1986	Barbara LeDuc	2004	Man Chun
1989	Ivan Correia	2004	Lauren Oleson
1989	Michael Polymenis	2005	Brigham B. Hyde
1993	Leena Kudchadker	2005	Michael Tagen
1994	Monette M. Cotreau-Bibbo	2005	Brenda Stoller
1997	Beverly Harrington	2006	Kathryn Heard
1998	Pamela Esposito	2008	Bodi Zhang
1998	Leah Hesse	2009	Erin Fields
1998	Kerry Culm	2010	Katie Weng
1999	Kristiana Kandere	2011	Tuiy Vien
2000	Jill Berry	2011	Arti Patel
2001	Sarah Poplawski	2018	Khlood Almehmadi

Medical, Dental and Masters Student Research Training

1985	Alicia Cartagena	M '88
1985-86	Aviva Lee-Parritz	M '88
1985-86	John Savala	M '90
1989-90	John Malcynski	M '91
1989-90	Jonathan Gorbach	M '93
1990	Todd Leventhal	M '92
1992	Ali Habibi	M '94
1992	Shahram Hoghaddam	D '94
1999	George Chiang	M '00
2004	Matthew Christian	M '05
2004	Craig Weikauf	M' 08
2005	Kristen Farwell	M'08
2007-10	Dean Papaliadis	M' 11
2010-11	John Stratigis	M' 14
2016	Linh Dang	M' 18
2017	Ashley Medeiros	M'20

Masters in Biomedical Sciences Thesis

2010-11 Petel Milonas
2011-12 Steven Punzell
2013 Lauren Arbetman
2014 Thomas Soussou
2015 Amal Ashgar
2016 Jacob Blitstein
2017 Alejandro Delgado
2018 Ablam Bogis
2018 Aarane M. Ratnaseelan
2018 Annie Won
2018 Alejandro Delgado
2018 Zachary Dai
2019 Rebecca S. Park

College Student Research Training

1990-91	John Solomonides	Tufts '91	
1990	Helen Delihatsiou	MIT '91	
1992	Patti Siri	Tufts '92	
1993	Jessica Greenwood	Tufts '93	
1993-94	Tania Mangones	BU '95	
1994	Eric Evans	Tufts '94	
1995	Lisa Alferes	Tufts '95	
1995	Nicholas Varelas	BunkerHill '99	
1995	Konstantinos Ligris	BU '98	
1995-99	Nicholas Alexakos	Tufts '97	
1995	Dana Wald	Tufts '96	
1996	Jose Betances	Amherst '98	(NIH - Minority Trainee)
1997	Panagiotis Theofilopoulos	U. Athens '98	
1997	Tracye D. Kyles	Southern U. '98	(NIH - Minority Trainee)
1998	Kim Bates, R.N.	Tufts '99	
1998-99	Marlon Green	U. Mass. Boston '01	(NIH-Minority Trainee)
1998	Kathleen Spear	Curry College '99	
1999-00	Antone Alfonso	Curry College '00	
2000	Sheila Jeudy	Tufts '03	(NIH-Minority Trainee)
2000	Athena-Eleni Mavroudhes	BU '00	
2000	Gregory Patakos	Tufts '02	
2006	Rachel Singh	Tufts '06	
2006	E.J. Isoba	Tufts '06	
2006	Lauren Hess	U. Texas at Austin '08	
2006-07	Nivine Baba	Am. U. Beirut '06	
2007	Vasilios Kotsiopoulos, BS	BU '07	
2009	Jennifer Eng	Tufts '11	
2009	Vangelis Papadimas	Cornell '09	
2011	Maria Deligiannides	Olivet Nazarene University ,12	
2018	Jaanvi Sant	Tufts '19	

Post-Baccalaureate Student Research Training

2005-07 Anthony Clemons NIH PREP Fellow PhD graduate, U Winsconsin

High School Student Summer Research Training

1985	Tracy Desmond	Museum of Science Internship
1986	Diane Pfaelzer	Museum of Science Internship
1992	Ruth Dorcelus	NIH Minority Trainee
1993	Novella Brady	Boston Latin Academy, NIH Minority Trainee
1993	Nicholas Karatzas	Woburn High, went to Boston U.
1993	Anastasia Condos	Windsor High, went to Harvard U.
1993	Konstantinos Ligris	Newton South, went to Boston U, Boston Law
1994	Jason Goler	Walpole High, NIH Minority Trainee
1995	Monica David	Newton North, NIH Minority Trainee
1996	Marlon Green	Madison Park, NIH Minority Trainee
1997	Paki Philips	Pinkerton Academy, NIH Minority Trainee
1998	Cynthia Mompoin	Montrose School, NIH Minority Trainee, went to Georgetown U.
1998	Daphne Duvalsaint	Stoughton High School, Stoughton, MA
1999	Sheila Jeudy	Fontbonne Academy, Milton, MA, NIH Minority Trainee, went to Tufts Univ
2001	Amma Asane	Milton Academy, NIH Minority Trainee
2001	David Tutor	Newton South
2002	Joshna Hicks	Brookline High, NIH Minority Trainee
2003	Rayna Briceno	Newton County Day, NIH Minority Trainee, will attend Tufts U.
2004	Kathleen Solage	Boston Latin, NIH Minority Trainee
2004	Tayrickia Adams	Arlington High, NIH Minority Trainee
2005	Harrison Barnes	Brimmer & Mary School, Chestnut Hill, MA, NIH Minority Trainee
2005	Linwood Jackson	Archbishop Williams High, Braintree, MA, NIH Minority Trainee
2007	Cedric S. White	St. Sebastian's School, MA, NIH Minority Trainee
2009	Kwaku Acheampong	Xaverian Brothers High School, MA
2009	Trisha Barungi	
2009	Chris Kalogeromitros	Psychico Athens Prep School, Athens, Greece
2010	Jodaele Racine	Prospect Hill Academy Charter School, Cambridge, MA
2011	Rose Fountotos	Marianopolis College, Montreal, Canada
2013	Mariana Athanasiou	Sadbury High school, MA

Graduate Student Doctoral Committee Chair

2011	Daniel O'Connell	Biochemistry
2011	Katherine Heard	Biochemistry
2012	Brendan H. Oakes	Pharmacology and Experimental Therapeutics
2012	Michael J Hanley	Pharmacology and Experimental Therapeutics
2013	Malek Najjar	Pharmacology and Experimental Therapeutics
2013	Fiaturi Najla	Pharmacology and Experimental Therapeutics
2013	Lei Cao	Pharmacology and Experimental Therapeutics
2016	Bina Julian	Pharmacology and Experimental Therapeutics

2017	Michael Holloway	Pharmacology and Experimental Therapeutics
2018	Smaro Panagiotidou	Pharmacology and Experimental Therapeutics

Courses taught

- Medical Pharmacology-Medical students
- Medical Pharmacology-Masters in Biomedical Sciences students
- Translational pharmacology-Graduate students
- How to be an Intern-Medical students
- Pharm 218: Immunopharmacology-Advances and Failures in Drug Discovery (Director)

Trainee Distinctions (on work performed in our laboratory)

1985	Alicia Cartagena, MD (M'88)	Dean's Research Fellowship; First Prize, Mennheim-Ingelheim National Student Pharmacology Assay Competition; 1988 Henry J. Kaiser Family Foundation National Medical Fellowship Merit Award, Tufts U.
1985	Mona Lambracht-Hall, PhD ('89)	Berlex Laboratory Graduate Fellowship
1985	Aviva Lee-Parritz, MD (M'88)	Dean's Research Fellowship; 1988 William Dameshek Research Award; 1988 Harry H. Brenner Memorial Award, Tufts University
1986	John H. Savala, MD ('90)	American Heart Association Student Stroke Scholarship
1988	Leticia Acquah, MD (M'88)	Kos Pharmaceuticals Student Fellowship
1990	Todd Leventhal, MD (M'92)	American Foundation for Urologic Disease Fellowship
1990	Mohamed G. Haggag, DDS	American Peace Fellowship
1991	John Solomonides, MD (T'90)	New England Hellenic Medical & Dental Society Award
1992	Shahram Hoghaddam (D'93)	Provost and NIH Student Summer Research Fellowship
1999	George Chiang (M'00)	American Urologic Association Student Summer Research Fellowship
1999	Marlon Green (UMass'00)	New England Biomedical Science Careers Award
2001	George Chiang (M'00)	William Dameshek Research Award, Tufts University
2001	Man Huang, M.D.	Christian Herter Fund Travel Award
2002	Man Huang, M.D.	Norris Cotton Cancer Graduate Student Award
2002	Natha Chandler, M.D. (M '02)	William Dameshek Research Award
2005	Jill Donelan, B.S.	Sackler 2004, Experimental Biology 2005 Travel Fellowships
2005	Kristen Farwell, M'08	Harold Williams Tufts Medical Student Research Fellowship
2006	Jill Donelan, B.S., Ph.D. '06	First Louis Lasagna Translational Research Award, Commencement speaker 2006, Tufts University
2008	Michael Tagen, B.S., Ph.D. '08	Experimental Biology 2008 Travel Award New England Pharmacologists 2008 Award Sackler 2008 Travel Award
2010	Bodi Zhang, M.D., M.P.H., Ph.D. '11	Sackler Earl Charton 2010 Award
2014	Alexandra Taracanova, B.S., Ph.D.'17	Dean's Fellowship

Summary of Publications and Citations

Type	Number	Page
a. Theses	2	32
b. Books	3	32
c. Live presentations	32	33-34
<hr/>		
d. Full papers	236	35-50
e. Reviews/Chapters	284	51-65
f. Commentaries/Editorials	35	66-67
g. Case reports	13	68
h. Abstracts/Proceedings	<u>198</u>	<u>69-82</u>
<hr/>		
Total	771	
<hr/>		
i. Non-print publications	1	83
j. Invited lectures	289	84-98
<hr/>		

Google Scholar: 452 publications in www.pubmed.gov (Google Scholar 37,390 citations; *h-index* 92).

a. Theses

- 1972 ***Medical Psychology in pre-Hippocratic Greece***
Joint Bachelor of Arts, Departments of Biology and History of Science and Medicine, Yale University (Professors Edgar J. Boell and Frederick L. Holmes, advisors)
- 1978 ***Regulation of Histamine Secretion in Rat Peritoneal Mast Cells***
Doctor of Philosophy, Department of Pharmacology, Yale University (Professor William W. Douglas, advisor)

b. Books

- Theoharides, T.C. *Pharmacokinetics: Administration, Uptake, Distribution, Biotransformation and Excretion of Drugs*, pp. 1-151. Pournaras: Thessaloniki, Greece, 1981.
- Theoharides, T.C. (ed.) *Essentials of Pharmacology*, pp. 1-479. Little, Brown and Company: Boston, 1992; 2nd edition, 1996.

Theoharides, T.C. (ed.) *Pharmacology: Basic Principles in Clinical Practice*, pp. 1-750. Litsas Publishers: Athens, Greece, 1997.

Web Sites

- www.mastcellmaster.com
- www.brain-gate.org

Live Presentations on Autism

- <http://www.autismmedia.org/media3.html>
- <http://www.firstgiving.com/fundraiser/DrTheo/drtheoautismresearchfund>
- <http://www.youtube.com/watch?v=O2F0krqfzMQ&feature=related>
- <http://www.youtube.com/watch?v=pNQsK9PQL3c>
- <http://www.youtube.com/watch?v=-clnT4plFgQ>
- <http://www.youtube.com/watch?v=TMehgaoeHr0>
- <http://www.youtube.com/watch?v=-9rp1DcPnEM>
- <http://www.youtube.com/watch?v=CR8PzLAm-2E&feature=relmfu>
- <http://www.youtube.com/watch?v=EsaBJPc34xM>
- <https://www.youtube.com/watch?v=3QFa36TBtvA>
Polly meets Theoharis Theoharides)
- <https://www.youtube.com/watch?v=9QbZp3WcC1Q>
ARI-Brain Allergy and Autism)
- https://m.youtube.com/watch?list=PLtw9iWxwfPle6Xf6u-cUA7HqevL_G1NqR&v=CwOD2J_Z_BM
AutismOne An Autism Subgroup With Brain Inflammation Is Treatable-2016

Live Presentations on Cancer, Chronic Fatigue Syndrome, Interstitial Cystitis and Mastocytosis

- <http://www.firstgiving.com/fundraiser/DrTheo/drtheoautismresearchfund>
- <http://www.youtube.com/watch?v=CplxXGpFeKQ>
- http://www.youtube.com/watch?v=h9oj2v_1_Wk
- <http://www.youtube.com/watch?v=1TggRs6FOYw>
- <http://www.youtube.com/watch?v=YDR7b5cRhoo>
- <http://www.youtube.com/watch?v=zaPo0r37wEc>
- <http://www.youtube.com/watch?v=ME979bUD1J8>
- <https://www.youtube.com/watch?v=92nrFwcNSwc>
- <https://www.youtube.com/watch?v=Owtt8NO7ahU>
My mystery symptoms and mast cells (30,309 views)
- <http://www.betterhealthguy.com/episode58>
On Mastocytosis, Mast cell activation, Lyme and Mold-2018)
- <http://youtu.be/FSPwp2AjVsk>
Interview with Dr. Theoharides on NewGreek-TV with YannaDarilyn on COVID-19

Radio presentations

- <http://www.blogtalkradio.com/thecoffeeklatch/2015/02/04/dr-theoharides--mast-cell-disorders-1>
Interview of Dr. Theoharides by Mary Ann Rousso to The BlockTakRadio/Coffee Klatch/Special Needs Radio on Mast Cell Disorders
- <http://drhoffman.com/podcast/a-promising-neuro-protective-nutraceutical-part-1/#sthash.m2leT3jZ.EDkqvsmU.dpbs>
Interview of Dr. Theoharides on intelligent radio by Dr. Hoffman on the benefits of luteolin
- <https://genefood.libsyn.com/supplements-that-battle-covid-19-repurposing-pharmaceuticals-the-cytokine-storm-and-getting-smarter-for-the-second-wave-with-dr-theoharis-theoharides>
The GeneFood Podcast (7/2020) Supplements That Battle Covid-19, Repurposing Pharmaceuticals, The Cytokine Storm, And Getting Smarter For The Second Wave With Dr. Theoharis Theoharides
<https://www.lookingatlyme.ca/2021/01/welcome-back-dr-theoharides-tells-us-about-mast-cells-and-neuroinflammation/>
Looking at Lyme (11/2020)

Presentations in Greek

- <https://www.youtube.com/watch?v=NG2UeT8UaxE&feature=youtu.be>
Program celebrating the life of Dr. Theoharides (2019)
- <http://www.ert.gr/o-dr-theocharis-theocharidis-exigi-sti-dipli-matia-ti-ine-to-sindromo-brain-fog-vid/>
Συνέντευξη του Δρ. Θεοχαρίδη Ζωντανά στη Διπλή Ματιά της ΕΡΤ για την «Ομίχλη του Εγκεφάλου.»
- <http://www.cnn.gr/synenteyxeis/video/5742/dr-theoxaridis-ti-einai-i-flegmoni-kai-pos-antimetopizetai>
Συνέντευξη του Δρ. Θεοχαρίδη στο **CNN.gr** για την «Φλεγμονή του Εγκεφάλου»
- <http://www.tovima.gr/science/article/?aid=815292>
Συνέντευξη του Δρ. Θεοχαρίδη για την «Ομίχλη του Εγκεφάλου» στο ΒΗΜΑ ΤΗΣ ΚΥΡΙΑΚΗΣ
- <https://m.youtube.com/watch?v=couGSFsGMFo>
Συνέντευξη του Δρ. Θεοχαρίδη στην ΚΡΗΤΗ-ΤV-Ο Κορωναίος στο Μικροσκόπιο της Επιστήμης
- <https://www.healthweb.gr/synenteykseis/34905-αποκλειστική-συνέντευξη-από-τον-δρ-θεοχάρη-θεοχαρίδη-σε-12-μήνες-μπορεί-να-βρεθεί-θεραπεία-για-τον-κοροναϊό>
Συνέντευξη του Δρ. Θεοχαρίδη στην Νικολέτα Ντάμπου (6/2020)
- <https://www.kathimerini.gr/society/561191395/i-mystiriodis-omichli-egkefaloy-ton-epizonton-toy-koronoioy/>
Συνέντευξη του Δρ. Θεοχαρίδη στην Μαρία Αθανασίου-Καθημερινή για COVID-19 Brain Fog (12/12/2020)
- https://www.ekirikas.com/omogeneia_ameriki_genika_nea/arthro/dr_theocharis_theocharidis_h_omixli_egkefalou_tou_koronoioy_thymizei_tin_omixli_egkefalou_asthenon_pou_kanoun_ximeiotherapeia-1583631/
Συνέντευξη του Δρ. Θεοχαρίδη στην ‘Αρια Σωκράτους-Εθνικό Κήρυκα για τον COVID-19 και την ομίχλη εγκεφάλου (23/1/2021)
- <https://www.moneyreview.gr/announcements/16919/koronoios-emvolia-farmaka-kai-alla-giati-den-syzitioyntai-vasika-erotimata/>
Άρθρο του Δρ. Θεοχαρίδη στην Καθημερινή για ερωτήματα σχετικά με COVID-19 (02/08/2021)

d. Full Peer-Reviewed Papers

1. Theoharides, T.C. Galen on marasmus. *Journal of the History of Medicine and Allied Sciences* 26:369-390, 1971.
2. Theoharides, T.C. Some considerations of the mechanism underlying malaria infections and the relative resistance exhibited by sickle cell disease in humans. *Folia Biochemica et Biologica Graeca* 11:21-29, 1974.
3. Theoharides, T.C. Biosynthesis of ornithine decarboxylase. *Recent Progress in Hormone Research* 31:90-91, 1975.
4. Theoharides, T.C. and Canellakis, Z.N. Spermine inhibits induction of ornithine decarboxylase by cyclic AMP but not by dexamethasone in rat hepatoma cells. *Nature* 255:733-734, 1975.
5. Canellakis, Z.N. and Theoharides, T.C. Hormonal induction of ornithine decarboxylase in rat hepatoma (HTC) cells in culture and its regulation by polyamines. *Folia Biochemica et Biologica Graeca* 12:39-48, 1975.
6. Theoharides, T.C. and Canellakis, Z.N. Antiserum monospecific to hepatic ornithine decarboxylase. *Journal of Biological Chemistry* 251:1781-1784, 1976.
7. Theoharides, T.C. and Canellakis, Z.N. Isozymes of ornithine decarboxylase in fast growing malignant cells in culture. *Materia Medica Graeca* 4, supplement III:201-206, 1976.
8. Canellakis, Z.N. and Theoharides, T.C. Stimulation of ornithine decarboxylase synthesis and its control by polyamines in regenerating rat liver and cultured rat hepatoma cells. *Journal of Biological Chemistry* 251:4436-4441, 1976.
9. Theoharides, T.C. and Canellakis, Z.N. Immunological properties of ornithine decarboxylase from regenerating rat liver and cultured rat hepatoma cells. *Folia Biochemica et Biologica Graeca* 13:11-23, 1976.
10. Theoharides, T.C. On viral infectivity and carcinogenesis. *Perspectives in Biology and Medicine* 20:603-606, 1977.
11. Theoharides, T.C. Historical notes on some early clinical and biochemical investigations on sickle cell disease. *Folia Biochemica et Biologica Graeca* 13:57-66, 1976.
12. Scheinman, S., Burrow, G.N., Theoharides, T.C. and Canellakis, Z.N. Stimulation of ornithine decarboxylase synthesis in the rat thyroid. *Life Sciences* 21:1143-1148, 1977.
13. Theoharides, T.C. and Douglas, W.W. Somatostatin induces histamine secretion from rat peritoneal mast cells. *Endocrinology* 102:1637-1640, 1978.
14. Sieghart, W., Theoharides, T.C., Alper, D.S., Douglas, W.W. and Greengard, P. Calcium-dependent protein phosphorylation during exocytotic release of mast cell secretory granules. *Nature* 275:329-331, 1978.
15. Theoharides, T.C. and Douglas, W.W. Secretion in mast cells induced by calcium entrapped within phospholipid vesicles. *Science* 201:1143-1145, 1978.
16. Theoharides, T.C., Sieghart, W., Greengard, P. and Douglas, W.W. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. *Science* 207:80-82, 1980.
17. Theoharides, T.C., Betchaku, T. and Douglas, W.W. Somatostatin-induced histamine secretion in mast cells. Characterization of the effect. *European Journal of Pharmacology* 69:127-137, 1981.
18. Baloyannis, S.J. and Theoharides, T.C. Mast cells in the central nervous system. *Materia Medica Graeca* 9: 142-150, 1981.

19. Theoharides, T.C. Mast cells and precursor protein molecules. *Perspectives in Biology and Medicine* 24:499-502, 1981.
20. Theoharides, T.C. and Douglas, W.W. Mast cell histamine secretion in response to somatostatin analogues. Structural considerations. *European Journal of Pharmacology* 73: 131-136, 1981.
21. Theoharides, T.C., Sieghart, W., Greengard, P. and Douglas, W.W. Somatostatin-induced phosphorylation of mast cell proteins. *Biochemical Pharmacology* 30:2735-2736, 1981.
22. Sieghart, W., Theoharides, T.C., Douglas, W.W. and Greengard, P. Phosphorylation of a single mast cell protein in response to drugs that inhibit secretion. *Biochemical Pharmacology* 30:2737-2738, 1981.
23. Canellakis, Z.N., Theoharides, T.C., Bondy, P.K. and Triarhos, E.T. The role of calcium in the induction of ornithine decarboxylase in rat HTC cells. *Life Sciences* 29:707-710, 1981.
24. Tamir, H., Theoharides, T.C., Gershon, M. and Askenase, P.W. Serotonin storage pools in basophil leukemia and mast cells: characterization of two types of serotonin binding proteins and radioautographic analysis of the intracellular distribution of ³H-serotonin. *Journal of Cell Biology* 93:638-647, 1982.
25. Tsakalos, N.D., Theoharides, T.C., Dwyer, J.M. and Askenase, P.W. Dialyzable leukocyte extract induces mast cell secretion. *Cellular Immunology* 66:383-393, 1982.
26. Theoharides, T.C., Bondy, P.K., Tsakalos, N.D. and Askenase, P.W. Differential release of serotonin and histamine from mast cells. *Nature* 297: 229-231, 1982.
27. Tsakalos, N.D., Theoharides, T.C., Kops, S.K. and Askenase, P.W. Induction of mast cell secretion by parathormone. *Biochemical Pharmacology* 32:355-360, 1983.
28. Theoharides, T.C. Mast cells and migraines. *Perspectives in Biology and Medicine* 26:672-675, 1983.
29. Kritsi, Z.I., Theoharides, T.C., Baumgarten, A., Bondy, P.K. and Canellakis, Z.N. Affinity chromatography with specific antibody increases activity and retains antigenicity of ornithine decarboxylase. *Preparative Biochemistry* 12:445-460, 1983.
30. Askenase, P.W., Loveren, H.V., Kops, S.K., Ron, Y., Meade, R., Theoharides, T.C., Nordlund, J.J., Scovern, H., Gershon, M.D. and Ptak, W. Defective elicitation of delayed-type hypersensitivity in W/W^v and Sl/Sl^d mast cell deficient mice. *Journal of Immunology* 131:2687-2694, 1983.
31. Theoharides, T.C., Kops, S.K., Bondy, P.K. and Askenase, P.W. Differential release of serotonin without comparable histamine under diverse conditions in the rat mast cell. *Biochemical Pharmacology* 34:1389-1398, 1985.
32. Baloyannis, S.J., Theoharides, T.C., Manolidou, P. and Manolides, L.S. Morphologic alterations in rat cortical and cerebellar neurons and synapses during prolonged oral barbiturate administration. *Hellenic Anesthesiology* 19:225-234, 1985.
33. Tsakalos, N.D., Theoharides, T.C., Goffinet, J., Dwyer, J.M., Whisler, R.L. and Askenase, P.W. Immune impairment in chronic renal failure: evidence for defective regulation of lymphocyte responses by macrophages and T cells from chronic renal impairment patients on hemodialysis. *Clinical and Experimental Immunology* 63:218-227, 1986.
34. Baloyannis, S.J., Theoharides, T.C. and Manolides, L.S. Synaptic alterations in the acoustic cortex of the rat following insulin-induced hypoglycemia. *Archives of Otorhinolaryngology* 244:36-43, 1987.

35. Miller, L.G., Lee-Parritz, A., Greenblatt, D.J. and Theoharides, T.C. High affinity benzodiazepine receptors on rat peritoneal mast cells and RBL-1 cells: binding characteristics and effects on granule secretion. *Pharmacology* 36:52-60, 1988.
36. Theoharides, T.C., Manolidis, S.L. and Manolides, L.S. Treatment of secretory otitis media with hydroxyzine. *Hellenic Otorhinolaryngology* 1:11-18, 1989.
37. Manolides, L.S., Baloyannis, S.J., Giala, M., Manolidis, S.L. and Theoharides, T.C. Controlled hypotension during anesthesia in otological operations. An ultrastructural study of the brain in experimental animals. *Archives of Otorhinolaryngology* 246:190-194, 1989.
38. Lambracht-Hall, M., Konstantinidou, A.D. and Theoharides, T.C. Serotonin release from rat brain mast cells *in vitro*. *Neuroscience* 39:199-207, 1990.
39. Dimitriadou, V., Lambracht-Hall, M., Reichler, J. and Theoharides, T.C. Histochemical and ultrastructural characteristics of rat brain perivascular mast cells stimulated with compound 48/80 and carbachol. *Neuroscience* 39:209-224, 1990.
40. Lambracht-Hall, M., Dimitriadou, V. and Theoharides, T.C. Migration of mast cells in the developing rat brain. *Developmental Brain Research* 56:151-159, 1990.
41. Kops, S.K., Theoharides, T.C., Cronin, C.T., Kashgarian, M. and Askenase, P.W. Ultrastructural characteristics of rat peritoneal mast cells during differential release of serotonin without histamine and without degranulation. *Cell Tissue Research* 262:415-424, 1990.
42. Theoharides, T.C., Flaris, N.A., Cronin, C.T., Ucci, A. and Meares, E. Mast cell activation in sterile bladder and prostate inflammation. *International Archives of Allergy and Applied Immunology* 92:281-286, 1990.
43. Vliagoftis, H., Dimitriadou, V. and Theoharides, T.C. Progesterone triggers selective mast cell secretion of 5-hydroxytryptamine. *International Archives of Allergy and Applied Immunology* 93:113-119, 1990.
44. Pothoulakis, C., LaMont, T., Eglow, R., Ning, G., Rubins, J., Theoharides, T.C. and Dickey, B.F. Characterization of rabbit ileal receptors for *Clostridium difficile* toxin A. Evidence for a receptor-coupled G protein. *Journal of Clinical Investigation* 88:119-125, 1991.
45. Dimitriadou, V., Buzzi, M.G., Moskowitz, M.A. and Theoharides, T.C. Trigeminal sensory fiber stimulation induces morphologic changes reflecting secretion in rat dura mater mast cells. *Neuroscience* 44:97-112, 1991.
46. Kouretas, D., Trnovsky, J., Holdridge, H. and Theoharides, T.C. Two dimensional gel electrophoretic profile of rat basophilic leukemia (RBL) and mast cells. *Life Sciences* 49:1289-1294, 1991.
47. Marathias, K., Lambracht-Hall, M., Savala, J. and Theoharides, T.C. Endogenous regulation of rat brain mast cell serotonin release. *International Archives of Allergy and Applied Immunology* 95:332-340, 1991.
48. Theoharides, T.C., Baloyannis, S.J. and Manolides, L.S. Activated rat peritoneal mast cells can cause syngeneic rat brain demyelination *in vitro*. *International Journal of Immunopathology and Pharmacology* 4:137-144, 1991.
49. Dimitriadou, V., Buzzi, M.G., Theoharides, T.C. and Moskowitz, M.A. Ultrastructural evidence for neurogenically mediated changes in blood vessels of rat dura mater and tongue following antidromic trigeminal stimulation. *Neuroscience* 48:187-203, 1992.
50. Conti, P., Reale, M., Barbacane, R.C., Panara, M.R., Bongrazio, M. and Theoharides, T.C. Role of lipoxins A4 and B4 in the generation of arachidonic acid metabolites by rat mast cells and their effect on [³H] serotonin release. *Immunology Letters* 32:117-124, 1992.

51. Vliagoftis, H., Boucher, W.S., Mak, L.L. and Theoharides, T.C. Inhibition of mast cell secretion by oxidation products of natural polyamines. *Biochemical Pharmacology* 10:2237-2245, 1992.
52. Buzzi, M.G., Dimitriadou, V., Theoharides, T.C. and Moskowitz, M.A. 5-Hydroxytryptamine₁ receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the dura mater after trigeminal stimulation. *Brain Research* 583:137-149, 1992.
53. Vliagoftis, H., Dimitriadou, V., Correia, I., Boucher, W.S., Raam, S. and Theoharides, T.C. Estradiol augments, while tamoxifen inhibits rat mast cell secretion. *International Archives of Allergy and Applied Immunology* 98:398-409, 1992.
54. Theoharides, T.C. Hydroxyzine for interstitial cystitis. *Journal of Allergy and Clinical Immunology* 91:686-687, 1993.
55. Letourneau, R. Sant, G.R., El-Mansoury, M. and Theoharides, T.C. Activation of bladder mast cells in interstitial cystitis. *International Journal of Tissue Reactions* 14:307-312, 1992.
56. Theoharides, T.C., El-Mansoury, M., Letourneau, R., Boucher, W.S. and Rozniecki, J.J. Dermatitis characterized by mastocytosis at immunization sites in mast cell deficient W/W^v mice. *International Archives of Allergy and Immunology* 102:352-361, 1993.
57. Theoharides, T.C., Dimitriadou, V., Letourneau, R., Vliagoftis, H., Rozniecki, J.J. and Holdridge, M. Synergistic action of estrogen and myelin basic protein on rat mast cell secretion and brain myelin changes resembling early stages of demyelination in Lewis, but not Sprague/Dawley rats. *Neuroscience* 57:861-871, 1993.
58. Trnovsky, J., Letourneau, R., Haggag, E., Boucher, W. and Theoharides, T.C. Quercetin-induced expression of rat mast cell protease II and accumulation of secretory granules in rat basophilic leukemia cells. *Biochemical Pharmacology* 46:2315-2326, 1993.
59. Theoharides, T.C., Manolidis, S.L., Vliagoftis, H. and Manolidis, L.S. Treatment of secretory otitis media with local installation of hydroxyzine. *International Archives of Allergy and Immunology* 103:195-101, 1994.
60. El-Mansoury, M., Boucher, W., Sant, G.R. and Theoharides, T.C. Increased urine histamine and methylhistamine in interstitial cystitis. *Journal of Urology* 152:350-353, 1994.
61. Castagliuolo, I., LaMont, J.T., Letourneau, R., Kelly, C., O'Keane, J.C., Jaffer, A., Theoharides, T.C. and Pothoulakis, C. Neuronal involvement in the intestinal effects of *Clostridium difficile* toxin A and *Vibrio cholera* enterotoxin in rat ileum. *Gastroenterology* 107:657-665, 1994.
62. Bakos, P., Agelakas, V., Letourneau, R., Brophy, C.M., Spanos, P. and Theoharides, T.C. Increased number of activated mast cells at sites of aortic aneurysms. *International Journal of Immunopathology and Pharmacology* 7:153-162, 1994.
63. Conti, P., Boucher, W., Barbacane, R.C., Reale, M., Placido, F.C., Haggag, I. and Theoharides, T.C. Down-regulation of histamine and serotonin release in a basophilic leukemia cell line by interleukin-1 receptor antagonist (IL-1RA). *Challenges of Modern Medicine* 8:323-330, 1994.
64. Rozniecki, J.J., Hauser, S.L. and Theoharides, T.C. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. *Annals of Neurology* 37:63-66, 1995.
65. Theoharides, T.C., Sant, G.R., El-Mansoury, M., Letourneau, R.J., Ucci, A. and Meares, E. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. *Journal of Urology* 153:629-636, 1995.

66. Pang, X., Cotreau-Bibbo, M.M., Sant, G.R. and Theoharides, T.C. Bladder mast cell expression of high affinity estrogen receptors in patients with interstitial cystitis. *British Journal of Urology* 75:154-161, 1995.
67. Pang, X., Marchand, J., Sant, G.R., Kream, R.M. and Theoharides, T.C. Increased number of substance P positive fibers in interstitial cystitis. *British Journal of Urology* 75:744-750, 1995.
68. Boucher, W., El-Mansoury, M., Pang, X., Sant, G.R. and Theoharides, T.C. Elevated mast cell tryptase in urine of interstitial cystitis patients. *British Journal of Urology* 76:94-100, 1995.
69. Conti, P., Boucher, W., Letourneau, R., Feliciani, C., Reale, M., Barbacane, R.C., Vliagopoulos, P., Bruneau, G., Thibault, J. and Theoharides, T.C. Monocyte chemotactic protein 1 (MCP-1) is a potent histamine and [³H]-5HT-releasing factor for mast cells and provokes cell aggregation. *Immunology* 86:434-440, 1995.
70. Theoharides, T.C., Spanos, C.P., Pang, X., Alferes, L., Ligris, K., Letourneau, R., Rozniecki, J.J., Webster, E. and Chrousos, G. Stress-induced intracranial mast cell degranulation. A corticotropin releasing hormone-mediated effect. *Endocrinology* 136:5745-5750, 1995.
71. Letourneau, R., Sant, G.R. and Theoharides, T.C. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. *British Journal of Urology* 77:41-54, 1996.
72. Conti, P., Boucher, W., Feliciani, C., Mammarella, S., Kudchadker, L., Barbacane, R.C., Reale, M., Haggag, I., Bruneau, G., Thibault, J. and Theoharides, T.C. Effect of interleukin-1 receptor antagonist (IL-1RA) on histamine and serotonin release by rat basophilic leukemia cells (RBL-2HC) and peritoneal mast cells. *Molecular Cell Biochemistry* 155:61-68, 1996.
73. Pang, X., Letourneau, R., Rozniecki, J.J., Wang, L. and Theoharides, T.C. Definitive characterization of rat hypothalamic mast cells. *Neuroscience* 73:889-902, 1996.
74. Correia, I., Wang, L., Pang, X. and Theoharides, T.C. Characterization of the 78 kDa mast cell protein phosphorylated by the antiallergic drug cromolyn and homology to moesin. *Biochemical Pharmacology* 52:413-424, 1996.
75. Spanos, C., El-Mansoury, M., Letourneau, R.J., Minogiannis, P., Greenwood, J., Siri, P., Sant, G.R. and Theoharides, T.C. Carbachol-induced activation of bladder mast cells is augmented by estradiol - implications for interstitial cystitis. *Urology* 48:809-816, 1996.
76. Spanos, C.P., Pang, X., Ligris, K., Letourneau, R., Alferes, L., Alexacos, N., Sant, G.R. and Theoharides, T.C. Stress-induced bladder mast cell activation: implications for interstitial cystitis. *Journal of Urology* 157:669-672, 1997.
77. Conti, P., Pang, X., Boucher, W., Letourneau, R., Reale, M., Barbacane, R.C., Thibault, J. and Theoharides, T.C. Monocyte chemotactic protein-1 is a proinflammatory chemokine in rat skin injection sites and chemoattracts basophilic granular cells. *International Immunology* 9:1563-1570, 1997.
78. Conti, P., Pang, X., Boucher, W., Letourneau, R., Reale, M., Barbacane, R.C., Thibault, J. and Theoharides, T.C. Impact of Rantes and MCP-1 chemokines on *in vivo* basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. *Blood* 89:4120-4127, 1997.
79. Conti, P., Pang, X., Boucher, W., Letourneau, R., Reale, M., Barbacane, R.C., Thibault, J. and Theoharides, T.C. RANTES is a proinflammatory chemokine and chemoattracts mast cells to extravascular sites. *J. Pathol.* 183:352-358, 1997.
80. Pang, X., Sant, G.R. and Theoharides, T.C. Altered expression of bladder mast cell growth factor receptor (c-kit) expression in interstitial cystitis. *Urology* 51:939-944, 1998.

81. Theoharides T.C., Singh, L., Boucher, W., Pang, X., Letourneau, R., Webster, E. and Chrousos, G. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. *Endocrinology* 139:403-413, 1998.
82. Conti, P., Reale, M., Barbacane, R.C., Felaco, M., Grilli, A. and Theoharides, T.C. Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw. *British J. Haematology* 103:798-803, 1998.
83. Pang, X., Gao, W., Seretakis, D. and Theoharides, T.C. A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process. *J. Pharmacol. Exp. Therapeutics* 287:307-314, 1998.
84. Minogiannis, P., El-Mansoury, M., Betances, J.A., Sant, G.R. and Theoharides, T.C. Hydroxyzine inhibits neurogenic bladder mast cell activation. *Intl J Immunopharmacol* 20:553-563, 1998.
85. Conti, P., Reale, M., Barbacane, R.C. and Theoharides, T.C. Intramuscular injection of hrRANTES causes mast cell recruitment and transcriptional activation of histidine decarboxylase in mice. Lack of effects in genetically mast cell-deficient W/W^y mice. *FASEB J.* 12:1693-1700, 1998.
86. Singh, L., Boucher, W., Pang, X., Letourneau, R., Seretakis, D., Green, M. and Theoharides, T.C. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of CRH receptors. *J. Pharmacol. Exp. Therap.* 288:1349-1356, 1999.
87. Olness, K., Hall, H., Rozniecki, J.J., Schmidt, W. and Theoharides, T.C. Mast cell activation in child migraine patients before and after training in self-regulation. *Headache* 39:101-107, 1999.
88. Alexacos, N., Pang, X., Boucher, W., Cochrane, D.E., Sant, G.R. and Theoharides, T.C. Neurotensin mediates rat bladder mast cell degranulation triggered by acute psychological stress. *Urology* 53:1035-1040, 1999.
89. Wang, L., Correia, I., Basu, S. and Theoharides, T.C. Calcium and phorbol ester effect on the mast cell phosphoprotein induced by cromolyn. *European J. Pharmacol.* 371:241-249, 1999.
90. Alexandrakis, M., Singh, L., Boucher, W., Letourneau, R., Theofilopoulos, P. and Theoharides, T.C. Differential effects of flavonoids on inhibition of secretion and on accumulation of secretory granules in rat basophilic leukemia cells. *Int. J. Immunopharm.* 21:379-390, 1999.
91. Theoharides, T.C., Letourneau, R., Patra, P., Hesse, L., Pang, X., Boucher, W., Mompoin, C. and Harrington, B. Stress-induced rat intestinal mast cell intragranular activation and the inhibitory effect of sulfated proteoglycans. *Digestive Diseases and Sciences* 44:87S-92S, 1999.
92. Singh, L.K., Pang, X., Alexacos, N., Letourneau, R. and Theoharides, T.C. Acute immobilization stress triggers skin mast cell degranulation via corticotropin-releasing hormone, neurotensin and substance P: A link to neurogenic skin disorders. *Brain, Behavior and Immunity* 13:225-239, 1999.
93. Rozniecki, J.J., Letourneau, R., Sugiultzoglou, M., Spanos, G., Gorbach, J. and Theoharides, T.C. Differential effect of histamine 3 receptor-active agents on brain, but not peritoneal, mast cell activation. *J. Pharm. Exp. Therap.* 290:1427-1435, 1999.
94. Filippou, A., Green, M., Sant, G.R. and Theoharides, T.C. Increased expression of intercellular adhesion molecule 1 in interstitial cystitis. *Int. J. Immunopathol. Pharmacol.* 12:49-53, 1999.
95. Vliagoftis, H., Mak, L.L. and Theoharides, T.C. Dual effect of spermine on mast cell secretion exhibits different calcium and temperature requirements. *Int. J. Immunopharmacol.* 21:547-559, 1999.

96. Rozniecki, J.J., Pang, X., Dimitriadou, V., Lambracht-Hall, M., Letourneau, R. and Theoharides, T.C. Morphological and functional demonstration of rat dura mast cell-neuron interactions *in vitro* and *in vivo*. *Brain Res.* 849:1-15, 1999.
97. Katsarou, A., Davoy, E., Xenos, K., Armenaka, M. and Theoharides, T.C. Effect of an antioxidant (Quercetin) on sodium lauryl sulfate induced skin irritation. *Contact Dermatitis* 42:85-89, 2000.
98. Deliargyris, E.N., Raymond, R.J., Theoharides, T.C., Boucher, W., Tate, D.A. and Dehmer, G.J. Elevated circulating levels of interleukin-6 are due to cardiac release in acute coronary syndromes, but not in congestive heart failure. *Am. J. Cardiol.* 86:913-918, 2000.
99. Theoharides, T.C., Wang, L., Pang, X., Letourneau, R., Culm, K.E., Basu, S., Wang, Y. and Correia, I. Cloning and cellular localization of the rat mast cell 78kD protein phosphorylated in response to the mast cell "stabilizer" cromolyn. *J. Pharmacol. Exp. Therap.* 294:810-821, 2000.
100. Dimitriadou, V., Pang, X., Letourneau, R. and Theoharides, T.C. Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation. *Int. J. Immunopharmacol.* 22:673-684, 2000.
101. Chiang, G., Patra, P., Letourneau, R., Jeudy, S., Boucher, W., Green, M., Sant, G.R. and Theoharides, T.C. Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effects in interstitial cystitis. *J. Urol.* 164:2119-2125, 2000.
102. Theoharides, T.C., Patra, P., Boucher, W., Letourneau, R., Kempuraj, D., Chiang, G., Jeudy, S., Hesse, L. and Athanassiou, A. Chondroitin sulfate inhibits connective tissue mast cells. *Br. J. Pharmacol.* 131:1039-1049, 2000.
103. Raymond, R.J., Dehmer, G.J., Theoharides, T.C. and Deliargyris, E.N. Elevated interleukin-6 levels in patients with asymptomatic mild to moderate left ventricular systolic dysfunction. *Am. Heart J.* 141:435-438, 2001.
104. Esposito, P., Jacobson, S., Pang, X., Georghe, D., Kandere, K. and Theoharides, T.C. Acute stress increases permeability of the blood-brain-barrier through activation of mast cells. *Brain Res.* 188:117-127, 2001.
105. Reuter, U., Bolay, H., Jansen-Olesen, J., Chiarugi, A., Sanchez del Rio, M., Letourneau, R., Theoharides, T.C., Waeber, C. and Moskowitz, M.A. Delayed inflammation in rat meninges: implications for migraine pathophysiology. *Brain* 124:2490-2502, 2001.
106. Esposito, P., Jacobson, S., Connolly, R., Gheorghe, D. and Theoharides, T.C. Non-invasive assessment of blood-brain barrier (BBB) permeability using a gamma camera to detect ^{99m}technetium-gluceptate extravasation in rat brain. *Brain Res. Protocols* 8:143-149, 2001.
107. Boucher, W.S., Letourneau, R., Huang, M., Kempuraj, D., Green, M., Sant, G.R. and Theoharides, T.C. Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress. *J. Urol.* 167: 380-384, 2002.
108. Lytinas, M., Kempuraj, D., Huang, M., Kandere, K., Boucher, W., Letourneau, R., Jeudy, S., Fitzgerald, K., Spear, K., Athanassiou, A. and Theoharides, T.C. Azelastine inhibits histamine and tryptase release from human umbilical cord blood-derived cultured mast cells, as well as rat skin mast cell-induced vascular permeability: comparison to olopatadine. *Allergy and Asthma Proc.* 23:45-51, 2002.
109. Kempuraj, D., Huang, M., Kandere, K., Boucher, W., Letourneau, R., Jeudy, S., Fitzgerald, K., Spear, K., Athanassiou, A. and Theoharides, T.C. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood derived cultured mast cells. *Annals Allergy, Asthma and Immunol.* 88:501-506, 2002.

110. Di Gioacchino, M., Verna, N., Cavallucci, E., Paolini, F., Caruso, R., Grana, M., Schiavone, C., Di Iorio, A., Ramondo, S., Reale, M., Paganelli, R., Theoharides, T.C. Steroid and antihistamines modulate RANTS release in cultured peripheral blood mononuclear cells of atopic patients. *Int. J. Immunopathol. Pharmacol.* 15:27-34, 2002.
111. Huang, M., Pang, X., Letourneau, R., Boucher, W. and Theoharides, T.C. Acute stress induces cardiac mast cell activation and histamine release effects that are increased in apolipoprotein E knockout mice. *Cardiovascular Res.* 55:150-160, 2002.
112. Huang, M., Berry, J., Kandere, K., Lytinas, M., Karalis, K. and Theoharides, T.C. Mast cell deficient W/W^v mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. *Int. J. Immunopathol. Pharmacol.* 15: 249-254, 2002.
113. Theoharides, T.C., Boucher, W., Spear, K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. *Int. Arch. Allergy Immunol.* 128:334-350, 2002.
114. Chandler, N., Jacobson, S., Esposito, P., Connolly, R. and Theoharides, T.C. Acute stress shortens the time to onset of experimental allergic encephalomyelitis in SJL/J mice. *Brain, Behavior Immunity* 16:757-763, 2002.
115. Di Gioacchino, M., Verna, N., Cavallucci, E., Paolini, F., Caruso, R., Grana, M., Schiavone, C., Di Iorio, A., Ramondo, S., Reale, M., Paganelli, R. and Theoharides, T.C. Steroid and antihistamines modulate RANTES release in cultured peripheral blood mononuclear cells of atopic patients. *Intl. J. Immunopathol. Pharmacol.* 15:27-34, 2002
116. Esposito, P., Kandere, K., Chandler, N., Basu, S., Jacobson, S., Connolly, R., Tutor, D. and Theoharides, T.C. Corticotropin-releasing hormone (CRH) and brain mast cell regulate blood-brain-barrier (BBB) permeability induced by acute stress. *J. Pharmacol. Exp. Therap.* 303:1061-1066, 2002.
117. Alexandrakis, M., Seretakis, D., Letourneau, R., Boucher, W. and Theoharides, T.C. Inhibitory effect of retinoic acid on proliferation maturation and tryptase level in human leukemic mast cells (HMC-1). *Intl. J. Immunopathol. Pharmacol.* 16:1-5, 2003.
118. Esposito, P., Basu, S., Letourneau, R., Jacobson, and Theoharides, T.C. Corticotropin-releasing factor (CRF) can directly affect brain microvessel endothelial cells. *Brain Res.* 968:192-198, 2003.
119. Lytinas, M., Kempuraj, D., Huang, M., Boucher, W., Esposito, P. and Theoharides, T.C. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine –1 receptor antagonists. *Intl. Arch. Allergy Immunol.* 130: 224-231, 2003.
120. Madhappan, B., Kempuraj, D., Christodoulou, S., Boucher, W., Tsapikidis, S., Karagiannis, V., Athanassiou, A. and Theoharides, T.C. High levels of intrauterine corticotropin-releasing hormone, urocortin, tryptase and interleukin-8 in spontaneous abortions. *Endocrinology* 144:2285-2290, 2003.
121. Huang, M., Pang, X., Karalis, K. and Theoharides, T.C. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. *Cardiovascular Res.* 59:241-249, 2003.
122. Kandere-Grzybowska, K., Gheorghe, D., Priller, J., Esposito, P., Huang, M., Gerard, N. and Theoharides, T.C. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 knock-out mice. *Brain Res.* 980:213-220, 2003.
123. Alexandrakis, M.G., Kyriakou, D.S., Kempuraj, D., Huang, M., Boucher, W., Seretakis, D. and Theoharides, T.C. The isoflavone genistein inhibits proliferation and increases histamine content in human leukemic mast cells. *Allergy Asthma Proc.* 24:1-5, 2003.

124. Alexandrakis, M., Letourneau, R., Kempuraj, D., Kandere-Grzybowska, K., Huang, M., Christodoulou, S., Boucher, W., Seretakakis, D. and Theoharides, T.C. Flavonoids inhibit proliferation and increase mediator content in human leukemic mast cells (HMC-1). *Eur. J. Hematol.* 71:1-7, 2003.
125. Kempuraj, D., Basu, S., Huang, M., Kandere-Grzybowska, K., Boucher, W., Letourneau, R., Athanassiou, A. and Theoharides, T.C. Azelastine inhibits synthesis and secretion of IL-6, IL-8 and TNF- α , by reducing NF- κ B expression and intracellular calcium ion levels in human umbilical cord blood-derived cultured mast cells. *Intl. Arch. Allergy Immunol.* 132:231-239, 2003.
126. Sant, G.R., Propert, K.J., Hanno, P.M., Burks, D., Culkin, D., Diokno, A.C., Hardy, C., Landis, J.R., Mayer, R., Madigan, R., Messing, E.M, Peters, K., Theoharides, T.C., Warren, J., Wein, A.J., Ratner, V., Steers, W., Kusek, J.W., Nyberg, L.M. and the Interstitial Cystitis Clinical Trials Group (ICCTG). A Pilot clinical trial of oral pentosan polysulfate and hydroxyzine in interstitial cystitis. *J. Urol.* 170:810-815, 2003.
127. Kandere-Grzybowska, K., Letourneau, R., Kempuraj, D., Donelan, J., Paplawski, S., Boucher, W., Athanassiou, A. and Theoharides, T.C. Interleukin-1 induces vesicular secretion of interleukin-6 without degranulation from human mast cells. *J. Immunol.* 171:4830-4836, 2003.
128. Letourneau, R., Rozniecki, J.J., Dimitriadou, V., and Theoharides, T.C. Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis (EAE). *J. Neuroimmunol.* 145:18-26, 2003.
129. Kempuraj D, Lytinas M, Kandere-Grzybowska K, Papadopoulou N, Huang M, Madhappan B, Christodoulou S, Athanassiou A, Theoharides TC. Corticotropin-releasing hormone (CRH) and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology* 145:43-48, 2004.
130. Haggag, E.G., Abou-Moustafa, M.A., Boucher, W. and Theoharides, T.C. The effect of a herbal water-extract on histamine release from mast cells and on allergic asthma. *J. Herbal Pharmacotherapy* 3:41-54, 2003.
131. Upadhyya, B., Kontos, J., Ardeshirpour, F., Pye, J., Boucher, W., Theoharides, T.C., Dehmer, G., Deliarhyris, E.N. Relation of serum levels of mast cell tryptase to left ventricular systolic function, left ventricular volume or congestive heart failure. *J. Cardiac Failure* 10:31-35, 2004.
132. Green, M., Sant, G.R. and Theoharides, T.C. Increased expression of intercellular adhesion molecules in the bladder of interstitial cystitis patients. *Urology* 63:688-693, 2004.
133. Gambi, R., Reale, M., Iarlori, C., Salone, A., Toma, L., Paladini, C., De Luca, G., Feliciani, C., Salvatore, M., Salerno, R.M., Theoharides, T.C., Conti, P., Exton, M. and Gambi, D. Alzheimer patients treated with an AChE inhibitor show higher IL-4 and lower IL-1 β levels and expression in peripheral blood mononuclear cells. *J. Clin. Psychopharmacol.* 24:314-321, 2004.
134. Kempuraj, D., Papadopoulou, N., Stanford, E.J., Christodoulou, S., Madhappan, B., Sant, G.R., Theoharides, T.C. Increased numbers of activated mast cells in endometriosis. *Am. J. Reprod. Immunol.* 52:267-275, 2004.
135. Deliarhyris, E.N., Upadhyya, B., Sane, D.C., Dehmer, G.J., Pye, J., Smith, S.C. Jr, Boucher, W.S., Theoharides T.C. Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. *Atherosclerosis.* 178:381-386, 2005.
136. Theoharides, T.C. and Sant, G.R. A pilot open label study of Cystoprotek in interstitial cystitis,. *Intl. J. Immunopathol. Pharmacol.* 18: 183-188, 2005.
137. Kempuraj, D., Madhappan, B., Christodoulou, S, Boucher, W., Cetrulo, C.L. and Theoharides, T.C. Inhibition of pro-inflammatory mediator release from human umbilical cord-derived cultured mast cells by select flavonols. *Br. J. Pharmacol.* 145:934-944, 2005.

138. Cao, J., Papadopoulou, N., Kempuraj, D., Boucher, W.S., Sugimoto, K., Cetrulo, C.L. and Theoharides TC. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor (VEGF). *J. Immunol.* 174:7665-7675, 2005.
139. Kalogeromitros, D., Kempura,j D., Katsarou-Katsari, A., Gregoriou, S., Makris, M., Boucher, W., Theoharides, T.C. Theophylline as add-on therapy in patients with delayed pressure urticaria: a prospective self-controlled study. *Int. J. Immunopathol. Pharmacol.* 18:595-602, 2005.
140. Papadopoulou, N., Kalogeromitros, D., Staurianeas, N.G.and Theoharides, T.C. CRH receptor and histidine decarboxylase expression in chronic urticaria. *J. Invest. Dermatol.* 125:952-955, 2005.
141. Papadopoulou, N., OLeson, L., Kempuraj, D., Donelan, J., Cetrulo, C.L., Theoharides, T.C. Expression and regulation of corticotropin-releasing hormone receptors in human umbilical cord blood derived mast cells. *J. Mol. Endocrinol.* 35:R1-R8, 2005.
142. Cao, J., Cetrulo, C.L. and Theoharides, T.C. Corticotropin-releasing hormone (CRH) induces vascular endothelial growth factor (VEGF) release from human mast cells via the camp/PKA/p38 MAPK pathway. *Mol. Pharmacol.*69:998-1006, 2006.
143. Logothetis, I., Mylonas, I.A., Baloyaniis, S., Pashalidou, M., Orologas, A., Zafeiropoulos, A., Kosta, V. and Theoharides, T.C. A pilot, open label clinical trial using hydroxyzine in multiple sclerosis. *Int. J. Immunopathol. Pharmacol.* 18:771-778, 2005.
144. Kalogeromitros, D., Kempuraj, D., Katsarou-Katsari, A., Makris, M., Gregoriou, S., Papalioidis, D. and Theoharides, T.C. Theophylline as “add-on” therapy to cetirizine in patients with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled pilot study. *Int. J. Allergy Immunol.* 139:258-264, 2006.
145. Donelan, J., Marchand, J., Kempuraj, D., Papadopoulou, N., Papalioidis, D. and Theoharides, T.C. Corticotropin-releasing hormone receptor 1 (CRHR-1) association with perifollicular mouse skin mast cells. *J. Inv. Dermatol.* 126:932-935, 2006.
146. Kandere-Grzybowska, K., Kempouraj, S., Cao, J. and Theoharides, T.C. Regulation of IL-1-induced selective IL-6 release from human mast cells. *Br. J. Pharmacol.* 148:208-215, 2006.
147. Donelan, J., Papadopoulou, N., Marchand, J., Kempuraj, D., Lytinas, M., Boucher, W., Papalioidis, D. and Theoharides, T.C. Corticotropin-releasing hormone (CRH) induces skin vascular permeability through a neurotensin (NT)-dependent process. *Proc. Natl. Acad. Sci. USA* 103:7759-7764, 2006.
148. Cao, J., Boucher, W., Donelan, J. and Theoharides, T.C. Intravesical corticotropin-releasing hormone (CRH) induces mast cell-dependent vascular endothelial growth factor (VEGF) release from mouse bladder explants. *J. Urol.* 176:1208-1213, 2006.
149. Kempuraj, D., Castellani, M.L., Petrarca, C., Frydas, S., Conti P., Theoharides, T.C., Vecchiet, J. Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. *Clin. Exp. Med.* 6(4):150-156, 2006.
150. Castellani, M.L., Kempuraj, D., Frydas, S., Theoharides, T.C., Simeonidou, I., Conti, P., Vecchiet, J. Inhibitory effect of quercetin on tryptase and MCP-1 chemokine release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. *Neuroimmunomodulation* 13(3):179-186, 2006.
151. Castellani, M.L., Perrella, A., Kempuraj, D.J., Boucher, W., Tagen, M., Salini, V., Vecchiet, J., Tete, S., Frydas, S., Theoharides, T.C., Conti, P. Immunological activation of human umbilical cord blood mast cells induces tryptase secretion and interleukin-6, and histidine decarboxiyase mRNA gene expression. *Pharmacol Res.* 55:57-63, 2006.

152. Vasiadi, M., Kempuraj, D., Boucher, W., Kalogeromitros, D. and Theoharides, T.C. Progesterone inhibits mast cell secretion. *Intl. J. Immunopathol. Pharmacol.* 19:787-794, 2006.
153. Bhattacharya, K., Farwell, K., Huang, M., Kempuraj, D., Donelan, J., Papaliadis, D, Vasiadi, M. and Theoharides, T.C. Lower serum IL-6 and less cardiac tissue necrosis in mast cell deficient W/W^v mice following myocardial ischemia-reperfusion. *Intl. J. Immunopathol. Pharmacol.* 20:69-74, 2007.
154. Boucher, W., Cao, J., Kempuraj, D., Donelan, J. and Theoharides, T.C. Intravesical IPD inhibits experimental bladder inflammation. *J. Urol.* 177:1186-1190, 2007.
155. Kalogeromitros, D., Syrigou, E., Makris, M., Kempuraj, D., Stavrianeas, N., Vasiadi, M., Theoharides, T.C. Nasal provocation of allergic rhinitis patients and the hypothalamic-pituitary-adrenal-axis. *Annals Allergy, Asthma, Immunol.* 98:269-273, 2007.
156. Tagen, M., Stiles, L., Kalogeromitros, D., Gregoriou, S., Kempuraj, D., Makris, M., Donelan, J., Vasiadi, M., Staurianeas, G., Theoharides, T.C. Skin corticotropin-releasing hormone receptor expression in psoriasis. *J. Inv. Dermatol.* 127:1789-91, 2007.
157. Kalogeromitros, D., Papagerorgiou, C., Gregoriou S, Chatziantonakis, N., Makris, M., Spanoudaki, N., Rabavilas, A., Rigopoulos, D., Theoharides, T.C. Depressive symptoms in urticaria patients treated with first or second-generation histamine-1 receptor antagonists. *J. Clin. Psychopharmacol.* 27:404-466, 2007.
158. Sugimoto, K., Theoharides, T.C., Kempuraj, D., Conti, P. Response of spinal myoclonus to combination therapy of autogenic training and biofeedback. *Biospsychosoc. Med.*, 1:18, 2007.
159. Speranza, L., De Lutiis, M.A., Shaik, Y.B., Felaco, M., Patrino, A., Tetè, A., Mastrangelo, F., Madhappan, B., Castellani, M.L., Conti, F., Vecchiet, J., Theoharides, T.C., Conti, P., Grilli, A. Localization and activity of iNOS in normal human lung tissue and lung cancer tissue. *Int. J. Biol. Markers* 22:226-231, 2007.
160. Boucher, W., Stern, J., Kempuraj, D., Papaliadis, D., Kotsinyan, V., Cohen, M.S. and Theoharides, T.C. Intravesical nanocrystalline silver inhibits experimental bladder inflammation. *J. Urol.* 179:1598-602, 2008.
161. Karapanou, V., Kempuraj, D., Theoharides, T.C. Interleukin-8 is increased in gingival crevicular fluid from patients with acute pulpitis. *J. Endodontics* 34:148-151, 2008.
162. Papaliadis, D., Boucher, W., Kempuraj, D., Theoharides, T.C. The flavonoid luteolin inhibits niacin-induced flush. *Br. J. Pharmacol.* 153:1382-1387, 2008.
163. Maffini, M.V., Soto, A.M., Sonnenenschein, C., Theoharides, T.C. Lack of c-kit receptor promotes mammary tumors in NMU-treated Ws/Ws rats. *Cancer Cell International* 8:5, 2008.
164. Kalogeromitros, D., Makris, M., Cliva, C., Aggelides, X., Kempuraj, D., Theoharides, T.C. A quercetin containing supplement reduces niacin-induced flush in humans. *Intl. J. Immunopathol. Pharmacol.* 21:467-472, 2008.
165. Kempuraj, D., Tagen, M., Iliopoulou, B.P., Clemons, A, Vasiadi, M., Boucher, W., House, M., Wolfberg, A., Theoharides, T.C. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. *Br. J. Pharmacol.* 155(7):1076-84, 2008.
166. Papaliadis, D., Boucher, W., Kempuraj, D., Michaelian, M., Wolfberg, A, House, M., Theoharides, T.C. Niacin-induced "flush" involves release of PGD₂ from mast cells and serotonin from platelets: evidence from human cells *in vitro* and an animal model. *J. Pharmacol. Exp. Therap.* 327(3):665-672, 2008.

167. Katsarou-Katsari, A., Makris, M., Lagogianni, E., Gregoriou, S., Theoharides, T., Kalogeromitros, D. Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study. *J. European Acad. Dermatol. Venereol.* 22(12):1405-11, 2008.
168. Castellani, M.L., Ciampoli, C., Felaco, M., Tetè, S., Conti, C.M., Salini, V., De Amicis, D., Orso, C., Antinolfi, P.L., Caraffa, A., Cerulli, G., Boscolo, P., Theoharides, T.C., Conti, P., Kempuraj, D. Neuropeptide substance P induces mRNA expression and secretion of CXCL8 chemokine, and HDC in human umbilical cord blood mast cells. *Clin Invest Med.* 31(6):E362-72, 2008
169. Theoharides T.C., Vakali, S., Kempuraj, D., Sant, G.R. Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek-an oral multiagent natural supplement. *Canadian J. Urol.* 15:4410-4414, 2008.
170. Huang, M., Kempuraj, D., Papadopoulou, N., Kourelis, T., Donelan, J., Manola, A., Theoharides, T.C. Urocortin induces IL-6 production from rat cardiomyocytes through of p38 MAP kinase, RSK and NF- κ B activation. *J. Mol. Endocrinol.* 42(5):397-405, 2009.
171. Castellani, M.L., Conti, P., Felaco, M., Vecchiet, J., Ciampoli, C., Cerulli, G., Boscolo, P., Theoharides, T.C. Substance P upregulates LTB₄ in rat adherent macrophages from granuloma induced by KMnO₄. *Neurotox Res.* 15(1):49-56, 2009.
172. Castellani, M.L., Vecchiet, J., Salini, V., Conti, P., Theoharides, T.C., Caraffa, A., Antinolfi, P., Tetè, S., Ciampoli, C., Cuccurullo, C., Cerulli, G., Felaco, M., Boscolo, P. Stimulation of CCL2 (MCP-1) and CCL2 mRNA by substance P in LAD2 human mast cells. *Transl Res* 154(1):27-33, 2009.
173. Tagen, M., Elorza A, Boucher W, Kepley CL, Sirihai, O., Theoharides, T.C. The mitochondrial uncoupling protein 2 (UCP2) inhibits mast cell activation and reduces histamine content. *J. Immunol.* 15;183(10):6313-9, 2009.
174. Theoharides TC. Autism spectrum disorders and mastocytosis. *Int J Immunopathol Pharmacol* 22(4):859-65, 2009.
175. Castellani ML, Vecchiet J, Salini V, Conti P, Theoharides TC, Caraffa A, Antinolfi P, Tetè S, Ciampoli C, Cuccurullo C, Cerulli G, Felaco M, Boscolo P. Stimulation of CCL2 (MCP-1) and CCL2 mRNA by substance P in LAD2 human mast cells. *Transl Res* 154(1):27-33, 2009.
176. Castellani ML, Conti P, Felaco M, Vecchiet J, Ciampoli C, Cerulli G, Boscolo P, Theoharides TC. Substance P upregulates LTB₄ in rat adherent macrophages from granuloma induced by KMnO₄. *Neurotox Res* 15(1):49-56, 2009.
177. Kalogeromitros D, Makris M, Koti I, Chliva C, Mellios A, Avgerinou G, Theoharides TC. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety. *Allergol Immunopathol (Madr).* 2010 Mar-Apr;38(2):69-73.
178. Vasiadi, M., Kalogeromitros, D., Kempuraj, D., Clemons, A., Zhang, B., Chliva, C., Makris, M., Wolfberg, A., House, M., Theoharides, T.C. Rupatadine inhibits pro-inflammatory mediator secretion from human mast cells triggered by different stimuli. *Int. Arch. Allergy Immunol.* 151(1):38-45, 2010.
179. Theoharides TC, Zang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos K-D, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S, Conti P. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. *Proc Natl Acad Sci USA* 107(9):4448-4453, 2010.
180. Kempuraj D, Asadi S, Zhang B, Manola A, Hogan J, Peterson E, Theoharides TC. Mercury induces VEGF release from human mast cells. *J Neuroinflammation* 7(1):20, 2010.

181. Boucher B, Kempuraj D, Michaelian M, Theoharides TC. Corticotropin-releasing hormone (CRH)-receptor 2 is required for acute stress-induced bladder vascular permeability. *Br J Urol Int* 106(9):1394-9, 2010.
182. Angelidou A, Francis K, Vasiadi M, Alysandratos KD, Kempuraj D, Theoharides A, Lykouras L, Kalogeromitros D., Theoharides TC. Increased serum neurotensin in young children with autism. *J Neuroinflamm* 7:48, 2010.
183. Kempuraj D, Conti P, Tagen M, Kalogeromitros D, Vasiadi M, Alysandratos K-D, Kourelis T, Gregoriou S, Makris M, Staurianeas NG, Theoharides TC. IL-32 is increased along with tryptase in lesional psoriatic skin is up-regulated by substance P in human mast cells. *European J Dermatol* 20(6):865-867, 2010.
184. Alysandratos K-D, Angelidou A, Zhang B, Vasiadi M, Theoharides TC. Increased affected skin gene expression of thymic stromal lymphopoietin in atopic dermatitis. *Annals Allergy Asthma Immunol* 105(5):403-4, 2010.
185. Rozniecki JJ, Sahagian G, Jacobson S, Kempuraj D, Zhang B, Theoharides TC. Acute restraint stress induces brain metastases of luciferase-tagged breast cancer cells in mice. *Brain Research* 1366:204-210, 2010.
186. Zhang B, Angelidou A, Alysandratos KD, Vasiadi M, Francis K, Asadi S, Theoharides A, Sideri K, Lykouras L, Kalogeromitros D, Theoharides TC. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. *J Neuroinflammation* 7(1):80, 2010.
187. Asadi S, Zhang B, Weng Z, Angelidou A, Kempuraj D, Alysandratos KD, Theoharides TC. Luteolin and thiosalicylate inhibit HgCl₂ and thimerosal-induced VEGF release from human mast cells. *Int J Immunopathol Pharmacol* 23(4):1015-20., 2010.
188. Clemons A, Vasiadi M, Kempuraj D, Kourelis T, Tagen M, House A, Theoharides TC. Amitriptyline and prochlorperazine inhibit human mast cell pro-inflammatory mediator release-possible relevance to chronic fatigue syndrome. *J Clin Psychopharmacol* 31(3): 385-387, 2011.
189. Zhang B, Alysandratos KD, Angelidou A, Asadi S, Sismanopoulos N, Delivanis D-A, Weng Z, Miniati A, Vasiadi M, Katsarou-Katsari A, Miao B, Leeman S, Kalogeromitros D. Theoharides TC. Human mast cell degranulation and granule-stored TNF secretion requires mitochondrial translocation to sites of exocytosis. *J Allergy Clin Immunol* 127(6):1522-1531, 2011.
190. Asadi S, Alysandratos-K-D, Angelidou-A, Miniati A, Sismanopoulos N, Vasiadi M, Zhang B, Kalogeromitros D, Theoharides TC. Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. *J Invest Dermatol*. Feb;132(2):324-9, 2012.
191. Zhang B, Weng Z, Sismanopoulos N, Alysandratos K-D, Angelidou A, Asadi S, Shirihai O, Theoharides TC. Mitochondria distinguish granule-stored from *de novo* synthesized, tumor necrosis factor secretion in human mast cells. *Intl Arch Allergy Immunol*. 27;159(1):23-32, 2012.
192. Vasiadi M, Therianou A, Sideri K, Smyrnioti M, Delivanis A-D, Sismanopoulos N, Asadi S, Katsarou-Katsari A, Petrakopoulou D, Theoharides A, Antoniou C, Stavrianeas N, Kalogeromitros D, Theoharides TC. Increased serum CRH with decreased lesional skin CRH-R1 gene expression in atopic dermatitis and psoriasis. *J Allergy Clin Immunol*. 129(5):1410-3, 2012.
193. Vasiadi M, Therianou A, Alysandratos KD, Katsarou-Katsari A, Petrakopoulou Th, Theoharides A, Papadavid E, Stavrianeas N, Antoniou C, Kalogeromitros D, Theoharides TC. Serum neurotensin (NT) is increased in psoriasis and induces VEGF release from human mast cells. *Br J Dermatol*. Jun;166(6):1349-52, 2012.
194. Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, Theoharides TC. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. *PLoS One*. 7(3):e33805, 2012.

195. Sismanopoulos N, Delivanis DA, Alysandratos KD, Angelidou A, Vasiadi M, Therianou A, Theoharides TC. IL-9 Induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in Atopic Dermatitis. *PLoS One*. 7(3):e33271, 2012.
196. Theoharides TC, Asadi S, Panagiotidou S. A case series of a luteolin formulation (NeuroProtek®) in children with autism spectrum disorders. *Intl J Immunopathol Pharmacol*. Apr-Jun;25(2):317-23, 2012.
197. Asadi S, Theoharides TC. CRH and extracellular mitochondria augment IgE-stimulated human mast cell VEGF release, which is inhibited by luteolin. *J Neuroinflamm* 4;9(1):85, 2012.
198. Alysandratos K-D, Asadi S, Angelidou A, Zhang B, Sismanopoulos N, Yang H, Theoharides TC. Neurotensin and CRH interactions augment human mast cell activation. *PLoS One* 7(11):e48934, 2012.
199. Zhang B, Therianou A, Weng Z, Asadi S, Sismanopoulos N, Vasiadi M, Theoharides A, Miniati A, Katsarou-Katsari A, Theoharides TC. Stimulated human mast cells secrete mitochondrial components with autocrine and paracrine inflammatory actions. *PLoS One* 7(12):e49767, 2012.
200. Vasiadi M, Mondolfi AP, Alysandratos K-A, Angelidou A, Therianou A, Katsarou-Katsari A, Petrakopoulou Th, Theoharides TC. Neurotensin serum levels and skin gene expression are increased in atopic dermatitis. *Br J Dermatol* 169(3):695-9, 2013.
201. Alevizos M, Karagkouni A, Vasiadi M, Sismanopoulos N, Makris M, Kalogeromitros D, Theoharides TC. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. *Ann Allergy Asthma Immunol* 111(6):542-7, 2013.
202. Miniati A, Weng Z, Zhang B, Therianou A, Vasiadi M, Nicolaidou E, Stratigos AJ, Antoniou C, Theoharides TC. Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. *Clin Exp Dermatol* 39(1):54-7, 2014.
203. Papatthasiou E, Flavia T, Griffin T, Arguello E, Finkelman M, Hanley J, Theoharides TC. IFN- γ , but not IL-4, IL-33 or TSLP, Gingival Crevicular Fluid levels are increased in inflamed, but not healthy sites in patients with periodontal disease. *J Periodontal Res* 49(1):55-61, 2014.
204. Alhelal MA, Palaska I, Panagiotidou S, Letourneau R, Theoharides TC. Trigeminal nerve stimulation triggers oral mast cell activation and vascular permeability. *Ann Allergy Asthma Immunol* 112(1):40-5, 2014.
205. Weng Z, Patel AB, Vasiadi M, Therianou A, Theoharides TC. Luteolin inhibits human keratinocyte activation and decreases NF- κ B induction that is increased in psoriatic skin. *PlosOne* 28;9(2):e90739, 2014.
206. Karamitopoulou E, Shoni M, Theoharides TC. Increased number of non-degranulated mast cells in pancreatic ductal adenocarcinoma but not in acute pancreatitis. *Int J Immunopathol Pharmacol* 27(2):213-20, 2014.
207. Vasiadi M, Newman J, Theoharides TC. Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome. *J Neuroinflammation* 11(1):168, 2014.
208. Tsilioni I, Dodman N, Petra AI, Taliou A, Francis K, Moon-Fanelli A, Shuster L, Theoharides TC. Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism. *Transl Psychiatry* 4:e466, 2014.
209. Weng Z, Patel AB, Panagiotidou S, Theoharides TC. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. *J Allergy Clin Immunol* 135(4):1044-1052.e5, 2014.
210. Tsilioni I, Taliou A, Francis K, Theoharides TC. Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6. *Transl Psychiatry* 5:e647, 2015.

211. Tsilioni I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC. Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with Fibromyalgia Syndrome, implicating mast cells. *J Pharmacol Exp Ther* 356(3):664-667, 2016.
212. Weng Z, Zhang B, Tsilioni I, Theoharides TC Nanotube Formation: A Rapid Form of "Alarm Signaling"? *Clin Ther* 38(5):1066-72, 2016.
213. Tellechea A, Leal EC, Kafanas A, Auster ME, Kuchibhotla S, Ostrovsky Y, Tecilazich F, Baltzis D, Zheng Y, Carvalho E, Zabolotny JM, Weng Z, Petra A, Patel A, Panagiotidou S, Pradhan-Nabzdyk L, Theoharides TC, Veves A. Mast Cells Regulate Wound Healing in Diabetes. *Diabetes* 65(7):2006-2019, 2016.
214. Weng Z, Zhang B, Tsilioni I, Theoharides TC. Nanotube formation: A rapid form of "Alarm Signaling"? *Clin Ther* 38(5):1066-72, 2016.
215. Theoharides TC, Stewart JM. Post-Lyme Syndrome-Associated Polyneuropathy Treated With Immune Immunoglobulin and a Luteolin-Containing Formulation. *J Clin Psychopharmacol* 36(3):290-1, 2016.
216. Patel AB, Tsilioni I, Leeman SE, Theoharides TC. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. *Proc Natl Acad Sci U S A* 113: E7049–E7058, 2016.
217. Palaska I, Gagari E, Theoharides TC. The effects of *P. gingivalis* and *E. coli* LPS on the expression of proinflammatory mediators in human mast cells and their relevance to periodontal disease. *J Biol Regul Homeost Agents* 30(3):655-664, 2016.
218. Theoharides TC, Stewart JM, Tsilioni I. Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. *Int J Immunopathol Pharmacol* 30(2):146-151, 2017.
219. Taracanova A, Alevizos M, Karagkouni A, Weng Z, Norwitz E, Conti P, Leeman SE, Theoharides TC. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. *Proc Natl Acad Sci U S A* 114(20):E4002-E4009, 2017.
220. Theoharides TC, Taracanova A, Tsilioni I, Conti P, Leeman SE. Reply to Fattori et al.: Action of SP and IL-33 on mast cells. *Proc Natl Acad Sci U S A* 114(47):E10036. 2017.
221. Patel AB, Theoharides TC. Methoxyluteolin Inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells. *J Pharmacol Exp Ther* 361(3):462-471, 2017.
222. Petra AI, Tsilioni I, Taracanova A, Katsarou-Katsari A, Theoharides TC. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. *Allergy Asthma Proc* 39(2):153-160, 2018.
223. Patel AB, Tsilioni I, Weng Z, Theoharides TC. TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin. *Exp Dermatol* 27(2):135-143, 2018.
224. Tsilioni I, Theoharides TC. Extracellular vesicles are increased in the serum of children with autism spectrum disorder, contain mitochondrial DNA and stimulate human microglia to secrete IL-1b. *J Neuroinflamm* 15(1):239, 2018.
225. Theoharides TC, Leeman SE. Effect of IL-33 on de novo synthesized mediators from human mast cells. *J Allergy Clin Immunol* 143(1):451, 2019.

226. Taracanova A, Tsilioni I, Conti P, Leeman SE, Theoharides TC. Substance P and IL-33 administered together markedly increase IL-1 α gene expression and secretion from human mast cells, responses that are inhibited by the natural flavone tetramethoxyluteolin. *Proc Natl Acad Sci U S A* 115(40):E9381-E9390, 2018.
227. Therianou A, Vasiadi M, Delivanis DA, Petrakopoulou T, Katsarou-Katsari A, Antoniou C, Stratigos A, Tsilioni I, Katsambas A, Rigopoulos D, Theoharides TC. Mitochondrial dysfunction in affected skin and increased mitochondrial DNA in serum from patients with psoriasis. *Exp Dermatol* 28(1):72-75. 2019.
228. Gross AR, Theoharides TC. Chondroitin sulfate inhibits secretion of TNF and CXCL8 from human mast cells stimulated by IL-33. *BioFactors* 45(1):49-61, 2019.
229. Tsilioni I, Pipis H, Freitag MSC, Izquierdo MDC, Freitag K, Theoharides TC. Effects of an extract of salmon milt on symptoms and serum TNF and Substance P in patients with Fibromyalgia Syndrome. *Clin Ther* 41(8):1564-1574.e2, 2019.
230. Almehmandi KA, Tsilioni I, Theoharides TC. Increased expression of microRNA-155 in the amygdala of children with autism spectrum disorder. *Autism Research* Sep 10;00: 1–6, 2019.
231. Lonergan A, Theoharides T, Tsilioni E, Rebeiz E. Substance P and Hemokinin 1 in nasal lavage fluid of patients with Chronic Sinusitis and Nasal Polyposis. *OTO Open* Sep 12;3(3):2473974X19875076, 2019.
232. Tellechea A, Bai S, Dangwal S, Theoharidis G, Nagai M, Koerner S, Cheong JE, Bhasin S, Shih TY, Zheng Y, Zhao W, Zhang C, Li X, Kounas K, Panagiotidou S, Theoharides T, Mooney D, Bhasin M, Sun L, Veves A. Topical Application Of A Mast Cell Stabilizer Improves Impaired Diabetic Wound Healing. *J Invest Dermatol* . 140(4):901-911.e11, 2020.
233. Tsilioni I, Patel A, Pantazopoulos H, Barretta S, Conti P, Leeman SE, Theoharides TC. IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin. *Proc Natl Acad Sci USA* 116(43):21659-21665, 2019.
234. Bawazeer MA, Theoharides TC. IL-33 stimulates human mast cells via MAPK and NF- κ B, inhibited by tetramethoxyluteolin. *Eur J Pharmacol*. Oct 26:172760. PMID: 31669588
235. Tsilioni E, Pantazopoulos H, Conti P, Leeman SE, Theoharides TC. IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder. *Proc Natl Acad Sci USA*. 117(28):16475-16480, 2020.
236. Pani P, Irimi Tsilioni I, McGlennen R, Carrie Brown C, Hawley CE, Theoharides TC, Papatheanasiou E. Association of IL-1B (3954)-SNP with increased IL-1beta levels in gingival crevicular fluid (GCF) and red complex species in patients with periodontitis. *J Period Res*. 9(13):1425-1434, 2020.
237. Demopoulos C, Antonopoulou S, Theoharides TC. COVID-19, microthromboses, inflammation, and platelet activating factor. *Biofactors*. 46(6):927-933, 2020.

e. Reviews/Book Chapters

1. Theoharides, T.C. Liposomes as carriers of biologically active molecules. *Folia Biochemica et Biologica Graeca* 14:11-21, 1978.
2. Theoharides, T.C. Liposomes as carriers of cytostatic drugs. In *Biological Basis of Cancer Chemotherapy* (L. Boutis, ed.), pp. 67-86. Theagenion Medical Institute: Thessaloniki, Greece, 1978.
3. Theoharides, T.C. Somatostatin: mast cell secretagogue and physiological implications. *Annual of Medicine* (in Greek) 13:258-272, 1980.
4. Theoharides, T.C. Polyamines spermidine and spermine as modulators of calcium dependent immune processes. *Life Sciences* 27:703-713, 1980.
5. Theoharides, T.C. The mechanism of secretion and the physiological role of the mast cell. *Pediatric Chronicle* 10:5-23, 90-113, 1981.
6. Tsakalos, N.D. and Theoharides, T.C. Agents transferring cellular immunity (transfer factor) or dialyzable leukocyte extract (DLE): an immunopharmacological enigma. *Materia Medica Greca* 9:541-550, 1981.
7. Theoharides, T.C. Mast cell secretion: basis for jelly-fish poisoning and prospects for relief. *U.N. Workshop on Jelly Fish Blooms* 1:63-73, 1984.
8. Theoharides, T.C. Allergy and antihistamines: a new riddle. *Archives of Dermatology* 122:995-996, 1986.
9. Theoharides, T.C. Neuroimmunology of tumor growth: the role of mast cells. *International Journal of Immunopathology and Pharmacology* 1:89-98, 1988.
10. Theoharides, T.C. Histamine₂ (H₂)-receptor antagonists in the treatment of urticaria. *Drugs* 37: 345-355, 1989.
11. Theoharides, T.C. Central effects of non-opioid analgesics. *Latin American Symposium on Antipyretic Analgesics in Perspective* (W.O. Spitzer and R. Campo, eds.), pp. 42-54, SIS: London, 1989.
12. Blatsios, V. and Theoharides, T.C. The importance of interleukin 2 in the treatment of cancer. *Hellenic Armed Forces Medical Review* 23:373-37, 1989.
13. Theoharides, T.C. Mast cells: the immune gate to the brain. *Life Sciences* 46:607-617, 1990.
14. Theoharides, T.C. and Sant, G. Mast cell activation in interstitial cystitis. *Seminars in Urology* 9:74-87, 1991.
15. Goumenos, G., Theoharides, T.C. and Smulow, J. New aspects of the role of mast cells in periodontal disease. *Periodontologica Analecta*, 3166-174, 1992.
16. Sant, G.R. and Theoharides, T.C. The role of the mast cell in interstitial cystitis. *Urologic Clinics of North America* 21:41-53, 1994.
17. Theoharides, T.C. Hydroxyzine in the treatment of interstitial cystitis. *Urologic Clinics of North America* 21:113-119, 1994.
18. Theoharides, T.C. Antidepressants, antihistamines, interstitial cystitis and cancer. *Journal of Urology* 154:1481-1482, 1995.
19. Theoharides, T.C. Neuroimmunoendocrine basis of interstitial cystitis. *Aktuelle Urology* (Germany), 1996.

20. Theoharides, T.C. and Sant, G.R. The mast cell as a neuroimmunoendocrine effector in interstitial cystitis. In: *Interstitial Cystitis*, edited by Sant, G.R., pp. 101-108. New York: Raven Press, 1997.
21. Theoharides, T.C. and Sant, G.R. Hydroxyzine for symptomatic relief of interstitial cystitis symptoms. In: *Interstitial Cystitis*, edited by Sant, G.R., pp. 241-245. New York: Raven Press, 1997.
22. Theoharides, T.C. Mast cell: a neuroimmunoendocrine master player. *International Journal of Tissue Reactions* 18:1-21, 1996.
23. Theoharides, T.C., Pang, X., Letourneau, R. and Sant, G.R. Interstitial cystitis: a neuroimmunoendocrine disorder. *Annals NY Academy of Science* 840:619-634, 1998.
24. Theoharides, T.C. and Sant, G.R. Hydroxyzine therapy for interstitial cystitis. *Urology* 49 (Supplement 5A):108-110, 1997.
25. Filippou, A., Sant, G.R. and Theoharides, T.C. Interstitial cystitis-The role of mast cells. *Hellenic Urology* 10:321-330, 1998.
26. Sant, G.R. and Theoharides, T.C. Interstitial cystitis. *Current Opinion in Urology* 9:297-302, 1999.
27. Alexandrakis, M. and Theoharides, T.C. Biologic actions of flavonoids on blood cells. *Hellenic Medicine* 65:210-219, 1999.
28. Filippou, A., Sant, G.R. and Theoharides, T.C. Mast cells in interstitial cystitis. *Urolog. Integr. Investig.*4:315-323, 1999.
29. Antelo, M., Filippou, A., Theoharides, T.C. and Sant, G.R. Medical treatment of interstitial cystitis. *Urolog. Integr. Investig.* 4:342-349, 1999.
30. Filippou, A., Theoharides, T.C. and Sant, G.R. Interstitial cystitis: a practical approach to diagnosis and treatment. *Aquarius (Netherlands IC Association Newsletter)*, 1-5, 1999.
31. Katsarou - Katsari A., Filippou A. and Theoharides, T.C. Effect of stress and other psychological factors on the pathophysiology and treatment of dermatoses. *Intl. J. Immunopathol. Pharmacol.* 12:7-11,1999.
32. Middleton, E., Kandaswami, C. and Theoharides, T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. *Pharmacol. Rev.* 52:673-751, 2000.
33. Theoharides, T.C. and Sant, G.R. New drugs for the treatment of interstitial cystitis. *Expert Opin. Investig. Drugs* 10:527-552, 2001.
34. Conti, P., Kempuraj, D., Boucher, W., Letourneau, R. and Theoharides, T.C. Mechanism by which IL-16 generated by mast cells mediates allergic inflammation. *Intl. J. Immunopathol. Pharmacol.* 14:1-4, 2001.
35. Theoharides, T.C., Kempuraj, D. and Sant, G.R. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. *Urology* 57 (Suppl 6A): 47-55, 2001.
36. Theoharides, T.C., Alexandrakis, M., Kempuraj, D. and Lytinas, M. Anti-inflammatory actions of flavonoids and structural requirements for new design. *Intl. J. Immunopathol. Pharmacol.* 14:119-127, 2001.
37. Samenuk, D., Link, M.S., Homoud, M.K., Contreras, R., Theoharides, T.C., Wang, P.J. and Estes, M. Adverse cardiovascular events temporarily associated with Ma Huang, an herbal source of ephedrine. *Mayo Clin Proc* 77:12-16, 2002.

38. Theoharides, T.C. and Kandere, K.. Mast cell involvement in neurogenic inflammation. In *Migraine: a Neuroinflammatory Disease?* Pp. 115-128, 1st Edition (*E.L.H. Spierings and M. Sanchez del Rio, eds.*), pp.115-32, Birkhäuser verlag:Basel, Switzerland, 2002.
39. Conti, P., Kempuraj D., Kandere K., Giacchino, M.D., Reale, M., Barbacane, R.C., Castellani, M.L., Mortari, U., Boucher, W., Letourneau, R. and Theoharides, T.C. IL-16 network in inflammation and allergy. *Allergy Asthma Proceedings*, 23:331-335, 2002.
40. Bielory, L., Kempuraj, D., and Theoharides, T.C. Topical immunopharmacology of ocular allergies. *Curr Opin Allergy Clin Immunol.* 2: 435-445, 2002.
41. Theoharides, T.C. Mast cells and stress: A psychoneuroimmunological perspective. *J. Clin. Psychopharmacol.*, 22:103-8, 2002.
42. Conti, P., Kempuraj, D., Di Gioacchino, M., Boucher, W., Letourneau, R., Kandere, K., Barbacane, R.C., Reale, M., Felaco, M., Frydas, S., Theoharides, T.C. Interleukin-6 and mast cells. *Allergy and Asthma Proc* 23: 331-335, 2002.
43. Conti, P., Reale, M., Barbacane, R.C. and Theoharides, T.C. Role of RANTES and MCP-1 in acute and chronic inflammatory reactions. *Intl. J. Immunopath. Pharmacol.*, in press.
44. Theoharides T.C. Antidepressants and risk of cancer: a case of misguided associations and priorities. *J. Clin. Psychopharmacol.* 23: 1-4, 2003.
45. Theoharides, T.C. Dietary supplements for arthritis and other inflammatory conditions: key role of mast cells and benefit of combining anti-inflammatory and proteoglycan products. *European J. Inflamm.* 1:128, 2003.
46. Theoharides, T.C. and Sant, G.R. Neuroimmune connections and regulation of function in the urinary bladder. In *Autonomic Neuroimmunology* (J. Bienenstock, E. Goetzl and M. Blennerhasset, eds.). *The Autonomic Nervous System (Series Editor: Geoffrey Burnstock)*, vol. 15:345 – 369. Harwood Academic Publishers: Reading, 2003.
47. Conti, P., Kempuraj, D., Frydas, S., Kandere, K., Boucher, W., Letourneau, R., Madhappan, B., Sugimoto, K., Christodoulou, S., Theoharides, T.C. IL-10, an inflammatory/inhibitory cytokine, but not always. *Immunol Lett*, 86:23-129, 2003.
48. Kempuraj, D., Frydas, S., Kandere, K., Madhappan, B., Letourneau, R., Christodoulou, S., Boucher, W., Riccioni, G., Conti, P., and Theoharides, T.C. Interleukin-19 (IL-19) network revisited. *Intl. J. Immunopath. Pharmacol.* 16:95-97, 2003.
49. Conti, P., Kempuraj, D., Frydas, S., Kandere, K., Boucher, W., Letourneau, R. Madhappan, B., Sugimoto, K., Christodoulou, S. and Theoharides, T.C. L-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. *Immunology Letters* 88:171-174, 2003.
50. Kempuraj, D., Frydas, S., Conti, P., Kandere, K., Boucher, W., Letourneau, R. Madhappan, B., Sugimoto, K., Christodoulou, S. and Theoharides, T.C. Interleukin-25 (or IL-17E): a new IL-17 family member with growth factor/inflammatory actions. *Intl. J. Immunopath. Pharmacol.* 16:185-188, 2003.
51. Conti, P., Huang, S., Frydas, S., Kempuraj, D., Barbacane, R.C., Grilli, A., Boucher, W., Letourneau, R., Madhappan, B., Papadopoulou, N., Di Gioacchino, M., De Lutiis, M., Theoharides, T.C. Interleukin-17 and the IL-17 family member network. *Immunol. Lett.* 88:171-174, 2003.
52. D’Orazio, N., Riccioni, G., Conti, P., Theoharides, T.C., Bollea, M.R. Conjugated linoleic acid: a functional food? *Intl. J. Immunopath. Pharmacol.* 16:215-220, 2003.

53. Maurer, M., Theoharides, T.C., Granstein, R.D., Bischoff, S.C., Bienenstock, J., Henz, B.M., Kovanen, P.T., Piliponsky, A.M., Kambe, N., Vliagoftis, H., Levi-Schaffer, F., Metz, M., Miyachi, H., Befus, D., Forsythe, P., Kitamura, Y., Galli, S. What is the physiological function of mast cells? *Exp. Dermatol.* 12:886-910, 2003.
54. Theoharides, T.C., Cochrane, D. Critical role of mast cells in neuroinflammatory diseases and the effect of acute stress. *J. Neuroimmunol.* 146:1-12, 2004.
55. Chiang, G., Patra, P., Letourneau, R., Jeudy, S., Boucher, W., Green, M., Sant, G.R. and Theoharides, T.C. Pentosanpolysulfate (Elmiron) is a potent inhibitor of mast cell histamine secretion. In *Bladder Disease: Research Concepts and Clinical Applications*, (A. Atala and D. Slade, Eds.). *Adv. Exp. Med. Biol.* 539:713-729, 2003.
56. Huang, S., Frydas, S., Conti, P., Kempuraj, D., Barbacane, R.C., Grilli, A., Boucher, W., Letourneau, R., Papadopoulou, N., Donelan, J., Madhappan, B., Theoharides, T.C., De Lutiis, M.A., Riccioni, G. and Sabatino, G. Interleukin-17: a revisited study. *Intl. J. Immunopathol. Pharmacol.* 17:1-4, 2004.
57. Theoharides, T.C., Conti, P. Mast cells: the Jekyll and Hyde of tumor growth. *Trends Immunol.* 25:235-241, 2004.
58. Kempuraj D, Donelan J, Frydas S, Iezzi T, Conti F, Boucher W, Papadopoulou NG, Madhappan B, Letourneau L, Cao J, Sabatino G, Meneghini F, Stellin L, Verna N, Riccioni G, Theoharides TC. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. *Int. J. Immunopathol. Pharmacol.* 17:103-106, 2004.
59. Conti, P., Huang, S., Frydas, S., Kempuraj, D., Barbacane, R.C., Grilli, A., Boucher, W., Letourneau, R., Madhappan, B., Papadopoulou, N., Di Gioacchino, M., De Lutiis, M., Theoharides, T.C. Interleukin-17 and interleukin-17 family member network. *Allergy Asthma Proc.* 25:17-21, 2004.
60. Theoharides, T.C., Bielory, L. Mast cells and mast cell mediators as targets of dietary supplements. *Ann. Allergy, Asthma Immunol.* 93 (Suppl 1):S24-S34, 2004.
61. Theoharides, T.C. Panic disorder, interstitial cystitis and mast cells. *J Clin. Psychopharmacol.* 24:361-364, 2004.
62. Theoharides, T.C., Donelan, J.M., Papadopoulou, N., Cao, J., Kempuraj, D. and Theoharides, T.C. Mast cells as targets of corticotropin-releasing factor and related peptides. *Trends Pharmacol. Sci.* 25:563-568, 2004.
63. Kempuraj, D., Konstantinidou, A., Karagouni, E., Boscolo, P., Ferro, F., Di Giannantonio, M., Conti, V.M.V., Doyle, R. and Theoharides, T.C. Cytokines and the brain. *Intl. J. Immunopath. Pharmacol.* 17:4, 2004.
64. Theoharides, T.C., Weinkauf, C. and Conti, P. Brain cytokines and neuropsychiatric disorders. *J. Clin. Psychopharmacol.* 24:577-581, 2004.
65. Riccioni, G., Di Ilio, C., Conti, P., Theoharides, T.C. and D'Orazio, N. Advances in therapy with antileukotriene drugs. *Ann. Clin. Lab. Sci.* 34:379-387, 2004.
66. Avgerinos, D.V. and Theoharides, T.C. Mesenteric traction syndrome or gut in distress. *Intl. J. Immunopathol. Pharmacol.* 18:195-199, 2005.
67. Theoharides, T.C., Donelan, J., Kandere-Grzybowska, K. and Konstantinidou A. The role of mast cells in migraine pathophysiology. *Brain Res. Rev.* 49:65-76, 2005.
68. Theoharides, T.C. and Sant, G.R. Immunomodulators for the treatment of interstitial cystitis. *Urology* 65:633-638, 2005.

69. Theoharides, T.C. Synovial mast cells in inflammatory arthritis. In *Encyclopedia of Molecular Cell Biology and Molecular Medicine* (ED Meyers, ed.), pp. 37-63. Wiley-VCH Verlag GmbH & Co. Weinheim, 2005.
70. Theoharides, T.C., Papaliadis, D., Tagen, M., Konstantinidou, A., Kempuraj, D. and Clemons A. Chronic fatigue syndrome, mast cells and tricyclic antidepressants. *J. Clin. Psychopharmacol.* 25:515-520, 2005.
71. Paus, R., Theoharides, T.C. and Arck, P.C. Neuroimmunoendocrine circuitry of the “brain-skin connection.” *Trends Immunol.* 27:32-39, 2006.
72. Theoharides, T.C. and O’Leary, M. Nutraceuticals in painful bladder syndrome/interstitial cystitis. *Semin. Prev. Altern. Med.* 2:6-14, 2006.
73. Lucas, H.J., Brauch, C.M., Settas, L. and Theoharides, T.C. Fibromyalgia-New concepts of pathogenesis and treatment. *Intl. J. Immunopathol. Pharmacol.* 19:5-10, 2006.
74. Arck, P.C., Slominski, A., Theoharides, T.C., Peters, E. and Paus, R. Neuroimmunology of stress: skin takes center stage. *J. Invest. Dermatol.* 126:1697-1704, 2006.
75. Theoharides, T.C. Migraines headaches: the immunologist’s view. *Hospital Chronicle Supplement*:79-83, 2006.
76. Theoharides, T.C. The role of mast cells in acute coronary syndromes. *Hospital Chronicles Supplement*:192-196, 2006.
77. Kumarasamy, N.A., Lam, F.S., Wang, A.L. and Theoharides, T.C. Glaucoma: current and developing concepts for pathology and treatment, *European J. Inflamm.* 19:129-137, 2006.
78. Theoharides, T.C. and Kalogeromitros, D. Mast cells in allergy and inflammation. *Annals New York Acad. Sci.* 1088:78-99, 2006.
79. Theoharides, T.C. and Konstantinidou, A. Corticotropin-releasing hormone and the blood-brain-barrier. *Frontiers Bioscience* 12:1615-1628, 2007.
80. Theoharides, T.C., Kempuraj, D., Tagen, M., Vasiadi, M. and Cetrullo, C.L. Human umbilical cord-derived mast cells: a unique model for the study of neuroimmunoendocrine interactions. *Stem Cell Rev.* 2:143-154, 2006.
81. Conti, P., Youinou, P., Theoharides, T.C. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). *Autoimmunity Rev.* 6:131-137, 2006.
82. Theoharides, T.C. Treatment approaches for painful bladder syndrome/interstitial cystitis. *Drugs* 67:215-235, 2007.
83. Theoharides, T.C., Kempuraj, D., Tagen, M., Conti, P. and Kalogeromitros, D. Differential release of mast cell mediators and the pathogenesis of inflammation. *Immunol. Rev.* 217:65-78, 2007.
84. Sant, G.R., Kempuraj, D., Marchand, J.E. and Theoharides, T.C. The mast cell in interstitial cystitis-role in pathophysiology and pathogenesis. *Urology* 69 (suppl 4A):34-40, 2007.
85. Tariverdian, N., Theoharides, T.C., Siedentopf, F., Gutiérrez, G., Jeschke, U., Rabinovich GA, Blois, S.M. and Arck, P.C. Neuroendocrine-immune disequilibrium and endometriosis: an Interdisciplinary approach. *Springer Seminars in Immunopathology* 29:193-210, 2007.
86. Theoharides, T.C., Kempuraj, D. and Iliopoulou, B.P. Mast cells, T Cells and inhibition by luteolin: Implications for the pathogenesis and treatment of multiple sclerosis. *Adv. Exper. Med. Biol.* 601:423-30, 2007.

87. Castellani, M.L., Bhattacharya, K., Tagen, M., Kempuraj, D., Perrella, A., De Lutiis, M., Boucher, W., Conti, P., Theoharides, T.C., Cerulli, G., Salini, V., Neri, G. Anti-chemokine therapy for inflammatory diseases. *Int J Immunopathol Pharmacol.* 20:447-453, 2007.
88. Kounis, N.G., Hahalis, G. and Theoharides, T.C. Drug-eluting stent thrombosis, hypersensitivity and the Kounis syndrome. *J. Intervent. Cardiol.* 20:314-323, 2007. Kounis, N.G., Hahalis, G. and Theoharides, T.C. Drug-eluting stent thrombosis, hypersensitivity and the Kounis syndrome. *J. Intervent. Cardiol.* 20:314-323, 2007.
89. Conti, P., Castellani, M.L., Kempuraj, D.J., Salini, V., Vecchiet, J., Tetè, S., Mastrangelo, F., Perrella, A., De Lutiis, M.A., Tagen, M. and Theoharides, T.C. Role of Mast cells in tumor growth. *Am. Clin. Lab. Sci.* 37:315-321, 2007.
90. Theoharides, T.C. Anti-inflammatory actions of flavonoids and structural requirements for new design. In *Chemistry and Molecular Aspects of Drug Design and Action* (E.A. Reka, P.N. Kourounakis, Eds.), Ch. 15, pp. 215-226. CRC Press: Boca Raton, FL, 2008.
91. Theoharides, T.C., Makris, M. and Kalogeromitros, D. Allergic inflammation and adipocytokines. *Int. J. Immunopathol. Pharmacol.* 21:1-4, 2008.
92. Boscolo, P., Youinou, P., Theoharides, T.C. and Conti, P. Environmental/occupational stress and autoimmunity. *Autoimmun. Rev.* 7:340-343, 2008.
93. Theoharides, T.C. and Doyle, R. Autism, gut-blood-brain-barrier and mast cells. *J. Clin. Psychopharm.*, Oct. 2008.
94. Theoharides, T.C., Doyle, R., Francis, K., Conti, P., Kalogeromitros, D. Novel therapeutic targets for autism. *Trends Pharmacol. Sci.* 29:375-382, 2008.
95. Manola, A., Kourelis, T., Kounis, G.N., Kounis, N.G., Theoharides, T.C. Mast cells and their activation: insights on the pathophysiology of Kounis syndrome. In *Angina Pectoris: Etiology, Pathogenesis and Treatment*, (F. Columbus, Ed.), Nova Science Publishers: Hauppauge, N.Y, 2008.
96. Kourelis, T., Manola, A., Kempuraj, D., Theoharides, T.C. Umbilical cord-derived mast cells as in vitro models for neuroinflammatory diseases. In *Perinatal Stem Cells* (C. Citrullo, Ed.) John Wiley and sons: Hoboken, NJ, 2008.
97. Theoharides, T.C. Mast cells and pancreatic cancer. *N. Engl. J. Med.* 24;358(17):1860-1, 2008.
98. Theoharides, T.C., Whitmore, K., Stanford, E., Moldwin, R., O'Leary, M. Interstitial cystitis-bladder pain and beyond. *Expert Opinion Pharmacotherapy* 9(17):2979-2994, 2008.
99. Theoharides, T.C., Rozniecki, J.J., Sahagian, G., Kempuraj, D., Kalogeromitros, D. and Conti, P. Impact of stress and mast cells on brain metastases. *J. Neuroimmunol.* 15;205(1-2):1-7, 2008.
100. Theoharides, T.C., Kempuraj, D., Kourelis, T., Manola, A. Human mast cells stimulate activated T cells: implications for multiple sclerosis. *Ann. N. Y. Acad. Sci.* 1144:74-82, 2008.
101. Castellani, M.L., Kempuraj, D., Salini, V., Vecchiet, J., Tete, S., Ciampoli, C., Conti, F., Cerulli, G., Caraffa, A., Antinolfi, P., Theoharides, T.C., De Amicis, D., Perrella, A., Cuccurullo, C., Boscolo, P., Shaik, Y. The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator. *J. Biol. Regul. Homeost. Agents.* 23(1):11-4, 2009.
102. Castellani, M.L., Conti, C.M., Kempuraj, D.J., Salini, V., Vecchiet, J., Tete, S., Ciampoli, C., Conti, F., Cerulli, G., Caraffa, A., Antinolfi, P., Galzio, R., Shaik, Y., Theoharides, T.C., De Amicis, D., Perrella, A., Cuccurullo,

- C., Boscolo, P., Felaco, M., Doyle, R., Verrocchio, C., Fulcheri, M. Autism and immunity: revisited study. *Int. J. Immunopathol. Pharmacol.* 22(1):15-9, 2009.
103. Castellani, M.L., Kempuraj, D.J., Salini, V., Vecchiet, J., Tete, S., Ciampoli, C., Conti, F., Cerulli, G., Caraffa, A., Antinolfi, P., Theoharides, T.C., De Amicis, D., Perrella, A., Cuccurullo, C., Boscolo, P., Shaik, Y. The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator. *J Biol Regul Homeost Agents* 23(1):11-4, 2009.
104. Theoharides, T.C., Kempuraj, D., Redwood, L. Autism-an emerging “neuroimmune disorder” in search for therapy. *Exp. Opinion Pharmacotherapy* 10(13):2127-43, 2009.
105. Karapanou, V., Kempuraj, D., Theoharides, T.C. Oral neuroimmune network and mast cells. *European J. Inflamm.* 7(1), 2009.
106. Felaco P, Castellani ML, De Lutiis MA, Felaco M, Pandolfi F, Salini V, De Amicis D, Vecchiet J, Tete S, Ciampoli C, Conti F, Cerulli G, Caraffa A, Antinolfi P, Cuccurullo C, Perrella A, Theoharides TC, Conti P, Toniato E, Kempuraj D, Shaik YB. IL-32: a newly-discovered proinflammatory cytokine. *J Biol Regul Homeost Agents* 23(3):141-7, 2009.
107. Theoharides TC. Luteolin as a therapeutic option for multiple sclerosis. *J Neuroinflammation* 13;6:29, 2009.
108. Pandolfi F, Cianci R, Cammarota G, Pagliari D, Landolfi R, Conti P, Theoharides TC. Recent insights in primary immunodeficiency diseases: the role of T-lymphocytes and innate immunity. *Ann Clin Lab Sci* 40(1):3-9, 2010.
109. Manola, A., Kourelis, T., Angelidou A, Theoharides, TC. Mast cell mediators and inflammatory diseases. In *Kounis Syndrome: The Coronary Hypersensitivity Syndrome* (Nicholas G. Kounis, ed.). Nova Science Publishers: Hauppauge, N.Y, 2010.
110. Kourelis, T., Manola, A., Alysandratos K-D, Theoharides, TC. Mast cell activation. In *Kounis Syndrome: The Coronary Hypersensitivity Syndrome* (Nicholas G. Kounis, ed.). Nova Science Publishers: Hauppauge, N.Y, 2010.
111. Castellani ML, Anogeianaki A, Felaco P, Toniato E, De Lutiis MA, Shaik B, Fulcheri M, Vecchiet J, Tetè S, Salini V, Theoharides TC, Caraffa A, Antinolfi P, Frydas I, Conti P, Cuccurullo C, Ciampoli C, Cerulli G, Kempuraj D. IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells. *J Biol Regul Homeost Agents* 24(2):131-5, 2010.
112. Castellani ML, De Lutiis MA, Toniato E, Conti F, Felaco P, Fulcheri M, Theoharides TC, Caraffa A, Antinolfi P, Conti P, Cuccurullo C, Ciampoli C, Felaco M, Orso C, Salini V, Cerulli G, Kempuraj D, Tetè S, Shaik B. Impact of RANTES, MCP-1 and IL-8 in mast cells. *J Biol Regul Homeost Agent* 24(1):1-6, 2010.
113. Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, Fulcheri M, Caraffa A, Antinolfi P, Tete S, Felaco M, Conti F, Pandolfi F, Theoharides TC, Shaik-Dasthagirisahab YB. IL-31 a Th2 cytokine involved in immunity and inflammation. *Int J Immunopathol Pharmacol* 23(3):709-13, 2010.
114. Castellani ML, Galzio RJ, Felaco P, Tripodi D, Toniato E, De Lutiis MA, Conti F, Fulcheri M, Conti C, Theoharides TC, Caraffa A, Antinolfi P, Felaco M, Tete S, Pandolfi F, Shaik-Dasthagirisahab YB. VEGF, substance P and stress, new aspects: a revisited study. *J Biol Regul Homeost Agents* 24(3):229-37, 2010.
115. Castellani ML, Anogeianaki A, Felaco P, Toniato E, De Lutiis MA, Shaik B, Fulcheri M, Vecchiet J, Tetè S, Salini V, Theoharides TC, Caraffa A, Antinolfi P, Frydas I, Conti P, Cuccurullo C, Ciampoli C, Cerulli G, Kempuraj D. IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells. *J Biol Regul Homeost Agents* 24(2):131-5, 2010.

116. Castellani ML, De Lutiis MA, Toniato E, Conti F, Felaco P, Fulcheri M, Theoharides TC, Caraffa A, Antinolfi P, Conti P, Cuccurullo C, Ciampoli C, Felaco M, Orso C, Salini V, Cerulli G, Kempuraj D, Tetè S, Shaik B. Impact of RANTES, MCP-1 and IL-8 in mast cells. *J Biol Regul Homeost Agents* 24(1):1-6, 2010.
117. Castellani ML, Galzio RJ, Felaco P, Tripodi D, Toniato E, De Lutiis MA, Conti F, Fulcheri M, Conti C, Theoharides TC, Caraffa A, Antinolfi P, Felaco M, Tete S, Pandolfi F, Shaik-Dasthagirisahab YB. VEGF, substance P and stress, new aspects: a revisited study. *J Biol Regul Homeost Agents* 24(3):229-37, 2010.
118. Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, Fulcheri M, Caraffa A, Antinolfi P, Tetè S, Felaco M, Conti F, Pandolfi F, Theoharides TC, Shaik-Dasthagirisahab YB. IL-31 a Th2 cytokine involved in immunity and inflammation. *Int J Immunopathol Pharmacol* 23(3):709-13, 2010.
119. Theoharides TC, Alysandratos K-D, Angelidou A, Zhang B. Mast cells and tumor microenvironment. In R.G. Bagley (ed.), *The Tumor Microenvironment, Cancer Drug Discovery and Development*. Chapter 17, 353-370. Springer Science+Business Media, LLC, 2010.
120. Anogeianaki A, Castellani ML, Tripodi D, Toniato E, DeLutiis MA, Conti F, Felaco P, Fulcheri M, Theoharides TC, Galzio R, Caraffa A, Antinolfi P, Cuccurullo C, Ciampoli C, Felaco M, Cerulli G, Pandolfi F, Sabatino G, Neri G, Shaik-Dasthagirisahab YB. Vitamins and mast cells. *Int J Immunopathol Pharmacol* 23(4):991-6, 2010.
121. Angelidou A, Alysandratos K-D, Asadi S, Zhang B, Francis K, Vasiadi M, Kalogeromitros D, Theoharides TC. Brief report: ‘allergic symptoms’ in children with autism spectrum disorders. More than meets the eye? *J Autism Dev Disorders* 41(11):1579-85, 2011.
122. Whitmore, K, Theoharides, T.C. When to suspect interstitial cystitis. *J Family Practice* 60(6):340-348, 2011.
123. Theoharides TC, Angelidou A, Alysandratos K-D, Zhang BD, Asadi S, Francis K, Toniato E, Kalogeromitros D. Mast cell activation and autism. *Biochim Biophys Acta* 1822(1):34-41, 2012.
124. Theoharides TC, Angelidou A, Alysandratos K-D, Zhang BD, Sismanopoulos N, Delivane D, Vasiadi M, Asadi S, Miniati A, Kalogeromitros D. Mast cells and inflammation. *Biochim Biophys Acta* 1822(1):21-33, 2012.
125. Theoharides TC, Sismanopoulos N, Delivanis D-A, Zhang B, Hatziagelaki EE, Kalogeromitros D. Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. *Trends Pharmacol Sci* 32(9): 534-42, 2011.
126. Theoharides TC, Asadi S, Zhang B. Serotonin-selective reuptake inhibitors and nonsteroidal anti-inflammatory drugs-Important considerations of adverse interactions especially for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome. *J Clinical Psychopharmacol* 31(4):403-405, 2011.
127. Theoharides TC, Angelidou A, Alysandratos K-D, Asadi S, Francis K, Lykouras L, Kalogeromitros D. Perinatal immune activation and risk of autism. In Tech-Autism-A Neurodevelopmental Journey from Genes to Behaviour. Valsamma Eapen. InTech Open Access Publisher:Rijeka, Croatia, 2011 (ISBN 978-953-307-493-1).
128. Theoharides TC, Asadi S, Conti P. Decreased mitochondrial function and increased brain inflammation in bipolar disorder and other neuropsychiatric diseases. *J Clin Psychopharmacol* 31(6): 685-687, 2011.
129. Theoharides TC, Asadi A. Neurotensin and extracellular mitochondrial DNA: Potential biomarkers and novel treatment targets. *Autism Science Digest* 1:36-41, 2011.
130. Theoharides TC, Zhang, B, Neuro-Inflammation, blood-brain barrier, seizures and autism. *J Neuroinflammation* 8(1):168, 2011.

131. Theoharides TC, Asadi A. Unwanted interactions among common popular treatment regimens in autism. *Autism Science Digest* 3: 114-124, 2011.
132. Theoharides TC, Asadi A, Chen J, Huizinga JD. Irritable bowel syndrome and the elusive mast cells. *Am J Gastroenterology* 107(5):727-729, 2012.
133. Sismanopoulos N, Delivanis D-A, Alysandratos K-D, Angelidou A, Therianou A, Kalogeromitros D, Theoharides TC. Mast cells in allergic and inflammatory diseases. *Current Pharmaceutical Design* 18(16):2261-77, 2012.
134. Miniati A., Weng Z, Zhang B, Stratigos AJ, Nicolaidou E, Theoharides TC. Neuro-immuno-endocrine processes in vitiligo pathogenesis. *Intl J Immunopathol Pharmacol* 25(1):1-7, 2012.
135. Tete S, Tripodi D, Rosati M, Conti F, Maccauro G, Saggini A, Cianchetti E, Caraffa A, Antinolfi P, Toniato E, Castellani ML, Conti P, Theoharides TC. IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. *Int J Immunopathol Pharmacol*.2012 Jan-Mar;25(1):31-8.
136. Tripodi D, Conti F, Rosati M, Maccauro G, Saggini A, Cianchetti E, Angelucci D, Fulcheri M, Tete S, Salini V, Caraffa A, Antinolfi P, Toniato E, Castellani ML, Conti P, Theoharides TC. IL-36 a new member of the IL-1 family cytokines. *J Biol Regul Homeost Agents* 26(1):7-14, 2012,
137. Angelidou A, Alysandratos K-D, Asadi S, Karagkouni A, Kourembanas S, Theoharides TC. Perinatal stress, brain inflammation and risk for autism-Review and proposal. *BMC Paediatrics* 12(1):89 2012.
138. Theoharides TC, Enakuaa S, Sismanopoulos N, Asadi S, Papadimas E, Alysandratos K-D, Angelidou A., Contribution of stress to asthma worsening through mast cell activation. *Annals Allergy, Asthma, Immunol* 109(1):14-19, 2012.
139. Theoharides TC, Asadi S. Unwanted interactions among psychotropic drugs and other treatments for autism spectrum diseases. *J Clin Psychopharmacol* 32(4):437-40, 2012.
140. Tetè S, Tripodi D, Rosati M, Conti F, Maccauro G, Saggini A, Salini V, Cianchetti E, Caraffa A, Antinolfi P, Toniato E, Castellani ML, Pandolfi F, Frydas S, Conti P, Theoharides TC. Role of mast cells in innate and adaptive immunity. *J Biol Regul Homeost Agents* 26(2):193-201, 2012.
141. Tetè S, Tripodi D, Rosati M, Conti F, Maccauro G, Saggini A, Salini V, Cianchetti E, Caraffa A, Antinolfi P, Toniato E, Castellani ML, Pandolfi F, Frydas S, Conti P, Theoharides TC. Endothelial cells, cholesterol, cytokines, and aging. *Int J Immunopathol Pharmacol* 25(2):355-63, 2012.
142. Tripodi D, Conti F, Rosati M, Maccauro G, Saggini A, Cianchetti E, Angelucci D, Fulcheri M, Tetè S, Salini V, Caraffa A, Antinolfi P, Toniato E, Castellani ML, Conti P, Theoharides TC. IL-36 a new member of the IL-1 family cytokines. *J Biol Regul Homeost Agents* 26(1):7-14, 2012.
143. Theoharides TC, Asadi S, Chen J, Huizinga JD. Irritable bowel syndrome and the elusive mast cells. *Am J Gastroenterol* 107(5):727-9, 2012.
144. Miniati A, Weng Z, Zhang B, Stratigos AJ, Nicolaidou E, Theoharides TC. Neuro-immuno-endocrine processes in vitiligo pathogenesis. *Int J Immunopathol Pharmacol* 25(1):1-7, 2012.
145. Tete S, Nicoletti M, Saggini A, Maccauro G, Rosati M, Conti F, Cianchetti E, Tripodi D, Toniato E, Fulcheri M, Salini V, Caraffa A, Antinolfi P, Frydas S, Pandolfi F, Conti P, Potalivo G, Theoharides TC. Nutrition and cancer prevention. *Int J Immunopathol Pharmacol* 25(3):573-81, 2012.

146. Tetè S, Saggini A, Maccauro G, Rosati M, Conti F, Cianchetti E, Tripodi D, Toniato E, Fulcheri M, Salini V, Caraffa A, Antinolfi P, Frydas S, Pandolfi F, Conti P, Potalivo G, Nicoletti M, Theoharides TC. Interleukin-9 and mast cells. *J Biol Regul Homeost Agents* 26(3):319-325, 2012.
147. Tetè S, Tripodi D, Rosati M, Conti F, Maccauro G, Saggini A, Salini V, Cianchetti E, Caraffa A, Antinolfi P, Toniato E, Castellani ML, Pandolfi F, Frydas S, Conti P, Theoharides TC. Role of mast cells in innate and adaptive immunity. *J Biol Regul Homeost Agents* 26(2):193-201, 2012.
148. Sismanopoulos N, Delivanis A-D, Theoharides TC. Obesity, asthma, inflammation and mast cells. *Allergy* 68(1):8-15, 2013.
149. Nicoletti M, Neri G, Maccauro G, Tripodi D, Varvara G, Saggini A, Potalivo G, Castellani ML, Fulcheri M, Rosati M, Toniato E, Caraffa A, Antinolfi P, Cerulli G, Pandolfi F, Galzio R, Conti P, Theoharides TC. Impact of neuropeptide substance P an inflammatory compound on arachidonic acid compound generation. *Int J Immunopathol Pharmacol* 25(4):849-57, 2012.
150. Sabatino G, Nicoletti M, Neri G, Saggini A, Rosati M, Conti F, Cianchetti E, Toniato E, Fulcheri M, Caraffa A, Antinolfi P, Frydas S, Pandolfi F, Potalivo G, Galzio R, Conti P, Theoharides TC. Impact of IL -9 and IL-33 in mast cells. *J Biol Regul Homeost Agents* 26(4):577-86, 2012.
151. Nicoletti M, Neri G, Maccauro G, Tripodi D, Varvara G, Saggini A, Potalivo G, Castellani ML, Fulcheri M, Rosati M, Toniato E, Caraffa A, Antinolfi P, Cerulli G, Pandolfi F, Galzio R, Conti P, Theoharides TC. Impact of neuropeptide substance P an inflammatory compound on arachidonic acid compound generation. *Int J Immunopathol Pharmacol* 25(4):849-57, 2012.
152. Shaik Y, Sabatino G, Maccauro G, Varvara G, Murmura G, Saggini A, Rosati M, Conti F, Cianchetti E, Caraffa A, Antinolfi P, Pandolfi F, Potalivo G, Galzio R, Conti P, Theoharides TC. IL-36 receptor antagonist with special emphasis on IL-38. *Int J Immunopathol Pharmacol* 26(1):27-36, 2013.
153. Theoharides TC. Extracellular mitochondrial components secreted from activated live mast cells act as “innate pathogens” and contribute to autism pathogenesis. *Intl Trends Immunity* 1(2):5-10, 2013.
154. Karagkouni A, Alevizos A, Theoharides TC. Stress and multiple sclerosis. *Automimmunity Rev* Aug;12(10):947-53, 2013.
155. Theoharides TC, Asadi S, Patel AB. Focal brain inflammation and autism. *J Neuroinflammation*. 10:46, 2013.
156. Theoharides TC. “Atopic conditions” in search of pathogenesis and therapy. *Clinical Therapeutics* 35(5):544-7, 2013.
157. Theoharides TC. Is a Subtype of Autism an “Allergy of the Brain”? *Clinical Therapeutics* 35(5):584-591, 2013.
158. Slominski AT, Zmijewski MA, Zbytek B, Tobin DJ, Theoharides TC, Rivier J. Key role of CRF in the skin stress response system. *Endocr Rev* 34(6):827-84, 2013.
159. Karagkouni A, Alevizos A, Panagiotidou S, Vasiadi M, Theoharides TC. Stress triggers coronary mast cells leading to cardiac events. *Annals Allergy, Asthma, Immunol*. Apr;112(4):309-16, 2014.
160. Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, Saggini A, Potalivo G, Caraffa A, Antinolfi P, Tete' S, Tripodi D, Conti F, Cianchetti E, Toniato E, Rosati M, Conti P, Speranza L, Pantalone A, Saggini R, Theoharides TC, Pandolfi F. Vascular endothelial growth factor (VEGF), mast cells and inflammation. *Int J Immunopathol Pharmacol* 26(2):327-35, 2013.

161. Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, Saggini A, Caraffa A, Antinolfi P, Tete' S, Tripodi D, Conti F, Cianchetti E, Toniato E, Rosati M, Speranza L, Pantalone A, Saggini R, Tei M, Speziali A, Conti P, Theoharides TC, Pandolfi F. Role of vitamins D, E and C in immunity and inflammation. *J Biol Regul Homeost Agents* 27(2):291-5, 2013.
162. Theoharides TC, Asadi S, Panagiotidou S, Weng Z. The "missing link" in autoimmunity and autism: Extracellular mitochondrial components secreted from activated live mast cells. *Autoimmunity Rev.* Oct;12(12):1136-42, 2013.
163. Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, Rosati M, Tei M, Speziali A, Saggini R, Pandolfi F, Theoharides TC, Conti P. Mast cell involvement in rheumatoid arthritis. *J Biol Regul Homeost Agents* 27(3):655-60, 2013.
164. Papathanasiou E, Palaska I, Theoharides TC. Stress hormones regulate periodontal inflammation. *J Biol Regul Homeost Agents* 27(3):621-6, 2013.
165. Frydas S, Varvara G, Murmura G, Saggini A, Caraffa A, Antinolfi P, Tete' S, Tripodi D, Conti F, Cianchetti E, Toniato E, Rosati M, Speranza L, Pantalone A, Saggini R, Di Tommaso LM, Theoharides TC, Conti P, Pandolfi F. Impact of capsaicin on mast cell inflammation. *Int J Immunopathol Pharmacol* 26(3):597-600, 2013.
166. Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, Rosati M, Tei M, Speziali A, Saggini R, Pandolfi F, Cerulli G, Theoharides TC, Conti P. Luteolin inhibits mast cell-mediated allergic inflammation. *J Biol Regul Homeost Agents* 27(4):955-9, 2013.
167. Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, Rosati M, Tei M, Speziali A, Saggini R, Pandolfi F, Cerulli G, Theoharides TC, Conti P. Impact of mast cells on the skin. *Int J Immunopathol Pharmacol* 26(4):855-9, 2013.
168. Palaska I, Papathanasiou E, Theoharides TC. Use of polyphenols in periodontal inflammation. *Eur J Pharmacol* 720(1-3):77-83, 2013.
169. Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, Rosati M, Tei M, Speziali A, Saggini R, Pandolfi F, Theoharides TC, Conti P. Mast cell involvement in rheumatoid arthritis. *J Biol Regul Homeost Agents* 27(3):655-60, 2013.
170. Papathanasiou E, Palaska I, Theoharides TC. Stress hormones regulate periodontal inflammation. *J Biol Regul Homeost Agents* 27(3):621-6, 2013.
171. Frydas S, Varvara G, Murmura G, Saggini A, Caraffa A, Antinolfi P, Tete' S, Tripodi D, Conti F, Cianchetti E, Toniato E, Rosati M, Speranza L, Pantalone A, Saggini R, Di Tommaso LM, Theoharides TC, Conti P, Pandolfi F. Impact of capsaicin on mast cell inflammation. *Int J Immunopathol Pharmacol* 26(3):597-600, 2013.
172. Mavrommati D, Theoharides TC. Dietary interventions for atopic disorders. *Curr Pharm Des* 20(6):996-1002, 2014.
173. Theoharides TC, Conti P, Economu M. Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. *J Clin Psychopharmacol* 34(2):187-9, 2014.
174. Theoharides TC. Mast cells in irritable bowel syndrome and ulcerative colitis: Function not numbers is what makes all the difference. *Dig Dis Sci* 59(5):897-8, 2014.
175. Alevizos M, Karagkouni A, Panagiotidou S, Vasiadi M, Theoharides TC. Stress triggers coronary mast cells leading to cardiac events. *Ann Allergy Asthma Immunol* 112(4):309-16, 2014.
176. Petra AI, Panagiotidou S, Stewart JM, Conti P, Theoharides TC. Spectrum of mast cell activation disorders. *Expert Rev Clin Immunol* 10(6):729-39, 2014.

177. Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, Rosati M, Tei M, Speziali A, Saggini R, Pandolfi F, Cerulli G, Theoharides TC, Conti P. *Luteolin inhibits mast cell-mediated allergic inflammation. J Biol Regul Homeost Agents* 27(4):955-9, 2014.
178. Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, Rosati M, Tei M, Speziali A, Saggini R, Pandolfi F, Cerulli G, Theoharides TC, Conti P. Impact of mast cells on the skin.. *Int J Immunopathol Pharmacol* 26(4):855-9, 2014.
179. Tsilioni I, Panagiotidou S, Theoharides TC. Exosomes in neurological and psychiatric disorders. *Clin Ther* 36(6):882-888, 2014.
180. Theoharides TC, Athanassiou M, Panagiotidou S, Doyle R. Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and Autism Spectrum Disorders. *J Neuroimmunol*, 279:33-8, 2015.
181. Theoharides TC. Petra A, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. *J Pharmacol Exp Ther* 354(1):24-31, 2015.
182. Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-microbiota-brain axis and effect on neuropsychiatric disorders with suspected immune dysregulation. *Clin Ther* 37(5):984-995, 2015.
183. Theoharides TC. On the Gut Microbiome-Brain Axis and Altruism. *Clin Ther* 37(5):937-40, 2015.
184. Theoharides TC. Mast cells promote malaria infection? *Clin Ther* Jun 1;37(6):1374-7. 2015.
185. Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. *Frontiers Neurosci* 9:225, 2015.
186. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis and related disorders. *New Engl J Med* 373(2):163-72, 2015.
187. Polyzoidis S, Koletsa T, Panagiotidou S, Ashkan K, Theoharides TC. Mast cells in meningiomas and brain inflammation. *J Neuroinflammation* 12(1):170, 2015.
238. Theoharides TC, Stewart JM. Genitourinary mast cells and survival. *Transl Androl Urol* 4(5):579-86, 2015.
239. Theoharides TC, Tsilioni I, Arbetman L, Panagiotidou S, Stewart JM, Gleason RM, Russell IJ. Fibromyalgia syndrome in need of effective treatments. *J Pharmacol Exp Ther* 355(2):255-63. 2015.
240. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. *J Pharmacol Exp Ther* 354(1):24-31, 2015.
188. Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. Mast cells, brain inflammation and autism. *Eur J Pharmacol* 778:96-102, 2016.
241. Theoharides TC, Tsilioni I, Patel AB, Doyle R. Atopic diseases and inflammation of the brain in autism spectrum disorders. *Transl Psychiatry* 6(6):e844, 2016.
242. Theoharides TC. Skin mast cells: are we missing the forest for the trees? *Exp Dermatol* 25(6):422-3, 2016.
243. Theoharides TC, Stewart JM. Antihistamines and mental status. *J Clin Psychopharmacol* 36(3):195-7, 2016.
244. Theoharides TC. Danger Signals and Inflammation. *Clin Ther* 38(5):996-999, 2016.

189. Theoharides TC, Stewart JM, Taracanova A, Conti P, Zouboulis CC. Neuroendocrinology of the skin. *Rev Endocr Metab Disord* 17(3):287-294, 2016.
245. Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. Mast cells, brain inflammation and autism. *Eur J Pharmacol* 778:96-102, 2016.
246. Theoharides TC, Tsilioni I. Autism Spectrum Disorders. Chapter 40. In *Neuroimmune Pharmacology* (H. Gendelman, Ed.), Springer, 2016. Caraffa A, Spinas E, Kritas SK, Lessiani G, Ronconi G, Saggini A, Antinolfi P, Pizzicannella J, Toniato E, Theoharides TC, Conti P. Endocrinology of the skin: intradermal neuroimmune network, a new frontier. *J Biol Regul Homeost Agents* 30(2):339-43, 2016.
247. Theoharides TC. Vitamin D and Atopy. *Clin Ther* 39(5):880-883, 2017.
248. Theoharides TC. Neuroendocrinology of mast cells: Challenges and controversies. *Exp Dermatol* 26(9):751-759, 2017.
249. Conti P, Lessiani G, Kritas SK, Ronconi G, Caraffa A, Theoharides TC. Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. *Tissue Cell* 49(3):393-400. 2017.
250. Conti P, Carinci F, Caraffa A, Ronconi G, Lessiani G, Theoharides TC. Link between mast cells and bacteria: Antimicrobial defense, function and regulation by cytokines. *Med Hypotheses* 106:10-14, 2017.
251. Conti P, Carinci F, Lessiani G, Spinas E, Kritas SK, Ronconi G, Caraffa A, Theoharides TC. Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. *Immunol Res* 65(5):982-986, 2017.
252. Conti P, Caraffa A, Kritas SK, Ronconi G, Lessiani G, Toniato E, Theoharides TC. Mast cell, pro-inflammatory and anti-inflammatory: Jekyll and Hyde, the story continues. *J Biol Regul Homeost Agents* 31(2):263-267, 2017.
253. Conti P, Caraffa A, Ronconi G, Kritas SK, Mastrangelo F, Tettamanti L, Theoharides TC. Impact of mast cells in mucosal immunity of intestinal inflammation: Inhibitory effect of IL-37. *Eur J Pharmacol* 818:294-299, 2018.
254. Theoharides TC. Mold and Immunity. *Clin Ther* 40(6):882-884, 2018.
255. Conti P, Caraffa A, Ronconi G, Conti CM, Kritas SK, Mastrangelo F, Tettamanti L, Theoharides TC. Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers). *Immunol Res* 66(3):323-331.
256. Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of mycotoxins on neuropsychiatric Symptoms and Immune Processes. *Clin Ther* 40(6):903-917, 2018.
257. Conti P, Caraffa A, Mastrangelo F, Tettamanti L, Ronconi G, Frydas I, Kritas SK, Theoharides TC. Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37. *Cell Prolif* 30:e12475, 2018.
258. Conti P, Caraffa A, Ronconi G, Kritas SK, Mastrangelo F, Tettamanti L, Frydas I, Theoharides TC. Mast cells participate in allograft rejection: Can IL-37 play an inhibitory role? *Inflamm Res* 67(9):747-755, 2018.
259. King L, Tsilioni I, Theoharides TC. Time to look past TNF and thalidomide for cachexia - could mast cells and flavonoids be the answer? *J Biol Regul Homeost Agents* 32(3):443-447, 2018.

260. Conti P, Caraffa A, Ronconi G, Conti CM, Kritas SK, Mastrangelo F, Tettamanti L, Theoharides TC. Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers). *Immunol Res* 66(3):323-331, 2018.
261. Conti P, Ronconi G, Kritas SK, Caraffa A, Theoharides TC. Activated mast cells mediate low-grade inflammation in Type 2 Diabetes: Interleukin-37 could be beneficial. *Can J Diabetes* 42(5):568-573, 2018.
262. Hatziagelaki E, Adamaki M, Tsilioni I, Dimitriadis G, Theoharides TC. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Metabolic disease or disturbed homeostasis in the hypothalamus? *J Pharmacol Exp Ther* 367(1):155-167, 2018.
263. Theoharides TC and Tsilioni I. Tetramethoxyluteolin for the treatment of neurodegenerative diseases. *Current Topics Medicinal Chemistry* 18(21):1872-1882, 2018.
264. Theoharides TC. In Search of Effective Treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Clin Ther* 41(5):796-797, 2019.
265. Theoharides TC, Sant J, Giota M-E. Autism Spectrum Disorder, Fear Response and Environmental Exposures. In *Environmental Exposures and Human Health Challenges*. ISI Gobal, Hershey, PA. 2018.
266. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation-or should it be mast cell mediator syndrome? *Exp Rev Clin Immunol* 15(6):639-656, 2019.
267. Conti P, Theoharides TC. IgE and macrophages for cancer rescue? *EBioMedicine* 43:7-8, 2019.
268. Theoharides TC, Tsilioni I, Bawazeer M. Mast cells neuroinflammation and pain in fibromyalgia syndrome. *Frontiers Cellular Neurosci* 13:353, 2019.
269. Kounis N, Ren H, Kavalioti M, Koniari I, Theoharides TC. Intimate contact could be dangerous for your health. *Clin Ther* 41(6):1222-1226, 2019.
270. Antonopoulos D, Tsilioni I, Balatsos NAA, Gourgoulianis KI, Theoharides TC. The mast cell - neurofibromatosis connection. *J Biol Regul Homeost Agents* 33(3):657-659, 2019.
271. Theoharides TC, Tsilioni I, Conti P. Mast cells may regulate the anti-inflammatory activity of IL-37. *Int J Mol Sci* 20(15), 2019.
272. Theoharides TC, Kavalioti M, Tsilioni I. Mast cells, stress, fear and Autism Spectrum Disorder. *Int J Mol Sci* 20(15), 2019.
273. Ren HL, Li JD, Yue FS, Sun JL, Rebeiz EE, Theoharides TC. Nasal cytology with emphasis on mast cells can improve the diagnosis and treatment of chronic rhinosinusitis. *Chin Med J (Engl)* 132(18):2237-2241, 2019.
274. Theoharides TC, Kavalioti M, Martinotti R. Factors adversely influencing neurodevelopment. *J Biol Regul Homeost Agents*. 2019;33(6):1663-1667.
275. Theoharides TC, Tsilioni I, Bawazeer M. Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. *Front Cell Neurosci*. 2019;13:353.
276. Theoharides TC. Stress, Inflammation, and Autoimmunity: The 3 Modern Erinyes. *Clin Ther*. 2020;42(5):742-744.
277. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. *Biofactors*. 2020;46(3):306-308.

278. Theoharides. Effect of Stress on Neuroimmune Processes. *Clin Ther.* 42(6):1007-1014, 2020.
279. Papathanasiou E, Conti P, Carinci F, Lauritano D, Theoharides TC. IL-1 superfamily members and periodontal disease. *J Dental Res.* 99(13):1425-1434. 2020.
280. Theoharides TC, Antonopoulou S, Demopoulos CA. COVID-19, Microthromboses and Platelet Activating Factor (PAF). *Clin Ther.* 42(10):1850-1852. 2020.
281. Theoharides TC, Conti P. COVID-19 and Multisystem Inflammatory Syndrome, or is it Mast Cell Activation Syndrome? *J Biol Regul Homeost Agents.* 34(5):1633-1636, 2020.
282. Theoharides TC. The impact of psychological stress on mast cells. *Ann Allergy Asthma Immunol.* 125(4):388-392, 2020.
283. Theoharides TC. Potential Association of Mast Cells with COVID-19. *Ann Allergy Asthma Immunol.* 126(3): 217–218, 2020.
284. Theoharides TC. COVID-19 brain inflammation and autism spectrum disorder. *J Child Adolesc Psych.* 4(3):1-6, 2020.

f. Commentaries/Editorials/Letters

1. Theoharides, T.C. The End. *Prosanatolismoi* (Anatolia Coll. Lit. Gazette) 7: 24, 1965.
2. Theoharides, T.C. Cyprus: A Greek View. *Yale Graduate Professional* 5(7): 2, 1975.
3. Theoharides, T.C. Jolly Graduate Fellows? *Yale Graduate Professional* 5(8): 2, 1975.
4. Theoharides, T.C. The cromolyn connection: zeroing in. *Wellcome Trends In Otorhinolaryngology and Allergy* 2: 3, 1980.
5. Theoharides, T.C. Research and public education in pharmacology. In *Health Care Delivery in Greece. Annals.* 5:23-39, 1983. Krikos: New York.
6. Theoharides, T.C. Allergy and antihistamines. A new riddle. *Arch of Dermatol* 122:995-996, 1986.
7. Theoharides, T.C. Leukotrienes in cardiovascular and pulmonary function. (A.M. Lefer and M.H. Gee, eds.), pp. 1-270 A.R. Liss: New York, 1985. *Journal of Clinical Psychopharmacology* 7: 111, 1987.
8. Theoharides, T.C. Pharmacology: From the lab to the bedside. *Tufts Medical Alumni Bulletin* 47: 15-18, 1987.
9. Theoharides, T.C. Miracles: a medical perspective. In *Health and Faith* (J. Chirban, ed.), pp. 117-120. University Press of America: New York, 1991.
10. Theoharides, T.C. Doctor's Forum: Interstitial cystitis and irritable bowel syndrome. *ICA Update* 6:6, 1991.
11. Theoharides, T.C. Doctor's Forum: Hydroxyzine for the treatment of interstitial cystitis. *ICA Update* 8:5, 1993.
12. Theoharides, T.C. Scientific discovery and medical practice: the God within. *Greek Orthodox Theological Review* 37: 35-41, 1993.
13. Theoharides, T.C. Always the Good Samaritan. *Tufts Medicine* 53: 22, 1994 (written by Majorie H. Dwyer).
14. Theoharides, T.C. Discovery holds promise of pre-empting allergies. *Dean's Rounds* Spring, 1994 (written by Robert Levy).
15. Theoharides, T.C. Doctor's Forum: Antihistamines, antidepressants and cancer growth? Not really. *ICA Update*, 1994.
16. Conti, P. and Theoharides, T.C. Action of Monocyte chemotactic protein-1 (MCP-1) is active on mast cells and causes clump formation. *Intl. J. Immunopathol. Pharmacol*, 73:149-151, 1994.
17. Theoharides, T.C. Directives for the development of orphan drugs. *Medical Press*, p. 27, December 1994 (written by Ekaterini Horeftaki).
18. Theoharides, T.C. and Sant, G.R. Letter to the Editor: Mast cell mediators in interstitial cystitis. *J.Urol.* 153:1952-1955, 1995.
19. Theoharides, T.C. and Sant, G.R. Letter to the Editor: Role of the immune response in interstitial cystitis. *Clin. Immunol. Immunopathol.* 77:115-116, 1995.
20. Pang, X., Sant, G.R. and Theoharides, T.C. Letter to the Editor: Oestrogen receptor status of mast cells in interstitial cystitis. *Br. J. Urol.* 77:475-478, 1996.

21. Sant, G.R. and Theoharides, T.C. Letter to the Editor: Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis. *J. Urol.* 156:1445-1446, 1996.
22. Theoharides, T.C. Response to neuroleptic malignant-like syndrome due to cyclobenzaprine? *J. Clin. Psychopharmacol.* 16:97-99, 1996.
23. Theoharides, T.C. Reply to letter to the Editors by Carroll and Taylor. *J. Clin. Psychopharmacol.* 17:235-238, 671997.
24. Theoharides, T.C. and Sant, G.R. Reply to the Editor concerning mast cell counts not being useful in the diagnosis of nonulcerative interstitial cystitis. *J. Urol.* 755:885-887, 1996.
25. Theoharides, T.C. Pathophysiology of migraines and the role of stress. *Hellenic Pain Society News Report* 3:2-3, 1997.
26. Theoharides, T.C. Mast cells may account for success of GAG. *Urology Times* 26:26, 1998.
27. Theoharides, T.C. U.S. State action on limiting ephedrine use. *J. Clin. Psychopharmacol.* 19:198-190, 1998.
28. Theoharides, T.C. In God We Trust. *The Hellenic Chronicle*, p. 4. April 11, 1999.
29. Theoharides, T.C. Health: The fabric of peace for a world community. *The Hellenic Chronicle*, pp.1, 4. October 27, 1999.
30. Theoharides TC. A timely multidisciplinary update on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Clin Ther* 2019 Apr;41(4):610-611, 2019.
31. Theoharides TC. In search of effective treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Clin Ther* 41(5):796-797, 2019.
32. Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. *J Biol Regul Homeost Agents.* 34(3):1241-1243, 2020.
33. Giniatullin R, Kalpna Gupta K, Theoharides T. Mast Cells in Itch, Pain and Neuro-Inflammation. *Front Cell Neurosci.* 2019; 13: 521. Published online 2019 Dec 3. doi: 10.3389/fncel.2019.00521.
34. Theoharides TC. Luteolin supplements: All that glitters is not gold. *Biofactors.* Nov 7. doi: 10.1002/biof.1689. Epub ahead of print, 2020.
35. Theoharides TC, Christodoulou S, Athanasiou A. Spontaneous miscarriages in patients with bladder pain syndrome/interstitial cystitis-effect of stress on inflammation? *J Biol Regul Homeost Agents.* Dec 30;35(1). doi: 10.23812/20-528-E. Online ahead of print. 2020.
36. Theoharides TC, Helbig S, Economou M. Antipsychotics and Anti-inflammatory Actions: Friends or Foes in COVID-19? *J Clin Psychopharm.* 2021. In press.

g. Case Reports

1. Theoharides, T.C., Harris, S.R. and Weckstein, D. Neuroleptic malignant-like syndrome due to cyclobenzaprine? *J. Clin. Psychopharmacol.* 15:79-81, 1995.
2. Pang, X., Boucher, W., Triadafilopoulos, G., Sant, G.R. and Theoharides, T.C. Mast cell (MC) and substance P (SP)-positive nerve involvement in the bladder and colon of a patient with both interstitial cystitis (IC) and irritable bowel syndrome (IBS). *Urology* 47:436-438, 1995.
3. Sant, G.R., Theoharides, T.C., Letourneau, R., Gelfand, J. and Ucci, A.A. Interstitial cystitis and bladder mastocytosis in a woman with chronic urticaria. *Scandinavian J. Urol. Nephrol.* 31:407-507, 1997.
4. Theoharides, T.C. Sudden death of a healthy college student related to ephedrine toxicity from Ma huang containing drink. *J. Clin. Psychopharmacol.* 17:437-439, 1997.
5. Katsarou-Katsari, A., Singh, L. and Theoharides, T.C. Alopecia areata and affected skin CRH receptor upregulation induced by acute emotional stress. *Dermatology* 203:157-161, 2001.
6. Theoharides, T.C., Kempuraj, D. and Sant, G.R. Massive extracellular tryptase from activated bladder mast cells in interstitial cystitis. *Urology* 58:605-606, 2001.
7. Pehlivanidis, C., Fotoulaki, M., Boucher, W., Kempuraj, D., Pang, X., Konstantinidou, A. and Theoharides, T.C. Acute stress-induced seizures and loss of consciousness in a ten-year-old boy with mastocytosis. *J. Clin. Psychopharmacol* 22:221-224, 2002.
8. Kalogeromitros, D., Gregoriou, S., Syrigou, E., Georgala, S., Panagiotides, G.J., Kempuraj, D. and Theoharides, T.C. Secondary anetoderma associated with mastocytosis. *Intl. Arch. Allergy Immunol.* 142:86-88, 2006.
9. Theoharides TC, Kempuraj D, Marchand J, Tzianoumis L, Vasiadi M, Katsarou-Katsari A, Makris M, Kalogeromitros D. Urticaria pigmentosa associated with acute stress and lesional skin mast-cell expression of CRF-R1. *Clin. Exp. Dermatol.* 34(5):e163-6, 2009.
10. Alevizos M, Karagkouni A, Kontou-Fili K, Theoharides TC. A probable case report of stress-induced anaphylaxis. *Ann Allergy Asthma Immunol* 112(4):383-4, 2014.
11. Theoharides TC, Petra AI, Stewart JM, Tsilioni I, Akin C. High serum CRH and bone marrow mast cell CRH receptor expression in a mastocytosis patient. *J Allergy Clin Immunol.* June 27. 134(5):1197-9, 2014.
12. Theoharides TC, Stewart JM. Post-Lyme Syndrome-Associated Polyneuropathy Treated With Immune Immunoglobulin and a Luteolin-Containing Formulation. *J Clin Psychopharmacol* 36(3):290-1, 2016.
13. Theoharides TC, Kavalioti M. Cutaneous mastocytosis and Autism Spectrum Disorde. *Autism Res.* In press, 2019.

h. Abstracts/Proceedings

1. Theoharides, T.C. and Canellakis, Z.N. Induction of ornithine decarboxylase (ODC) in rat hepatoma cultured cells (HTC) by cellular uptake of cyclic AMP enclosed in phospholipid vesicles. *Federation of European Biochemical Societies* 10:188, 1975.
2. Theoharides, T.C. and Canellakis, Z.N. Induction of ornithine decarboxylase (ODC) in enucleated cultured hepatoma cells (HTC). *International Congress of Biochemistry* 10:07-8-144, 1976.
3. Canellakis, Z.N. and Theoharides, T.C. Some properties of ornithine decarboxylase induction in normal and neoplastic tissue. In *Genetic Polymorphism*, p. 20. European Society for Human Genetics: Athens, Greece, 1976.
4. Askenase, P.W. and Theoharides, T.C. Differential release of serotonin and histamine in the mast cell. *Federation Proceedings (Fed. Am. Soc. Exp. Biol.)* 39:905, 1980.
5. Theoharides, T.C. and Askenase, P.W. Amitriptyline permits release of serotonin but not histamine from mast cells. *European Journal of Cell Biology* 22:181, 1980.
6. Tamir, H., Askenase, P.W., Theoharides, T.C. and Gershon, M. Serotonin binding proteins of neuronal and mesenchymal (mast cell and basophil) origin. *Society for Neuroscience Abstracts* 6:119, 1980.
7. Askenase, P.W., Tamir, H., Theoharides, T.C. and Gershon, M. Serotonin binding proteins (SBP) derived from rat mast cells or basophil leukemia (RBL) cells. *Federation Proceedings (Fed. Am. Soc. Exp. Biol.)* 40:1022, 1981.
8. Tamir, H., Askenase, P.W., Theoharides, T.C. and Gershon, M. Serotonin binding proteins: studies of a mast cell model. *Transactions of the American Society of Neurochemistry* 12:232, 1981.
9. Theoharides, T.C., Tsakalos, N.D., Dwyer, J.M. and Askenase, P.W. Transfer factor stimulates secretion in rat peritoneal mast cells. *Journal of Cell Biology* 91:75, 1981.
10. Tsakalos, N.D., Theoharides, T.C., Kops, S.K. and Askenase, P.W. Parathyroid hormone stimulates mast cell secretion *in vitro* and *in vivo*. *Clinical Research* 30:359, 1982.
11. Baloyannis, S.J. and Theoharides, T.C. Mast cells may induce demyelination of rat brain slices *in vitro*. *Clinical Research* 30:407, 1982.
12. Kops, S.K., Tsakalos, N.D., Theoharides, T.C. and Askenase, P.W. Mast cell secretion of serotonin and histamine induced by parathyroid hormone (PTH). *Federation Proceedings (Fed. Am. Soc. Exp. Biol.)* 41:376, 1982.
13. Tsakalos, N.D., Theoharides, T.C., Dwyer, J.M., Goffinet, J. and Askenase, P.W. Spontaneous suppressor cell activity in patients with chronic renal failure. *Clinical Research* 31:355, 1983.
14. Kops, S.K., Theoharides, T.C. and Askenase, P.W. Morphologic changes accompanying differential release in the rat peritoneal mast cell. *Journal of Cell Biology* 97:436, 1983.
15. Theoharides, T.C., Kops, S.K. and Askenase, P.W. Rat mast cell ultrastructural changes accompanying differential release of serotonin. *Federation Proceedings (Fed. Am. Soc. Exp. Biol.)* 43:1626, 1984.
16. Theoharides, T.C. Tricyclic antidepressant drug amitriptyline alters the permeability of mast cell secretory granules and permits selective release of serotonin. *Proc. 14th Congress Collegium Internationale Neuropsychopharmacologicum* (Florence) 234, 1984.

17. Theoharides, T.C. Psychotropic agents alter the permeability of mast cell secretory granules. *Proc. 9th International Congress of Pharmacology* (London) 53, 1984.
18. Theoharides, T.C., Baloyannis, S.J. and Manolides, L.S. Mast cell degranulation may cause neuronal degeneration. *International Congress Series* (E.H. Meyers, ed.) 680:140-141. Excerpta Medica: Amsterdam, 1985.
19. Baloyannis, S.J., Theoharides, T.C. and Manolides, L.S. Synaptic alterations in the acoustic pathway following hypoglycemia. *International Congress Series* (E.H. Myers, ed.) 680:89-90. Excerpta Medica: Amsterdam, 1985.
20. Marathias, K.P. and Theoharides, T.C. Serotonin secretion from brain mast cells. *Journal of Cell Biology* 101:124, 1985.
21. Theoharides, T.C. and Kotkow, K.J. Calcium ion levels during differential mast cell secretion. *Federation Proceedings (Fed. Am. Soc. Exp. Biol.)* 45:387, 1986.
22. Lambracht-Hall, M., Marathias, K.P. and Theoharides, T.C. Compound 48/80-induced serotonin release from brain mast cells. *Federation Proceedings (Fed. Am. Soc. Exp. Biol.)* 45:437, 1986.
23. Cartagena, A. and Theoharides, T.C. Inhibition of mast cell degranulation by naturally occurring polyamines. *Federation Proceedings (Fed. Am. Soc. Exp. Biol.)* 45:437, 1986.
24. Theoharides, T.C., Lee-Parritz, A., Berringer, R.W. and Dorkin, H. Rat mast cell secretion with cystic fibrosis homozygote serum. *Clinical Research* 34:278, 1986.
25. Theoharides, T.C., Johnson, H.A., Lee-Parritz, A., Bergman, K. and Reinhold, R.B. Systemic mastocytosis serum induces rat mast cell secretion. *Clinical Research* 34:278, 1986.
26. Pothoulakis, H., Theoharides, T.C., McAndrew, P.E. and LaMont, J.T. Clostridium difficile toxin A releases mediators from mucosal-like rat basophil leukemia (RBL) cells. *Clinical Research* 34:871, 1986.
27. Theoharides, T.C. Peritoneal mast cell secretion due to 48/80 decreases after fusion to rat basophil leukemia (RBL) cells. *J Cell Biology* 103:458, 1986.
28. Theoharides, T.C. and Cartagena, A. Naturally occurring polyamines inhibit inflammatory cell secretion. *Proc. 2nd World Conference on Inflammation* (Monte Carlo), p. 390. Bioscience Ediprint: Switzerland, 1986.
29. Lambracht-Hall, M. and Theoharides, T.C. Release of inflammatory mediators from brain mast cells. *Proc. 2nd World Conference on Inflammation* (Monte Carlo), p. 391. Bioscience Ediprint: Switzerland, 1986.
30. Theoharides, T.C., Baloyannis, S.J. and Manolides, L.S. Brain demyelination during release of mast cell mediators. *Proc. 2nd World Conference on Inflammation* (Monte Carlo), p. 392. Bioscience Ediprint: Switzerland, 1986.
31. Manolides, L.S., Baloyannis, S.J., Theoharides, T.C. and Apostolides, T.H. A clinical and laboratory study on 1,000 children suffering from secretory otitis media. *Proc. International Symposium on Acute Secretory Otitis Media* (Miami), pp. 563-569. Krueger: Amsterdam, 1986.
32. Baloyannis, S.J., Manolides, L.S. and Theoharides, T.C. Ultrastructural changes accompanying mast cell-induced brain demyelination. *Proc. 10th International Congress of Neuropathology* (Stockholm), p. 415, 1986.
33. Theoharides, T.C. New findings concerning the mechanism of action of non-narcotic analgesics. *5th World Congress of Pediatrics* (Panama City), 1987.

34. Theoharides, T.C. Substance P-induced release of brain mast cell nociceptive mediators. *Pain Supplement* 4:262, 1987.
35. Theoharides, T.C. New findings concerning the mechanism of action of non-narcotic analgesics. *Proc. 3rd E.N.T.-Neuro-Ophthalmology-Neurosurgery Congress* (Rome), p. 89. Rivista Italiana: Rome, 1987.
36. Theoharides, T.C. and Hauser, S.L. Tricyclics inhibit brain mast cell secretion and neuronal demyelination. *Proc. International Workshop on Diagnostic and Therapeutic Trials in Multiple Sclerosis: a New Look*, H.L. Weiner and D.W. Patty (eds.), pp. 44-46, National Multiple Sclerosis Society, New York, 1988.
37. Konstantinidou, A.D., Flaris, N., Lambracht-Hall, M. and Theoharides, T.C. Functional localization of brain mast cells. *Society for Neuroscience Abstracts* 14:226, 1988.
38. Lambracht-Hall, M., Konstantinidou, A.D., Holdridge, M. and Theoharides, T.C. Tricyclic compounds inhibit thalamic mast cell secretion. *Society for Neuroscience Abstracts* 14:25, 1988.
39. Vliagoftis, H., Raam, S. and Theoharides, T.C. Female sex hormones trigger mast cell secretion. *Journal Cell Biology* 109:52, 1989.
40. Theoharides, T.C., Vliagoftis, H. and Hauser, S.L. Myelin basic protein (MBP) degranulates mast cells from rats with experimental allergic encephalomyelitis (EAE). *Proc. 8th Annual Meeting of New England Pharmacologists*, 46 (Boston), 1989.
41. Konstantinidou, A.D., Lambracht-Hall, M., Holdridge, M. and Theoharides, T.C. Amitriptyline inhibits thalamic mast cell secretion and neuronal depolarization. *Proc. 3rd Interscience World Conference on Inflammation* (Monte Carlo), p. 251. Bioscience Ediprint: Switzerland, 1989.
42. Savala, J., Konstantinidou, A.D., Lambracht-Hall, M. and Theoharides T.C. Clonidine stimulates the release of vasoactive substances from brain mast cells. *Proc. 3rd Interscience World Conference on Inflammation* (Monte Carlo), p. 252. Bioscience Ediprint: Switzerland, 1989.
43. Lambracht-Hall, M., Konstantinidou, A., Holdridge, M. and Theoharides, T.C. Somatostatin and substance P stimulate release of brain mast cell mediators. *Proc. 3rd Interscience World Conference on Inflammation* (Monte Carlo), p. 253. Bioscience Ediprint: Switzerland, 1989.
44. Vliagoftis, H., Cartagena, A. and Theoharides, T.C. Spermine inhibits mast cell secretion by two distinct mechanisms. *Proc. 3rd Interscience World Conference on Inflammation* (Monte Carlo), p. 254. Bioscience Ediprint: Switzerland, 1989.
45. Panagiotacopoulos, P., Conti, P., Vliagoftis, H., Serhan, C. and Theoharides, T.C. Modulation of rat mast cell secretion by leukotrienes and lipoxins. *Proc. 3rd Interscience World Conference on Inflammation* (Monte Carlo), p. 255. Bioscience Ediprint: Switzerland, 1989.
46. Theoharides, T.C., Vliagoftis, H. and Hauser, S.L. Myelin basic protein induces mast cell secretion from EAE-susceptible Lewis, but not resistant Sprague-Dawley, rats. *Proc. 3rd Interscience World Conference on Inflammation* (Monte Carlo), p. 256. Bioscience Ediprint: Switzerland, 1989.
47. Theoharides, T.C. Treatment of allergic rhinitis and secretory otitis media with tricyclic drugs. *Proc. 4th E.N.T. - Neurosurgery Congress* (Thessaloniki), 1990.
48. Theoharides, T.C., Lambracht-Hall, M., Massacesi, L. and Hauser, S.L. Reduced incidence of experimental allergic encephalomyelitis (EAE) with the tricyclic SEP-CH. *Proc. XIth International Congress of Pharmacology* (Amsterdam). *European J. Pharmacol.* 183:626-627, 1990.

49. Dimitriadou, V., Massacesi, L., Hauser, S.L. and Theoharides, T.C. Ultrastructural evidence of mast cell involvement in monkey experimental allergic encephalomyelitis (EAE). *Proc. 1st International Congress on Inflammation* (Barcelona), p. 282, 1990.
50. Dimitriadou, V., Buzzi, M.G., Theoharides, T.C. and Moskowitz M.A. Dura mast cell activation induced by trigeminal ganglion stimulation in the rat. *Proc. 1st International Congress on Inflammation* (Barcelona), p. 280, 1990.
51. Theoharides, T.C., Dimitriadou, V. and Vliagoftis, H. Testosterone inhibits rat mast cell degranulation. *Proc. 1st International Congress on Inflammation* (Barcelona), p. 279, 1990.
52. Pothoulakis, C., Linevsky, J., Becker, S., Holdridge, M., Theoharides, T.C. and LaMont, J.T. Release of mast cell mediators in an animal model for inflammatory bowel disease. *Proc. 1st International Congress on Inflammation* (Barcelona), p. 281, 1990.
53. Dimitriadou, V., Lambracht-Hall, M. and Theoharides, T.C. Can inhibition of carbachol and substance P-induced selective release from dura mast cells be associated with analgesia? *Pain Suppl.* 5:S14, 1990.
54. Lambracht-Hall, M., Holdridge, M., Dimitriadou, V. and Theoharides, T.C. Myelin basic protein (MBP), substance P (SP) and carbachol (C) induce histamine release from rat dural mast cells. *FASEB Journal* 4:903, 1990.
55. Linevsky, J., Becker, J., Pothoulakis, H., Holdridge, M., Theoharides, T.C. and LaMont, J.T. *Clostridium difficile* toxin A stimulates release of mast cell mediators in rabbit ileal loops. *Gastroenterology* 98:459, 1990.
56. Kouretas, D., Trnovsky, J., Holdridge, M. and Theoharides, T.C. Two-dimensional protein electrophoretic pattern of mast and rat basophilic leukemia (RBL) cells during growth and differentiation. *The Pharmacologist* 32:153, 1990.
57. Buzzi, M.G., Dimitriadou, V., Theoharides, T.C. and Moskowitz, M.A. Morphological effects of electrical trigeminal ganglion stimulation (ETG) on intra- and extracranial vessels. *Society for Neuroscience Abstracts* 16:160, 1990.
58. Dimitriadou, V., Buzzi, M.G. Lambracht-Hall, M., Moskowitz, M.A. and Theoharides, T.C. *In vivo* and *in vitro* ultrastructural evidence for stimulation of dura mast cells by neuropeptides. *Society for Neuroscience Abstracts* 16:161, 1990.
59. Solomonides, J., Dimitriadou, V. and Theoharides, T.C. Intimate contact between rat basophilic leukemia (RBL) and pheochromocytoma (PC-12) cells combined in culture. *Society for Neuroscience Abstracts* 16:973, 1990.
60. Correia, I. and Theoharides, T.C. Inhibition of mast cell secretion is associated with phosphorylation of the major protein kinase C substrate. *FASEB Journal* 5:1008, 1991.
61. Trnovsky, J., Letourneau, R. and Theoharides, T.C. Quercetin induces differentiation/maturation of rat basophilic leukemia cells. *FASEB Journal* 5:1006, 1991.
62. Moskowitz, M.A., Buzzi, M.G., Theoharides, T.C., Dimitriadou, V., Heath, H.H. and Carter, B. Evidence that serotonin receptors on trigeminovascular axons mediate the anti-migraine effects of ergot alkaloids and sumatriptan. *Neurology* 41(suppl. 1):164, 1991.
63. Leventhal, T., El-Mansoury, M. and Theoharides, T.C. Carbachol induces rat bladder mast cell serotonin release. *Clinical Research* 39:319, 1991.
64. Kouretas, D., Correia, I., Dimitriadou, V. and Theoharides, T.C. High affinity binding of progesterone to rat basophilic leukemia cells. *Clinical Research* 39:320, 1991.

65. Vliagoftis, H. and Theoharides, T.C. Cholera toxin inhibits rat mast cell secretion. *Journal of Cell Biology*, 115:24, 1991.
66. Buzzi, M.G., Dimitriadou, V., Theoharides, T.C. and Moskowitz, M.A. Neurogenic inflammatory response in rat dura mater is blocked by drugs that share 5-HT₁ like mechanisms. *Proc. 2nd International Union of Pharmacology Satellite Meeting on Serotonin* (Basel, Switzerland), 1991.
67. Moskowitz, M.A., Buzzi, M.G., Dimitriadou, V. and Theoharides, T.C. Evidence that antimigraine drugs via 5HT₁-receptors block peptide release and sterile inflammation in dura mater. *Proc. 16th International Conference on Stroke and Cerebral Circulation* (San Francisco), 1991.
68. Moskowitz, M.A., Buzzi, M.G., Carter, B., Dimitriadou, V., Theoharides, T.C. and Health, H. Evidence that serotonin-like heteroreceptors block neuropeptide release and neurogenic plasma extravasation to mediate the actions of ergot alkaloid and sumatriptan (GR 43175) in migraine headaches. *Proc. 15th International Symposium on Cerebral Blood Flow and Metabolism* (Miami), 1991.
69. El-Mansoury, M., Letourneau, R. and Theoharides, T.C. Carbachol-induced bladder mast cell secretion may be involved in neurogenic bladder inflammation and interstitial cystitis (IC). *Proc. 4th Interscience World Conference on Inflammation* (Geneva), 376, 1991.
70. Dimitriadou, V., Solomonides, J., Delihatsios, H. and Theoharides, T.C. Morphological and functional association of rat basophilic leukemia (RBL) and pheochromocytoma (PC-12) cells *in vitro*. *Proc. 4th Interscience World Conference on Inflammation* (Geneva), 377, 1991.
71. Dimitriadou, V., Buzzi, M.G., Theoharides, T.C. and Moskowitz, M.A. Anti-inflammatory effects of dihydroergotamine and sumatriptan in blood vessels and mast cells of dura mater. *Proc. 5th International Headache Congress* (Washington, D.C.), *Cephalalgia* 11(suppl. 11): 9-10, 1991.
72. Lambracht-Hall, M., Holdridge, M., Konstantinidou, V. and Theoharides, T.C. The antidepressant sertraline promotes serotonin secretion from thalamic mast cells and neurons. *Proc. 3rd IBRO World Congress of Neuroscience*, 23, 1992.
73. Rozniecki, J.J., Sugiultozglu, M. and Theoharides, T.C. Azatadine inhibits serotonin secretion from brain mast cells. *Proc. 8th International Congress of Immunology* (Budapest), 159, 1992.
74. Sant, G.R. and Theoharides, T.C. Activation of bladder mast cells in interstitial cystitis. *Proc. Can. Soc. Urology*, 47, 1992.
75. Bakos, P., Agelakas, J., Brophy, C.M., Letourneau, R.J. and Theoharides, T.C. Increased numbers of activated mast cells in abdominal aortic aneurysms. *FASEB Journal* 6:998, 1992.
76. Rozniecki, J.J., Sugiultozglu, M.K. and Theoharides, T.C. Histamine 3 (H₃)-receptor agonists inhibit brain mast cell and neuronal serotonin (5HT) secretion. *FASEB Journal* 6:1559, 1992.
77. Theoharides, T.C. and Sant, G.R. Hydroxyzine for the treatment of interstitial cystitis. *Journal Urology* 147:461, 1992.
78. Rozniecki, J.J., Letourneau, R.J., Sugiultozglu, M.K. and Theoharides, T.C. Histamine 3 (H₃) receptor antagonists potentiate brain mast cell (MC) and neuronal serotonin (5HT) and histamine secretion. *Molecular Biology of the Cell (suppl)*, 3:194, 1992.
79. Rozniecki, J.J., Hauser, S.L. and Theoharides, T.C. Elevated mast cell tryptase in cerebrospinal fluid (CFS) of patients with multiple sclerosis (MS). *FASEB Journal* 7:852, 1993.

80. Marchand, J., Pang, X., Sant, G.R., Kream, R.M. and Theoharides, T.C. Substance P (SP)-positive nerve fibers in interstitial cystitis (IC). *Society of Neuroscience Abstracts* 19:947, 1993.
81. Habibi, A., Pothoulakis, I., Letourneau, R. and Theoharides, T.C. Mast cells (MC) are increased in neoplastic as compared to non-neoplastic human thyroid tissue. *Molecular Biology of the Cell* suppl. 4:219, 1993.
82. Correia, I. and Theoharides, T.C. Characterization of the 78 kD phosphoprotein involved in inhibition of mast cell secretion - homology to Moesin. *Proc. 5th Interscience World Conference on Inflammation* (Geneva), 294, 1993.
83. Pang, X., Raam, S., Sant, G.R. and Theoharides, T.C. Estrogen receptor positive bladder mast cells in interstitial cystitis (IC). *Proc. 7th ICA/NIDDK IC Scientific Workshop* (Orlando), 18, 1993.
84. Theoharides, T.C. Treatment of interstitial cystitis (IC) symptoms with hydroxyzine. *Proc. 7th ICA/NIDDK IC Scientific Workshop* (Orlando), 50, 1993.
85. El-Mansoury, M., Boucher, W., Spanos, C., Sant, G.R. and Theoharides, T.C. Elevated urinary tryptase levels in interstitial cystitis patients. *Proc. 7th ICA/NIDDK IC Scientific Workshop* (Orlando), 1993.
86. Pang, X., Marchand, J., Sant, G.R., Kream, R.M. and Theoharides, T.C. Increased numbers of substance P (SP)-positive nerve fibers associated with bladder mast cells in interstitial cystitis (IC). *Proc. 7th ICA/NIDDK IC Scientific Workshop* (Orlando), 44, 1993.
87. Deliargyris, E.N., Theoharides, T.C. Differential effects of plant flavonoids on mast cell secretion. *European Academy of Allergology and Clinical Immunology* (Rotterdam, The Netherlands), p.109, 1993.
88. Rozniecki, J.J. and Theoharides, T.C. Functional relationship between dural mast cells and neurons. *Canadian Journal of Physiology and Pharmacology*, 72(suppl), 425, 1994.
89. Spanos, C.P., Rozniecki, J.J., Letourneau, R. and Theoharides, T.C. Dura mast cell activation and cerebrospinal (CSF) fluid rat mast cell protease (RMCP) elevations in a rat stress model. *Canadian Journal of Physiology and Pharmacology*, 72(suppl), 425, 1994.
90. Rozniecki, J.J., Spanos, C.P., Letourneau, R.J. and Theoharides, T.C. Heterogeneity of intracranial mast cells. *FASEB Journal*, 8:108, 1994.
91. Pang, X., Raam, S., Sant, G.R. and Theoharides, T.C. Estrogen receptor positive bladder mast cells in interstitial cystitis. *Journal of Urology, Proc 7th ICA/NIDDK IC Workshop*, (Orlando), 1993
92. Wang, L., Correia, I., Pang, X., Wang, Y. and Theoharides, T.C. Rat moesin: cloning phosphorylation and localization in mast cells. *FASEB Journal* 9A803:1995.
93. Boucher, W., Pang, X., Webster, E., Chrousos, G., Papanicolaou, D. and Theoharides, T.C. Corticotropin releasing hormone (CRH) induces rat mast cell (MC) secretion. *FASEB Journal* 9:A919, 1995.
94. Spanos, C., Letourneau, R., Sant, G.R. and Theoharides, T.C. Degranulation of rat bladder mast cells in a non-traumatic stress model. Implications for the pathophysiology of interstitial cystitis. *NIH Interstitial Cystitis Scientific Research Symposium*, (Bethesda), 110, 1995.
95. Pang, X., Letourneau, R., Triadafilopoulos, G., Sant, G.R. and Theoharides, T.C. Mast cell (MC)- substance P (SP) increases in the bladder and colon of a patient with interstitial cystitis (IC) and irritable bowel syndrome (IBS). *NIH Interstitial Cystitis Scientific Research Symposium*, (Bethesda), 59, 1995.

96. Theoharides, T.C., Pang, X., El-Mansoury, M. and Sant, G.R. Estrogen-positive mast cells (MC) are increased and their secretion in response to substance P (SP) is augmented by estradiol in interstitial cystitis (IC). *NIH Interstitial Cystitis Scientific Research Symposium*, (Bethesda), 77, 1995.
97. Webster, E., Papanicolaou, D.A., Boucher, W. Pang, X., Conlon, P., DeSouze, E., Theoharides, T.C. and Chrousos, G. The mast cell as a target of peripheral "immune" corticotropin-releasing hormone (CRH) and mediator of its proinflammatory properties: clinical implications. *The Endocrine Society*, 77:PI-669, 1995.
98. Theoharides, T.C., Wang, L., Correia, I., Pang, X. and Wang, Y. Inhibition of mast cell exocytosis by a unique phosphoprotein: cloning, phosphorylation and localization in mast cells. *NIH Immunology Workshop on "Signal transduction in mast cell activation and development"*, (Bethesda), 1995.
99. Spanos, C.P., Pang, X., Alexacos, N., Alferes, L., Ligris, K., Cochrane, D., Sant, G.R. and Theoharides, T.C. Neural activation of rat bladder mast cells (MC) by immobilization stress and significance for the etiology of interstitial cystitis (IC). *International Bladder Symposium*, 1996.
100. Rozniecki, J.J., Pang, X. and Theoharides, T.C. Colocalization of substance P-reactive neurons and mast cells in the dura mater - implications for headaches. *Proceeding 3rd EHF Conference*, February 29, 1996.
101. Theoharides, T.C. and Sant, G.R. Interstitial cystitis: a neuroimmunoendocrine disorder. *NeuroImmunoModulation*. 3:176, 1996.
102. Alexandrakis, M. and Theoharides, T.C. Inhibition of basophil leukemic cell (RBL) activation by flavonoids. *Proceedings 7th Panhellenic Hematology Congress*, p. 269 (Thessaloniki, Greece) December 14-17, 1996.
103. Pang, X., Spanos, C.P. and Theoharides, T.C. Stress-induced cardiac mast cell activation: implication for silent ischemia. *FASEB Journal*, 10:A34, 1996.
104. Sant, G.R., El-Mansoury, M. and Theoharides, T.C. *In situ* human bladder mast cell secretion in interstitial cystitis. *Br. Assn. Urol. Surgeons*, 1996, in press.
105. Spanos, C.P., Pang, X., Alexacos, N., Alferes, L., Ligris, K., Cochrane, D., Sant, G.R. and Theoharides, T.C. Neural activation of rat bladder mast cells (MC) by immobilization stress and significance for the etiology of interstitial cystitis (IC). *International Bladder Symposium* (Boston), 1996.
106. Boucher, W., Singh, L. and Theoharides, T.C. Differential effect of corticotropin-releasing hormone (CRH) on rat mast cell (MC) secretion. *FASEB J.* 10:A1290, 1996
107. Singh, L., Boucher, W., Pang, X., and Theoharides, T.C. Corticotropin-releasing hormone and immobilization stress induce skin mast cell degranulation and increased vascular permeability. *Society for Neuroscience Abstracts*, 23:714, 1997.
108. Theoharides, T.C., Boucher, W., Singh, L. and Pang, X. Urocortin is a potent inducer of skin mast cell activation and vasodilation: implications for stress-induced atopic diseases. *79th Annual Meeting of the Endocrine Society*, June 1997.
109. Theoharides, T.C., Boucher, W., Singh, L., Pang, X., Seretakis, D., Green, M. and Bastas, G. Urocortin powerfully induces mast cell-dependent skin vasodilation which may explain the role of stress in atopic diseases. *EAACI '97 Annual Meeting*, June 1-4, 1997.
110. Theoharides, T.C., Singh, L., Boucher, W., Pang, X., Seretakis, D., Green, M. and Bastas, G. Urocortin (Ucn) and corticotropin-releasing factor (CRF) trigger mast cell activation and increased vascular permeability: implications for the pathophysiology of stress-induced atopic and inflammatory syndromes. *7th Interscience World Conference*, Geneva, Switzerland, May 19-21, 1997.

111. Alexacos, N., Pang, X., Cochrane, D., Sant, G.R. and Theoharides, T.C. Bladder mast cell (MC) activation by acute psychological stress is blocked by a neurotensin (NT) receptor antagonist, a possible approach to the treatment of interstitial cystitis (IC). Proceedings, *ICA/NIDDK International Scientific Symposium*, p. 40 (Washington, D.C.) October 30-31, 1997.
112. Theoharides, T.C., Boucher, W. and Sant, G.R. Inhibitory effect of sulfated proteoglycans on mast cell (MC) secretion may explain their benefit in interstitial cystitis (IC). Proceedings, *ICA/NIDDK International Scientific Symposium*, p. 35 (Washington, D.C) October 30-31, 1997.
113. Theoharides, T.C., Boucher, W., Singh and Pang, X. Urocortin is a potent inducer of skin mast cell activation and vasodilation: Implications for stress-induced atopic diseases. Proceedings *79th Annual Meeting of The Endocrine Society*, p. 89 (Minneapolis, MN) June 11-14, 1997.
114. Theoharides, T.C., Pang, X., Alexakos, N., Seretakis, D. and Cochrane, D. A neurotensin (NT) receptor antagonist blocks stress-induced cardiac mast cell (MC) degranulation. Proceedings *ISHR World Congress* (Rhodes, Greece) May 27-31, 1998. *J. Mol. Cellular Cardiol.* 30:A189, 1998.
115. Theoharides, T.C., Boucher, W. Sulfated polysaccharides inhibit mast cell (MC) secretion and may be useful in bone inflammation. *FASEB, J.* 12:A761, 1998.
116. Alexandrakis, M., Huang, M., Theofilopoulos, P., Boucher, W., Seretakis, D., Letourneau, R. and Theoharides, T.C. Flavonoids inhibit proliferation and constitutive secretion of human leukemic mast cells (HMC-1) in culture. *FASEB, J.* 12:A896, 1998.
117. Patra, P.B., Hesse, L., Boucher, W., Letourneau, R. and Theoharides, T.C. Chondroitin sulfate (CS) inhibits mast cell secretion. *FASEB J.* 13:A149, 1999.
118. Esposito, P., Pang, X., Boucher, W. and Theoharides, T.C. Acute psychological stress induces mast cell dependent increase in brain vascular permeability: implications for multiple sclerosis (MS). *FASEB J.* 13:A326, 1999.
119. Chiang, G., Patra, P., Boucher, W., Letourneau, R., Jeudy, S., Sant, G.R. and Theoharides, T.C. Elmiron is a potent inhibitor of mast cell secretion. *FASEB J.* 14:A779, 1999.
120. Deliargyris, E.N., Dehmer, G.J., Tate, D.A., Smith, S.C., Boucher, W.S. and Theoharides, T.C. Elevated mast cell mediators in the coronary circulation of patients with coronary artery disease (CAD). *Atherosclerosis* 144(Suppl. I):I120, 1999.
121. Deliargyris, E.N., Kontos, J.L., Dehmer, G.J., Boucher, W.S. and Theoharides, T.C. Tryptase, a novel modulator of fibrinogen activity is elevated in patients with coronary artery disease. *Proc. 4th Int. Fibrinogen Symposium (Paris, February 3-4) Blood Coagulation & Fibrinolysis* 10 (Suppl):S108 1999.
122. Theoharides, T.C., Patra, P., Letourneau, R., Theofilopoulos, P., Boucher, W. and Lytinas, M. Chondroitin sulfate is a natural anti-allergic agent. *Proc. 18th Congress of the European Association of Allergology and Clinical Immunology* (Brussels, Belgium, July 3-7) *European J Allergy Clinical Immunol* 54 (Suppl 52):154, 1999.
123. Deliargyris, E.N., Raymond, R.J., Theoharides, T.C., Boucher, W.S., Tate, D.A., Smith, S.C. and Dehmer, G.J. Interleukin-6 release in the coronary circulation of patients with acute coronary syndromes. *Proc. 21st Congress of the European Society of Cardiology* (Barcelona, August 28-Sept. 1) *Eur. Heart J.* 20 (Suppl. I):I395, 1999.

124. Deliargyris, E.N., Raymond, R.J., Theoharides, T.C., Boucher, W.S., Tate, D.A. and Dehmer, G.J. Elevated serum interleukin-6 levels are from cardiac sources in acute coronary syndromes, but not in congestive heart failure. *Proc. Circulation* 100(Suppl. I):I-372, 1999.
125. Rozniecki, J.J., Pang, X. and Theoharides, T.C. Colocalization of substance P - reactive neurons and mast cells in the rat dura mater - implications for headaches. *3rd European Headache Foundation Conference*, in press.
126. Filippou, A., Sant, G.R. and Theoharides, T.C. Increased expression of ICAM-1 in bladder of interstitial cystitis patients. *Proc. Annual Meeting of the Urology Association (Dallas TX, May 1-6, 1999)*, in press.
127. Theoharides, T.C., Wang, L., Pang, X., Letourneau, R., Culm, K.E., Basu, S., Wang, Y. and Correia, I. Cloning and cellular localization of the rat mast cell 78kD protein phosphorylated in response to the mast cell "stabilizer" cromolyn: a target of the ERM family of proteins linking the cell surface to the cytoskeleton. *Proc. European Conference on Biomedical Research and Peace (Cyprus, October 17-21)*, p57. 1999.
128. Theoharides, T.C., Esposito, P., Pang, X., Boucher, W. and Spear, K. Acute psychological stress induces mast cell dependent increase in brain vascular permeability: implications for multiple sclerosis (MS) and inhibition by hydroxyzine. *Proc. European Conference on Biomedical Research and Peace (Cyprus, October 17-21, 1999)*, p58.
129. Chiang, G., Patra, P., Boucher, W., Letourneau, R., Jeudy, S., Sant, G.R. and Theoharides, T.C. Elmiron is a potent inhibitor of mast cell secretion. *Proc. International Bladder Symposium (Washington DC, November 5-6, 1999)*.
130. Deliargyris, E.N., Dehmer, G.J., Pye, J.P., Smith, S.C., Boucher, W.S. and Theoharides, T.C. Mast cell tryptase: a new inflammatory marker in patients with stable coronary artery disease. *Eur Heart J* 21(Suppl. I):I-159, 2000.
131. Deliargyris, E.N., Raymond, R.S., Theoharides, T.C., Boucher, W.S., Pye, J.P., Smith, S.C. and Dehmer, G.J. Elevated serum IL-6 levels in asymptomatic left ventricular systolic dysfunction. *Eur Heart J*, 21(Suppl. I): I-664, 2000.
132. Deliargyris, E.N., Raymond, R.S., Theoharides, T.C., Boucher, W.S., Pye J.P., Smith Jr. S.C. and Dehmer, G.J. Cytokine production in subclinical left ventricular dysfunction. *Eur J Heart Fail*, (Suppl. I):I-9, 2000.
133. Deliargyris, E.N., Raymond, R.S., Theoharides, T.C., Pye, J.P., Boucher, W.S. and Dehmer, G.J. Elevated serum IL-6 levels in patients with asymptomatic left ventricular dysfunction. *Circulation (Suppl. II)* 102:II-781, 2000.
134. Theoharides, TC. Acute stress induces cardiac IL-6 release and inflammation: Therapeutic effect of natural flavonoids. *Proceedings Sixth Conference of the World Hellenic Biomedical Association, Athens, Greece (October 11-14, 2000)*.
135. Esposito, P., Jacobson, S., Gheorge, D., Kandere, K. and Theoharides, T.C. Acute immobilization stress increases blood-brain-barrier permeability in mast cell rich brain regions. *Soc. for Neuroscience*.26:1271, 2000.
136. Esposito, P., Jacobson, S., Georghe, D., Pang, X., Kandere, K. and Theoharides, T.C. Acute immobilization stress increases ⁹⁹Technetium extravasation in distinct brain areas. *FASEB J.*, in press.
137. Huang, M., Kempuraj, D., Boucher, W., Letourneau, R. and Theoharides, T.C. Differential release of histamine and IL-6 from umbilical cord blood-derived human cultured mast cells. *FASEB J.*, in press.
138. Kandere-Grzybowska, K., Theoharides, T.C. IL-1 induces differential release of IL-6 from human cells. *Experimental Biology 2002 (Louisiana, April 20-24)* 16:A245.8, 2002.

139. Huang, M., Theoharides, T.C. Stress-induced interleukin-6 release in mice is mast cell-dependent and also involves cardiomyocytes stimulated by urocortin. *Experimental Biology 2002* (Louisiana, April 20-24) 16:A182, 2002.
140. Kempuraj, D., Theoharides, T.C. Effect of flavonoids on mediator release from human umbilical cord blood-derived cultured mast cells. *FASEB J*, (Louisiana, April 20-24,) 16:A549, 2002.
141. Kempuraj, D., Huang, M., Boucher, W., Kaudere, K., Letourneau, R., Jeudy, S., Fitzgerald, K., Spear, K., Athanasiou, A. and Theoharides, T.C. Azelastine is more potent than olopatadine in inhibiting interleukin-6 (IL-6) and other mediator release from human umbilical cord blood - derived cultured mast cells. *Am. Acad, Allergy, Asthma and Immunol*, 88:501-506, 2002.
142. Kandere, K., Boucher, W., Letourneau, R. and Theoharides, T.C. Laser Doppler flowmetry and 99-Tc-Gluceptate (⁹⁹Tc-G) extravasation to assess cortical cerebral blood flow (cCBF) and dura vascular permeability during acute restraint stress in knock-out mice. *Proc. XIVth World Congress of Pharmacology* (San Francisco, July 7-12, 2002), *The Pharmacologist*: 44:A58, 2002.
143. Theoharides, T.C, Stein, M., Spear, K., and Hauser, S.. A pilot, double-blind, study using hydroxyzine in remitting-relapsing multiple sclerosis (RR-MS), *Proceedings XIVth World Congress on Pharmacology*, San Francisco, CA (July 7-12, 2002). *The Pharmacologist* 44:A165, 2002.
144. Kandere-Grzybowska, K., Theoharides, T.C. IL-1 induces differential release of IL-6 from human mast cells. *Proc. New England Pharmacologists 31st Annual Meeting* (Hanover, NH, January 25-26, 2002).
145. Kandere-Grzybowska, K., Theoharides, T.C. IL-1 induces differential release of IL-6 from human mast cells. *FASEB J*, (New Orleans, April 20-24, 2002).
146. Kempuraj, D., Huang, M., Boucher, W., Letourneau, R., Jeudy, S., Bates, K., Spear, K., Athanasiou, A. and Theoharides, T.C. Azelastine inhibits interleukin-6 production and intracellular calcium ion levels in human umbilical cord blood-derived cultured mast cells. *Intl Arch Allergy Immunol*.
147. Sugimoto, K., Kandere, K., Kempuraj, D., Letourneau, R., Athanasiou, A. and Theoharides, T.C. Human mast cell expression of corticotropin-releasing hormone (CRH) receptors and selective release of interleukin-6 (IL-6) by CRH may explain stress-induced atopic diseases. *Proc. XIVth World Congress of Pharmacology* (San Francisco, July 7-12, 2002), *The Pharmacologist*: 44:A241, 2002.
148. Basu, S., Boucher, W., Huang, M., Sant, G.R., Theoharides, T. C. Pentosan polysulfate (PPS) inhibits intravesical carbachol-induced urine histamine and interleukin-6 (IL-6) release, as well bladder NF-kappaB (NF- κ B) activation. *Proc. 71st Annual Meeting, New England Section of the AUA*, 2002, in press.
149. Boucher, W., Huang, M., Sant, G.R., Theoharides, T.C. Chondroitin sulfate (CS) and sodium hyaluronate (SH) inhibit intravesical carbachol triggered urine histamine release. *Proc. 71st Annual Meeting, New England Section of the AUA*, 2002, in press.
150. Upadhyay, B., Kontos, J.L., Ardeshirpour, F., Pye, J.P., Boucher, W.C., Theoharides, T.C. Dehmer, G.J., Deliargyris, E.N. Mast cell tryptase is not elevated in patients with left ventricular systolic dysfunction. *J Heart Fail* 7:72, 2002.
151. Kempuraj, B., Kempuraj, D., Christodoulou, S., Boucher, W., Tsapikidis, S., Athanassiou, A., Theoharides, T.C. High intrauterine levels of corticotropin-releasing hormone, urocortin, tryptase and IL-8 in habitual abortions. *Experimental Biology 2003* (San Diego, CA, April 11-15, 2003) *FASEB* 130:A446. 2003.

152. Mattheos, S., Christodoulou, S., Kempuraj, D., Kempuraj, B., Karalis, K., Theoharides, T.C. Mast cells and corticotropin-releasing hormone (CRH) are required for experimental inflammatory arthritis. *FASEB, Proc. Am. Assoc. Immunologist 90th Anniv Meeting* (Colorado, May 6-10, 2003), 17:C44, 2003.
153. Cao, J., Papadopoulou, N. Theoharides, T.C. Identification of functional corticotropin-releasing hormone (CRH) receptor isoforms in human leukemic mast cells (HMC-1). *Molecular Biology of the Cell* (San Francisco, December 13-17, 2003) The American Society for Cell Biology 43rd Annual Meeting, 14:L212, 2003
154. Christodoulou, S., Papadopoulou, N., Mattheos, S., Kempuraj, D., Kempuraj, B., Karalis, K. and Theoharides, T.C. Mast cells and corticotropin-releasing hormone (CRH) are required for experimental inflammatory arthritis. *Molecular Biology of the Cell*, The American Society for Cell Biology 43rd Annual Meeting, (San Francisco; December 13-17, 2003) 14:L357, 2003.
155. Wei, D., Li, L., Rugg, A., Abdul-Hadi, K., Rogers, J., Rosenberg, A., Rounsley, S., McCarroll, R., Trusheim, M., Wiegand, R., Boucher, W., Sant, G.R., Theoharides, T.C. Diagnosis of interstitial cystitis using biochemical profiling. *Proc. Intl. Consultation on Interstitial Cystitis Japan* (March 28-30, 2003) Kyoto, Japan.
156. Osborne, J., Sant, G.R., Theoharides, T.C. Increased rate of spontaneous abortions in interstitial cystitis patients? *Proc. NIDDK/ICA Conf. on Interstitial Cystitis* (October 31-November 1, 2003) Washington, DC
157. Green, M., Sant, G.R., Theoharides, T.C. Increased expression of intercellular adhesion molecules in interstitial cystitis. *Proc. NIDDK/ICA Conf. on Interstitial Cystitis* (October 31-November 1, 2003) Washington, DC
158. Theoharides, T.C. Sant, G.R. A pilot, open-label, clinical study on the effect of CystoProtek in interstitial cystitis. *Proc. NIDDK/ICA Conf. on Interstitial Cystitis* (October 31-November 1, 2003) Washington, DC
159. Wei, D., Li, L., Rugg, A., Abdul-Hadi, K., Rogers, J., Rosenberg, A., Rounsley, S., McCarroll, R., Trusheim, M., Wiegand, R., Boucher, W., Sant, G.R., Theoharides, T.C. Rapid and sensitive diagnosis of interstitial cystitis using biochemical profiling. *Proc. NIDDK/ICA Conf. on Interstitial Cystitis* (October 31-November 1, 2003) Washington, DC
160. Donelan, J.M., Boucher, W., Letourneau, R. and Theoharides, T.C. Corticotropin-releasing hormone (CRH) and neuropeptides in stress-induced skin mast cell activation. *Ann. Meeting N.E. Pharmacologists*, P9 (Feb. 6-7, 2004) Portland, Maine.
161. Kempuraj, D., Boucher, W., Letourneau, R., Madhappan, B., Christodoulou, S., Athanassiou, A., and Theoharides, T.C. Comparative inhibitory effect of flavonoids quercetin, kaempferol, myricetin and morin to that of cromolyn on pro-inflammatory mediator release and on intracellular calcium ion levels from human mast cells. *Experimental Biology 2004* (Washington, DC, April 15-17, 2004) *FASEB* 131:A446. 2004.
162. Kempuraj, D., Papadopoulou, N., Oleson, L., Cao, J. and Theoharides, T.C. Human umbilical cord blood-derived mast cells (hCBMCs) express corticotropin-releasing hormone (CRH) receptor 2 which is up-regulated by proinflammatory molecules. *Proc. 6th International Cord Blood Society Congress* (Boston, MA October 3, 2004).
163. Cao, J., Papadopoulou, N., Kempuraj, D. and Theoharides, T.C. Human umbilical cord blood-derived mast cells (hCBMCs) express multiple isoforms of corticotropin-releasing hormone (CRH) receptors. *Experimental Biology 2005* (San Diego, CA, March 31-April 5, 2005).
164. Cao, J., Kempuraj, D., William B. and Theoharides, T.C. Corticotropin-releasing hormone (CRH) induces secretion of vascular endothelial growth factor (VEGF) from human mast cells. *Experimental Biology 2005* (San Diego, CA, March 31-April 5, 2005).

165. Donelan, J., Marchand, J., Lytinas, M., Boucher, W., Papaliadis, D. and Theoharides, T.C. Co-expression of corticotropin-releasing hormone (CRH) and neurotensin (NT) in mouse dorsal root ganglia (DRG) and effect on skin vascular permeability. *Experimental Biology 2005* (San Diego, CA, March 31-April 5, 2005).
166. Farwell, K., Bhattacharya, K., Huang, M., D. Kempuraj, D., Cao, J., Donelan, J. and T.C. Theoharides. Myocardial ischemia-reperfusion Injury results in less cardiac tissue damage and no serum IL-6 concentration change in W^V/W^V mast cell deficient mice as compared to their normal littermates. *Experimental Biology 2006*, in press
167. Kempuraj, K., Geiger, B., Tagen, M., Boucher, W. and Theoharides, T.C. Myelin basic protein (MBP) triggers IL-8 and tryptase release from human umbilical cord blood-derived mast cells. *J Immunol* (Boston, May 12-16) 176:S4, 2006.
168. Hyde, B.B., Papadopoulou, N. and Theoharides, T.C. Human mast cells express TLR 3, 7 and TLR-9 mRNA is induced by viral sequence K3 CPG-ODN. *Proc. Am. Association of Immunologists* (Boston, May 12-16), 176:S322, 2006.
169. Boucher, W., Donelan, J., Leeman, S. and Theoharides, T.C. The neurotensin (NT) receptor antagonist SR-48,692 inhibits mast cell-dependent rat skin vascular permeability induced by NT, but also compound 48/80, SP and VIP. *Proc. Am. Association of Immunologists* (Boston, May 12-16) C167, 2006.
170. Bhattacharya, K., Farwell, K., Huang, M., Kempuraj, D. and Theoharides, T.C. Mast-cell deficient mice produce less circulating IL-6 and exhibit less cardiac tissue damage than their littermates following myocardial ischemia reperfusion injury. *Circulation Res.* 99 (5):E43-43 (September 1, 2006).
171. Makris, M., Kalogeromitros, D., Kempuraj, D., Katsarou-Katsari, A., Grigoriou, S. and Theoharides, T.C. Theophylline as “add-on” therapy to cetirizine in patients with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled pilot study. *Proc. European Histamine Research Society XXXV Annual Meeting* (May 10-13 2006, Delphi, Greece).
172. Theoharides, T.C., Kempuraj, D. Amitriptyline inhibits mast cell histamine secretion: implications for chronic fatigue syndrome therapy. *Proc. European Histamine Research Society XXXV Annual Meeting* (May 10-13 2006, Delphi, Greece).
173. Kalogeromitros, D., Papadopoulou, N., Staurianeas, N.G., Tiblalex, D., Theoharides, T.C. Skin histidine decarboxylase (HDC) and corticotropin-releasing hormone receptor-1 (CRH-R1) genes are overexpressed in chronic urticaria (CU). *Proc. European Histamine Research Society XXXV Annual Meeting* (May 10-13 2006, Delphi, Greece).
174. Theoharides, T.C., Cao, J., Papadopoulou, N., Kempuraj, D., Tagen, M. Evidence of human mast cell function in inflammatory diseases. *Proc. European Histamine Research Society XXXV Annual Meeting* (May 10-13 2006, Delphi, Greece).
175. Cao, J., W. Boucher, W., Donelan, J.M. and Theoharides, T.C. Intravesical corticotropin-releasing hormone (CRH) induces mast cell-dependent vascular endothelial growth factor (VEGF) release from mouse bladder explants. *Proc. NIDDK International Symposium: Frontiers in Painful Bladder Syndrome and Interstitial Cystitis* (October 24-27, 2006; Bethesda, MD).
176. Marchand, J., Kempuraj, D., Vasiadi, M., Theoharides, T.C. Corticotropin-releasing hormone receptor expression in human urothelium and association with mast cells. *Proc. NIDDK International Symposium: Frontiers in Painful Bladder Syndrome and Interstitial Cystitis* (October 24-27, 2006; Bethesda, MD).

177. Boucher, W., Kempuraj, D., Cao, J., Theoharides, T.C. Intravesical suplatast tosilate (IPD-1151T) inhibits experimental Bladder inflammation. *Proc. NIDDK International Symposium: Frontiers in Painful Bladder Syndrome and Interstitial Cystitis* (October 24-27, 2006; Bethesda, MD).
178. Theoharides, T.C., Vakali, S., D. Kempuraj, D., Sant, G.R. A retrospective open label study of CYSTOPROTEK® in painful bladder syndrome/interstitial cystitis (PBS/IC). *Proc. NIDDK International Symposium: Frontiers in Painful Bladder Syndrome and Interstitial Cystitis* (October 24-27, 2006; Bethesda, MD).
179. Boucher, W., Stern, J.M., Kempuraj, D., Papaliadis, D., Cohen, M.S., Theoharides, T.C. Intravesical nanocrystalline silver (NCS) inhibits experimental bladder inflammation in rats. *Proc. NIDDK International Symposium: Frontiers in Painful Bladder Syndrome and Interstitial Cystitis* (October 24-27, 2006; Bethesda, MD).
180. Boucher, W., V. Kotsinyan, V., Kempuraj, D., Shing, R., Theoharides, T.C. Corticotropin-releasing hormone receptor (CRH-R) involvement in CRH-induced mouse bladder inflammation. *Proc. NIDDK International Symposium: Frontiers in Painful Bladder Syndrome and Interstitial Cystitis* (October 24-27, 2006; Bethesda, MD).
181. Kempuraj, D., Tagen, M., Iliopoulou, B.P., Vasiadi, M., Boucher, W., House, M., Theoharides, T.C. Myelin basic protein stimulates human mast cells and together they activate T cells: inhibition by luteolin and implications for multiple sclerosis. *Proc. Keystone Symposia. Mast cells, Basophils, and IgE: Host Defenses and Disease*, p. 52 (January 20-24, 2007; Copper Mountain, CO).
182. Maliakal, J.C., Tagen, M., Drori, T., Kempuraj, D., Biran, I., Theoharides, T.C. Live cell imaging of human mast cells on a pico-well live cell array at single cell resolution. *Proc. Keystone Symposia. Mast cells, Basophils, and IgE: Host Defenses and Disease*, p. 56 (January 20-24, 2007; Copper Mountain, CO).
183. Karapanou, V., Theoharides, T.C. Interleukin-8 and TNF-alpha detection in gingival crevicular fluid of teeth with acute pulpitis. *Proc. Annual Meeting of the American Society of Endodontics* (April 27-29, 2007; Philadelphia, PA).
184. Kempuraj D., Boucher W., Theoharides T.C. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells: implications for the treatment of allergic and inflammatory disorders. *Proc. BIO International Convention* (May 7-9, 2007; Boston, MA).
185. Theoharides, T.C. Kounis syndrome. In: Drug-Eluting Stents: Thrombosis and Hypersensitivity. *Proc. 56th Annual Scientific Session, Am. College of Cardiology* (March 24-27, 2007; New Orleans, LO), in press.
186. Kempuraj, D., Iliopoulou, B.P., Clemons, A., Boucher, W., Tagen, M., Vasiadi, M., House, M., Wolfberg, A., Theoharides, T.C. Substance P stimulates human mast cells and together they activate T cells: Inhibition by luteolin. *Proc. Am. Association of Immunologists* (2007).
187. Theoharides, T.C. CRH, mast cells and bladder function. *HANS SELYE and Saint Justine Hospital Centennial Symposium: Stress: basic Mechanisms and Clinical Implications* (July 11-14, 2007, UNIVERSITÉ DU QUÉBEC À MONTRÉAL (UQAM), Montreal, Quebec, Canada).
188. Theoharides TC. Mast cells, T cells and inhibition by luteolin: Implications for the pathogenesis and treatment of multiple sclerosis. *2nd International Immune Mediated Diseases Congress* (September 10-14, 2007, Moscow, Russia).
189. Tagen, M., Elorza, A., Shirihai, O., Theoharides, T.C. Inhibition of mast cell degranulation by PPAR α agonists is mediated through UCP2. *Experimental Biology 2008-Abstract #1139.1*. (April 5-9; San Diego, CA)

190. Tagen, M., Elorza, A., Shirihai, O., Theoharides, T.C. Uncoupling protein 2 regulates histamine production and mast cell activation *New England Pharmacologists Meeting 2008*-Abstract O-15. (Feb 29-March 1; Dedham, MA).
191. Vasiadi, M., Kalogeromitros, D., Kempuraj, D., Theoharides, T.C. *Rupatadine inhibits mediator secretion from human mast cells*. XXVII Congress of the European Academy of Allergology and Clinical Immunology (June 7-11; Barcelona, Spain), in press.
192. Kempuraj, D., Iliopoulou, B.P, Clemons, A, Boucher, W, Tagen, M, Vasiadi, M, House, M, Wolfberg, A, Theoharides, T.C. Human mast cells stimulate activated T cells, an effect increased by substance P and inhibited by the flavonoid luteolin. XXVII Congress of the European Academy of Allergology and Clinical Immunology (June 7-11; Barcelona, Spain), in press.
193. Tagen, M., Elorza, A., Shirihai, O., Theoharides, T.C. Uncoupling protein 2 regulates mast cell histamine production and activation. *FASEB 2008*, in press. 5th International Innate Immunity Conference (June 21-26; Hania, Greece, 2008).
194. Kempuraj, D., Hogan, J., Zhang, B., Kourelis, T., Manola, A., Theoharides, T.C. Mercury chloride triggers human mast cells to release vascular endothelial growth factor (VEGF)-relevance to autism. AAI, in press.
195. Asadi S, Zhang B, Weng Z, Angelidou A, Kempuraj D, Alysandratos K-D, Theoharides TC. Thimerosal induces VEGF release from human mast cells, but its effect is weakened by its thiosalicylate component and is blocked by luteolin. *The Emerging Neuroscience of Autism Spectrum Disorders: Etiologic Insights; Treatment Opportunities*. Society of Neuroscience (November 11-12, 2010; San Diego, CA).
196. Angelidou A, Francis K, Vasiadi M, Alysandratos K-D, Zhang B, Asadi S, Theoharides A, Lykouras L, Kalogeromitros D, Theoharides TC. Neurotensin is increased in serum of young children with autism. *The Emerging Neuroscience of Autism Spectrum Disorders: Etiologic Insights; Treatment Opportunities*. Society of Neuroscience (November 11-12, 2010; San Diego, CA).
197. Zhang B, Alysandratos K-D, Angelidou A, Vasiadi M, Kempuraj D, Tagen M, Asadi S, Theoharides TC. TNF secretion from human mast cells is regulated by mitochondrial dynamics and mitochondrial uncoupling protein 2 (UCP2). *Am. Assn. Immunol.* (May 14, 2010; Baltimore, MD)
198. Theoharides TC, B. Zhang B, Asadi S, Weng Z. Human mast cells secrete mitochondrial DNA that has inflammatory actions, is increased in the serum of children with autism and is inhibited by luteolin. *Am. Assn. Immunol.* (May 7, 2013; Honolulu, Hawaii)

i. Non-print publications

1. The *Pharmacology TextStack*. Educational Software for pharmacology available for Macintosh and windows. Keyboard Publishing, PA, 1992.

The *Pharmacology TextStack* is an electronic edition of *Pharmacology*, a student-friendly succinct text, problem and review book edited by Theoharis C. Theoharides and published by Little, Brown & Co, 1992. In addition to the complete text and all figures, diagrams and tables appearing in the textbook, this program also includes all of the review and self-testing materials from the text, with complete feedback on all questions and easy access to the full text for additional review.

This was the **only** textbook of pharmacology available in an electronic edition at the time and was ideal for teaching purposes. Each chapter in the *Pharmacology TextStack* begins with a statement of objectives and ends with a self-testing module linked to related sections in the chapter, making it ideal for easy incorporation into the pharmacology curriculum in medical, dental, pharmacy and basic science programs.

The *Pharmacology TextStack* enables you to locate, view, manipulate, tag and save information on key topics. As with other Keyboard Series software, the *Pharmacology TextStack* is fully searchable - locate any word or phrase from this 600 page text quickly and easily.

In addition, the *Pharmacology TextStack* includes a unique Transcript function that lets you build customized lessons for easy review and learning, letting you add your own notes to further enhance the materials provided by the program.

k. Invited Lectures

- 1) 1975 Genetics Colloquium, University of Michigan, Ann Arbor, MI
- 2) 1978 Biological Basis of Cancer Chemotherapy, Thessaloniki, Greece
- 3) 1980 Immunology Rounds, Johns Hopkins University/Good Samaritan Hospital, Bethesda
- 4) 1980 IXth Congress of the European Association of Poison Control Centers, Greece
- 5) 1981 Cystic Fibrosis Rounds, University of Florida, Gainesville
- 6) 1982 Health Care Delivery in Greece, New York
- 7) 1983 United Nations Environment Program - Mediterranean Action Plan, Athens
- 8) 1984 Gastroenterology Rounds, Boston University Medical Center, Boston
- 9) 1984 Ninth International Congress of Pharmacology, London
- 10) 1985 Immunotherapy of Cancer, Thessaloniki, Greece
- 11) 1986 Second World Conference on Inflammation, Monte Carlo
- 12) 1986 Conference on Healing, New York
- 13) 1986 Third E.N.T.- Neurosurgery Italian-Greek-Jugoslav Congress, Rome
- 14) 1986 National Conference on Cancer Treatment, Thessaloniki, Greece
- 15) 1987 World Conference on Analgesics, Caracas
- 16) 1987 Internal Medicine Association of Guatemala, Guatemala City
- 17) 1987 Neurology Grand Rounds, Social Security Administration of Mexico
- 18) 1987 Conference on Science and Religion, Boston
- 19) 1987 World Congress of Pediatrics, Panama
- 20) 1987 Fifth World Congress on Pain, Hamburg
- 21) 1987 35th Meeting of the European Tissue Culture Society, Patras, Greece
- 22) 1989 Third Interscience World Conference on Inflammation, Monte-Carlo
- 23) 1989 Fourth E.N.T. - Neurosurgery Italian-Greek-Jugoslav Congress, Greece
- 24) 1990 Annual Meeting, National Nutritional Foods Association, Boston
- 25) 1990 Panel speaker: 3rd ICA/NIH National Meeting on Interstitial Cystitis, New Orleans, LA
- 26) 1991 Sixth Panhellenic Congress of Otorhinolaryngology-Allergic Rhinitis, Thessaloniki
- 27) 1991 Panel Speaker: 4th ICA/NIH National Meeting on Interstitial Cystitis, Arlington, VA
- 28) 1992 First Panhellenic Congress of Allergy and Clinical Immunology, Athens

- 29) 1992 Pharmacology Program, Mt. Sinai School of Medicine, New York
- 30) 1992 Immunology Program, McMaster University, Canada
- 31) 1992 XI International Symposium on Infection and Allergy of the Nose, Rome
- 32) 1993 Fifth World Conference on Inflammation, Geneva
- 33) 1993 Keynote speaker: New trends in IC therapy, PA ICA Association, Harrisburg, PA
- 34) 1993 Keynote speaker: 7th NIH/ICA National Meeting, Orlando, FL.
- 35) 1993 Keynote speaker: *Pathophysiology of interstitial cystitis: the role of the mast cells*, First International Seminar on Female Urology in Patras, Greece (November 19-21, 1993).
- 36) 1994 *New Trends in the treatment of urticaria: neuroimmunoendocrine stimulation of skin mast cells*. Fourth International Symposium on Dermatology, Jeddah, Saudi Arabia (January 31-February 3, 1994).
- 37) 1994 *Differentiation and pathophysiology of bone marrow-derived mast cells*, Evangelismos General Hospital, Athens, Greece (February 7, 1994).
- 38) 1994 Keynote speaker: *The mast cell and inhibitors of its degranulation*, Second Panhellenic Congress of Allergy and Clinical Immunology in Athens, Greece (February 10-12, 1994).
- 39) 1994 *Pathophysiology of neuroimmunoendocrine syndromes*, AHEPA General Hospital, Thessaloniki, Greece (February 14, 1994).
- 40) 1994 *Inhibition of mast cell secretion by a unique phosphoprotein*, Yale University School of Medicine (May 20, 1994).
- 41) 1994 Keynote speaker: *Scientific and social implications of generic drug use*, Second Panhellenic Congress of Hospital Pharmacists, Thessaloniki, Greece (May 27, 1994)
- 42) 1994 Keynote speaker: *Politics and funding of drug development for orphan diseases*, Seventh Panhellenic Pharmaceutical Congress, Athens, Greece (June 11, 1994).
- 43) 1994 Keynote speaker: *Neuroimmunoendocrine involvement in interstitial cystitis*. Tenth Annual Meeting, Texas ICA, Houston, TX (November 5, 1994).
- 44) 1994 State of the Art Lecture: *Pathophysiology and treatment of interstitial cystitis*. C.E. Acken International Meeting in Wuppertal-Barmen, West Germany (December 1, 1994).
- 45) 1995 *Neuroimmunoendocrine stimulation of mast cells: new implications for pathophysiology and therapy*, Pulmonary and Critical Care Division, Tufts-New England Medical Center.
- 46) 1995 Plenary Lecture: *Neurogenic inflammation and neuroinflammatory disorders*. Sixth World Conference on Inflammation, Geneva, (March 28, 1995).
- 47) 1995 *Stress-induced skin mast cell activation*. International Meeting on Mast Cell-Neuron Interactions, Berlin (September 1995).
- 48) 1995 *Pharmacology of interstitial cystitis: workshop*. Eighth Annual ICA Meeting, San Diego (October 1995).

- 49) 1996 *The mast cell: a neuroimmunoendocrine master player.* 2nd European Medical Students' Symposium, Thessaloniki, Greece (May 4-5, 1996).
- 50) 1996 *New trends explaining the pathophysiology of allergy: correlation with neuroinflammatory syndromes.* Pan Cretan Medical Congress, Heraklion, Greece (October 24-27, 1996).
- 51) 1996 *Neuroimmunoendocrine basis of interstitial cystitis.* 3rd International Society for Neuroimmunomodulation, Bethesda MD (November 13-15, 1996).
- 52) 1996 *Pathophysiology of migraines and the role of stress.* First Pain Congress of the Hellenic Pain Society, Volos, Greece (December 1-3, 1996).
- 53) 1997 *Urocortin-induced skin mast cell activation and vasodilation: implications for the role of stress in atopic diseases.* Section of Allergy and Clinical Immunology, Yale University School of Medicine, New Haven, CT (March 7, 1997).
- 54) 1997 *A natural phosphoprotein inhibiting mast cell secretion: implications for the therapy of atopic diseases.* Annual Congress of the European Association of Allergy and Clinical Immunology, Rhodes, Greece (June 1-5, 1997).
- 55) 1997 *Urocortin and CRF trigger mast cell activation and increased vascular permeability: implications for the pathophysiology of stress-induced atopic and inflammatory syndromes.* Seventh Interscience World Conference on Inflammation, Geneva (May 19-21, 1997).
- 56) 1997 *Chairman, Round table discussion on post graduate medical education.* Third European Medical Student Congress, Crete, Greece (April 11-13, 1997).
- 57) 1997 *Chairman, Symposium on Immune-Neuronal-Endocrine Interactions in the Pathophysiology of Allergic and Autoimmune Diseases.* Annual Congress of the European Association of Allergy and Clinical Immunology, Rhodes, Greece (June 1-5, 1997).
- 58) 1997 *Grand Rounds. Interstitial Cystitis and Pelvic Pain.* Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (October 9, 1997).
- 59) 1997 *Pharmacology and Interstitial Cystitis.* Interstitial Cystitis Association's Ninth Annual Meeting, Arlington, VA (November 1 & 2, 1997).
- 60) 1997 *CRH-Induced Vascular Permeability and Its Role in Stress-Induced Syndromes.* University of Pennsylvania Medical Center (November 5, 1997).
- 61) 1998 *Allergy and mast cell mediators in cyclic vomiting.* 2nd International Scientific Symposium on Cyclic Vomiting Syndrome, Milwaukee, WI (April 24-25, 1998).
- 62) 1998 *Psychological stress triggers cardiac mast cell activation and myocardial ischemia in mice.* XVI World Congress of the International Society for Heart Research, Rhodes (May 30, 1998).
- 63) 1998 *Sex Differences in Pain Perception in Neuroinflammatory Syndromes.* 5th Congress of the Hellenic Anesthesiology and Intensive Care Medicine Society, Thessaloniki (June 5, 1998).
- 64) 1998 *Pharmacokinetics and polypharmacy in the elderly. The problem of benzodiazepines.* 5th Congress of the Hellenic Anesthesiology and Intensive Care Medicine Society, Thessaloniki (June 5, 1998).
- 65) 1998 *Health Care Opportunities in the Private Sector. Prospects and Challenges for the Greek and International Health Care Sector of Today and Tomorrow.* The Economist Conferences, Athens (November 11-12, 1998).
- 66) 1998 *Corticotropin releasing hormone and mast cells: a new view of neurogenic inflammation.* Endocrinology Grand Rounds, New England Medical Center (Nov 24).

- 67) 1999 *Biomedical research and health as stabilizing factors among world communities*. Key Note Address: Fifth World Hellenic Biomedical Conference, New York City (December 4-6, 1998).
- 68) 1999 *Novel approaches to pain: gender, sex and neurogenic inflammation*. HIT: Hellenic-Israeli-Turkish Conference on Pain, Crete (May 1999).
- 69) 1999 *Effect of acute stress on inflammatory processes*. European Conference on Biomedical Research and Peace, Cyprus (October 17-21, 1999).
- 70) 2000 *Pathophysiology and treatment of neuro-inflammatory syndromes*. First Congress of the Hellenic Pharmacological Society, Athens (February 19, 2000).
- 71) 2000 *The use and abuse of ethical medications: the next millennium*. The Economist Conferences, Athens (June 10, 2000).
- 72) 2000 *Translational Research: a case study*. First Conference on Biomedical Research in Education, Heraklion, Greece (October 6-8, 2000).
- 73) 2000 *Acute stress induces cardiac IL-6 release and inflammation: therapeutic effect of natural flavonoids*. Sixth Conference of the World Hellenic Biomedical Association, Athens, Greece (October 11-14, 2000).
- 74) 2001 *Benefits and risks of epharma*. European Conference on Health, Thessaloniki, Greece (March 8, 2001).
- 75) 2001 *Structural requirements for anti-inflammatory effects of flavonoids*. Advanced Medicinal Chemistry Seminars, Thessaloniki, Greece (May 18, 2001).
- 76) 2001 *Design and implementation of an electronic drug interactions program for Greece: why it is needed and why it is not in place. **The First Flessas Memorial Lecture***. The Hellenic Medical Society of New York and Hellenic Link, Inc. , New York City (June 10, 2001).
- 77) 2001 *Stress-induced inflammation: asthma, migraines, multiple sclerosis and beyond*. Plenary Lecture, National Minority research Symposium, Cancun, Mexico (October 18-20, 2001).
- 78) 2002 *Acute stress-induced blood-brain-barrier permeability, a mast cell and corticotropin releasing hormone dependent process*. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School (March 25, 2002).
- 79) 2002 *Selective release of IL-6 from human mast cells*. Keynote speaker. 8th Annual Meeting, The Mastocytosis Society, Windsor Locks, CT (October 4&5, 2002).
- 80) 200 2 *The role of mast cells in the neurocutaneous axis*. 1st International Workshop on cutaneous neuroendocrinology, Hamburg, Germany (Sept. 13-15, 2002).
- 81) 2002 *Dietary supplement effect on mast cells*. International Symposium on Complementary Alternative Medicine - Allergy, Asthma & Immunology, American College of Allergy, Asthma and Immunology, San Antonio, TX (Nov, 14, 2002).
- 82) 2003 *Mast cells in inflammatory arthritis*. Department of Biochemistry, Tufts University School of Medicine. Boston, MA (January 9, 2003).
- 83) 2002 *Abuse of OTC drugs*. Brookline High School, Brookline, MA. (December 2002 series).
- 84) 2003 *Abuse of dietary supplements*. Brookline High School, Brookline, MA (January 2003 series).
- 85) 2003 *Stress induced-bladder inflammation*. International IC Conference, Kyoto, Japan (March 28 – 30, 2003).
- 86) 2003 *Global health, leadership and world peace*. Keynote Address at 10th Annual Conference of the Midwest Institute, Cleveland, OH (April 5, 2003).

- 87) 2003 *Code 99: Cardiac mast cells feel the squeeze.* Department of Medicine, Tufts - New England Medical Center (April 8, 2003).
- 88) 2003 *Global education and world leadership.* Keynote address, St. Louis Community College, St. Louis, MO (August 25, 2003).
- 89) 2004 *The mast cell as an immune sensor of stress.* Dept. Of veterinary PathoBiology, College of veterinary Medicine, University of Minnesota, St. Paul, MN (April 28, 2004).
- 90) 2004 *Co-Chairman, Emerging Infectious Diseases and New Problems,* 3rd International Workshop on Immunology and Infectious Diseases, Naples, Italy (June 8-10, 2004).
- 91) 2004 *Corticotropin-releasing factor-mast cell axis: Link to allergic diseases.* Stress and Asthma, Arlington, VA (October 2, 2004).
- 92) 2004 *Stem cell physiology/The role of mast cells.* 6th International Cord Blood Society Congress, Boston, MA (October 3, 2004).
- 93) 2004 *Mast cells as key modulators of environmental and psychological stress.* 3rd International Conference on Innate Immunity, Hersonisos, Crete, Greece (October 11, 2004).
- 94) 2004 *Acute stress triggers selective mast cell activation through CRH and IL-1.* Gastroenterology Division, Beth Israel/Deaconess Medical Center-Harvard Medical School, Boston, MA (October 27, 2004).
- 95) 2004 *Selective mast cell activation mediates the effect of acute stress.* The Mind/Body Medical Institute-Harvard Medical School, Boston, MA (November 22, 2004).
- 96) 2005 *Activation of distinct CRH receptors leads to selective secretion of either IL-6 or VEGF from human mast cells.* 5th Mast Cell Workshop: Mast Cell Signaling and Function in Health and Disease, Eilat, Israel (February 6-10, 2005).
- 97) 2005 *Stress, mast cells and CR: The fateful triangle of inflammatory diseases.* 39th Annual Scientific Meeting of the European Society for Clinical Investigation, Athens, Greece (April 9, 2005).
- 98) 2005 *Critical role of mast cells in stress-induced inflammatory disorders.* 6th Meeting of the International Society for NeuroImmunoModulation. Athens, Greece (September 25-28, 2005).
- 99) 2005 *Neuroimmune aspects of painful bladder syndrome/interstitial cystitis and endometriosis: two major chronic pelvic pain disorders.* 6th Congress on Women's health & Disease. Athens, Greece (September 25-28, 2005).
- 100) 2005 *Critical role of mast cells and neuropsychiatric disorders.* Annual Meeting of the Systemic Mastocytosis Society, Santa Ana, CA (October 7-10, 2005).
- 101) 2005 *Mast cells in chronic fatigue syndrome and fibromyalgia.* Munich, Germany (November 28, 2005).
- 102) 2006 *Role of mast cells in inflammatory disorders.* 10th Medical Meeting of the Naval Hospital, Athens, Greece (February 10-11, 2006).
- 103) 2006 *Migraine headaches: the immunologist's view.* Cardiology Update 2006- Cardiology & Neurology at a Crossroad, Athens, Greece (April 14-15, 2006).
- 104) 2006 *The role of mast cells in acute coronary syndromes.* Cardiology Update 2006-Coronary Artery Disease Prevention & Therapy Update, Athens, Greece (April 14-15, 2006).
- 105) 2006 *Stress-induced skin mast cell activation and increased vascular permeability.* Conference on Stress and skin, New York, NY (June 2-5, 2006).

- 106) 2006 *Stress, mast cells and the blood-brain-barriers: the fateful triangle in MS pathogenesis*. Sero Pharmaceutical, Geneva, Switzerland (June 16, 2006).
- 107) 2006 *The immune sensor of environmental stress*. Hellenic Armed Forces Medical Symposium, Thessaloniki, Greece (Nov. 25, 2006).
- 108) 2007 *The spectrum of mastocytosis*. University of Carolina College of Pharmacy, Columbia, SC (January 23, 2007).
- 109) 2007 *Mastocytosis and mast cell activation diseases*. Hellenic Hematology Association, Athens, Greece (Feb. 3, 2007).
- 110) 2007 *The effect of stress on inflammatory diseases*. Open Public University and Hellenic Medical Society, Municipality of Hania, Crete, Greece (Feb. 21, 2007).
- 111) 2007 *Skin corticotropin-releasing hormone receptor expression in urticaria, psoriasis and mastocytosis-implications for multiple sclerosis*. Section of Allergy and Clinical Immunology, Yale University School of Medicine, New Haven, CT (March 9, 2007).
- 112) 2007 *Mast cell-dependent T cell stimulation and inhibition by luteolin*. Section of Allergy and Clinical Immunology, Yale University School of Medicine, New Haven, CT (March 9, 2007).
- 113) 2007 *Kounis syndrome*. In: *Drug-Eluting Stents: Thrombosis and Hypersensitivity*. 56th Annual Scientific Session, Am. College of Cardiology (March 24-27, 2007; New Orleans, LO).
- 114) 2007 *CRH, mast cells and bladder function*. HANS SELYE and Saint Justine Hospital Centennial Symposium: Stress: basic Mechanisms and Clinical Implications (July 11-14, 2007, UNIVERSITÉ DU QUÉBEC À MONTRÉAL (UQAM), Montreal, Qubec, Canada).
- 115) 2007 *Mast cells, T cells and inhibition by luteolin: Implications for the pathogenesis and treatment of multiple sclerosis*. 2nd International Immune Mediated Diseases Congress (September 10-14, Moskow, Russia).
- 116) 2007 *Selective release of mast cell mediators*. Department of Pathology, Boston University (October 2, 2007).
- 117) 2007 *Selective mediator release and effect of stress in urticaria pigmentosa*. Annual Meeting, US Systemic Mastocytosis Society (October 12, 2007; Houston, TX).
- 118) 2007 *CRH dysregulation in psoriasis*. 3rd Attikes Dermatology Days Congress (November 5, 2007; Athens, Greece).
- 119) 2007 *Regulation of selective release of mast cell mediators*. Brigham and Women's Hospital-Dana Farber Cancer Center, Harvard University (November 29, 2007; Boston, MA).
- 120) 2007 *Role of mast cells in wound healing*. 8th Annual Meeting on Wound Healing-Science and Industry-CME lecture (St. Thomas, USA; December 14, 2007).
- 121) 2008 *Interstitial Cystitis/Painful Bladder Syndrome*. University of Phoenix, (January 1, 2008; Phoenix, AZ).
- 122) 2008 *Mast cells, myelin basic protein and substance P enhance T cell activation: inhibition by luteolin and implications for multiple sclerosis*. International Conference on Neural Signaling (Feb. 16-20, 2008; Pacific Grove, CA).
- 123) 2008 *Interstitial Cystitis: Bladder Pain and Beyond*. Lakeland Medica Center-CME lecture, (March 20, 2008; St. Joseph, MI).
- 124) 2008 *Mast cells, myelin basic protein and substance P enhance T cell activation: and multiple sclerosis*. Department of Immunology, University of Connecticut (April 17, 2008; Farmington, CT).

- 125) 2008 *Chair, Round Table Discussion on pharmacology teaching.* 5th Panhellenic Congress of Pharmacology (May 23-25, 2008; Athens, Greece).
- 126) 2008 *Rupatadine inhibits mediator secretion from human mast cells.* XXVII Congress of the European Academy of Allergology and Clinical Immunology (June 7-11, 2008; Barcelona, Spain).
- 127) 2008 *Human mast cells stimulate activated T cells, an effect increased by substance P and inhibited by the flavonoid luteolin.* XXVII Congress of the European Academy of Allergology and Clinical Immunology (June 7-11, 2008; Barcelona, Spain).
- 128) 2008 *Mast cell-T cell interactions in health and disease.* 5th International Innate Immunity Conference (June 21-26, 2008; Hania, Greece).
- 129) 2008 *Role of mast cells in cancer growth.* 3rd PanHellenic Forum on Oncology (July 6-7, 2008; Hania, Greece).
- 130) 2008 *Novel therapeutic targets for autism.* Defeat Autism Now (October 24-26, 2008; San Diego, CA).
- 131) 2008 *New aspects of regulation of mast cell activation.* 5th Balkan Congress of Alleregology and Clinical Immunology October 17-19, 2008; Thessaloniki, Greece).
- 132) 2008 *Autism, food intolerance and mast cells.* 5th Balkan Congress of Alleregology and Clinical Immunology October 17-19, 2008; Thessaloniki, Greece).
- 133) 2008 *Neuropeptide interactions in skin inflammation.* Attica Dermatologic Days IV (November 21-23, 2008; Athens, Greece).
- 134) 2008 *Role of mast cells in mesenteric traction syndrome.* T-NEMC Anesthesia Grand Rounds (Dec. 8, 2008).
- 135) 2009 *Perinatal mast cell activation and risk of autism.* Yale University Allergy and Clinical Immunology Grand Rounds (February 9, 2009; New Haven, CT).
- 136) 2009 *Mast cells disrupt the gut-blood-brain barriers and contribute to autism.* Autism One 2009 Conference (Chicago, IL; May 22-24, 2009).
- 137) 2009 *Rupatadine: mechanism of action and anti-inflammatory effects. Why multiple actions? The Pharmacologist's point of view.* II Multidisciplinary Symposium. (Guatemala; May 29, 2009).
- 138) 2009 *Novel antihistamines: Dual anti-mediator action and anti-inflammatory effects.* XIX World Congress of Oto-Rhino-Laryngology (São Paulo, Brazil; June 3, 2009).
- 139) 2009 *Role of mast cells in blood-brain-barrier permeability and autism.* Autism 1 Conference (Chicago, IL; May 22, 2009).
- 140) 2009. *Mastocytosis, allergic symptomatology and autism.* National Autism Association (Fort Lauderdale, FL; Nov. 12, 2009).
- 141) 2009 *IL-33 augments substance P-induced VEGF release from human mast cells and its expression is increased in psoriasis.* Attica Dermatologic Days V (November 25, 2009; Athens, Greece).
- 142) 2009 *Anti-inflammatory effects of rupatadine.* Regional Allergy Update (Nicosia, Cyprus; Dec.7, 2009).
- 143) 2009 *Anti-inflammatory actions of newer anti-histamines.* (Berlin, Germany; Dec. 17, 2009).
- 144) 2010 *Mast cells and mitochondria: culprits in the pathogenesis of allergy.* PanHellenic Allergy Conference (Athens, Greece; April 17, 2010).

- 145) 2010 “Allergic-like” symptoms, brain inflammation and autism: beneficial effect of a luteolin formulation (NeuroProtek).” Autism 1 Conference (Chicago, IL; May 28, 2010).
- 146) 2010 “Mast cells and mitochondria-culprits in the pathogenesis of autism: novel treatment.” National Autism Association Conference (Tampa, FL; November 12, 2010).
- 147) 2010 “Mast cells and mitochondria: culprits in inflammation and auto-immunity” UCLA. (Los Angeles: December 13, 2010).
- 148) 2010 “Mast cells: multitasking at the edge of wounds.” Wound Healing Conference (St. Thomas; December 10, 2010).
- 149) 2011 “The role of IL-9 and IL-33 in mast cell activation.” Brigham & Women’s Hospital-Harvard Medical School. (Boston, MA; February 8, 2011).
- 150) 2011 “Neuroinflammation and disruption of the gut-blood-brain barriers-benefits of NeuroProtek .” Autism One (The Westin Hotel, Lombard, IL; May 26, 2011)
- 151) 2011 “Neurotensin and extracellular mitochondrial DNA as potential biomarkers and novel treatment targets.” (The Westin Hotel, Lombard, IL; May 26, 2011)
- 152) 2011 “Aberrant inflammatory response in autism-Mast cell activation and the latest research in novel biomarkers and treatment directions”. International Autism Biomedical Conference (Queen Mary University of London’ June 18-19, 2011)
- 153) 2011 “Neurotensin and extracellular mitochondrial DNA as potential biomarkers and novel treatment targets..” New York Metro Chapter –National Autism Association (New York, NY; September 8, 2011)
- 153) 2011 “Neuroinflammation and disruption of the gut-blood-brain barriers-benefits of NeuroProtek .” New York Metro Chapter –National Autism Association (Westchester, NY; September 9, 2011)
- 154) 2011 “Neurotensin and extracellular mitochondrial DNA as potential biomarkers and novel treatment targets.” Autism Canada Foundation- Changing the course of autism conference. (Kitchener/Waterloo, Canada; October 14, 2011)
- 155) 2011 “Role of Mast cells in blood-brain-barrier permeability and beneficial effect of select flavonoids.” Interscience Conference on Multiple Sclerosis (Athens Greece; October 1 2011)
- 156) 2011 “Mast cells and mitochondria: culprits in the pathogenesis of inflammatory skin diseases.” Second Seminar in Dermatology Research (Heraklion, Crete; October 1 2011)
- 157) 2011 “Neurotensin and extracellular mitochondrial DNA as potential biomarkers and novel treatment targets.” Autism One/Spectrum Possibilities (St. Michael, Barbados; November 5 2011)
- 158) 2011 “Increased oxidative stress and immune dysregulation in Autism Spectrum Disorders.” National Autism Conference (St. Pete Beach, FL; November 13 2011)
- 159) 2012 “Comparison of Cromolyn, Quercetin and Luteolin in Human Mast Cell Inhibition.” Regional Mastocytosis Conference (National Jewish Health Main Campus, Denver, CO; May 5th, 2012).
- 160) 2012 “Novel Treatment Approaches for Autism.” The Massachusetts Chapter of TACA.org (Talk About Autism Now, Wrentham Senior Center, Wrentham, MA ; May 8, 2012).
- 161) 2012 “Can we block mast cell activation?” Regional Mastocytosis Conference (Edwardsville Library, Edwardsville, IL; May 5, 2012).

- 162) 2012 “*Can the peptide neurotensin connect the dots and serve as a novel target for autism therapy?*” Autism One (The Westin Lombard Yorktown Center, Lombard, IL; May 25, 2012).
- 163) 2012 “*Is there an intervention that combines anti-oxidant, anti-inflammatory, metal chelating, mitochondrial protective, and neuroprotective effects?*” Autism One (The Westin Lombard Yorktown Center, Lombard, IL; May 27, 2012).
- 164) 2012 “*Flavonoid combinations for cancer treatment.*” Emory University (Atlanta, GA; June 1, 2012).
- 165) 2012 “*How genes and environment contribute to brain inflammation and symptoms.*” Family Café (Hilton, Orlando, FL; June 15, 2012).
- 166) 2012 “*Novel Treatment Approaches to Autism: How genes and environment contribute to brain inflammation and symptoms.*” (West Palm Beach, FL;
- 167) 2012 “*Novel Treatment Approaches to Autism: How genes and environment contribute to brain inflammation and symptoms.*” Autism in Motion (Montreal, Canada; August 19, 2012).
- 168) 2012 “*Neuro-inflammatory actions of human mast cells and comparison of the inhibitory effects of ketotifen, cromolyn, quercetin and luteolin.*” (Cincinnati, OH; September 22, 2012).
- 170) 2012 “*Activation of mast cells by the unique target mTOR leads to neurological symptoms inhibited by luteolin.*” 18th Annual Conference of the Mastocytosis Society (Bellevue, WA; October 11-14, 2012).
- 171) 2012 “*Activation of mast cells and neuroglia leads to brain inflammation inhibited by luteolin-implications for treatment of Alzheimer’s disease and Autism.*” 8th Annual Conference of the European Nutraceutical Association (Munich, Germany: November 3, 2012).
- 172) 2012 “*Novel Treatment Approaches to Autism: How genes and environment contribute to brain inflammation and symptoms.*” National Autism Association (St. Petersburg, FL; November 9-11, 2012).
- 173) 2013 “*Neurotensin triggers brain inflammation blocked by liposomal luteolin-implications for the pathogenesis and treatment of autism.*” Tufts Medical Center (Boston, MA;
- 174) 2013 “*Innate Pathogens*” causing focal brain inflammation.” Autism One (Chicago, IL; May 23, 2013).
- 175) 2013 “*A cell for all seasons: The mast cell.*” (West Roxbury VA Medical Center (West Roxbury, MA; June 3, 2013).
- 176) 2013 “2013 “*New autism treatments target: Innate pathogens causing brain inflammation-Cutting down autism by fighting brain immunity storms.*” ICare4Autism (New York, NY; June 6, 2013).
- 177) 2013 “*New autism treatments target: Innate pathogens causing brain inflammation.*” Family Café (Orlando, FL; June 7, 2013).
- 178) 2013 “*Fibromyalgia neuro-inflammatory findings point to new treatments.*” Family Café (Orlando, FL; June 7, 2013).
- 179) 2013 “*Mast Cell Disorders and Neurological Symptoms.*” The Mastocytosis Society Annual Meeting (Greenville, SC; Sep 26-29, 2013)
- 180) 2013 “*Mast Cells, Coronary Hypersensitivity, Kounis syndrome and Takotsubo Cardiomyopathy*” The Mastocytosis Society Annual Meeting (Greenville, SC; Sep 26-29, 2013)

- 181) 2013 “*Allergy of the Brain*” Medical Academy of Pediatric Special Needs Conference (MAPS) Clinician’s CME Training (Tampa, FL; Oct 3-5, 2013).
- 182) 2013 “*New Autism Treatments Target Pro-Inflammatory “Innate Pathogens”*”, Autism Avenue 2013 Regional “Possibilities and Potential” Autism/Asperger Conference and Expo (Greensboro, NC; Oct 28, 2013).
- 183) 2013 “*Could autism be related to brain inflammation?*” Fourth Annual Meeting for Health Prevention and Promotion-“Gazing at Children” (Syros, Greece; Nov 1-3, 2013).
- 184) 2013 “*Is autism allergy of the brain?*”, National Autism Association (St. Petersburg, FL; Nov 14-17, 2013).
- 185) 2014 “*Activated mast cells secrete “innate pathogens” causing focal brain inflammation inhibited by luteolin.*” Molecular Basis of Brain Diseases (Miami, FL; Jan 26, 2014).
- 186) 2014 “*New autism treatments target pro-inflammatory innate pathogens.*” SouthWestern “Across the Spectrum” Autism/Asperger Conference (Atlanta, GA; March 13-14, 2014).
- 187) 2014 “*The missing link in autoimmunity and autism*” Ninth International Congress on Autoimmunity (Nice, France; March 26-30, 2014).
- 188) 2014 “*Autism and brain immunity storms.*” Autism One 2014 (Chicago, IL; May 23, 2014).
- 189) 2014 “*Environmental and stress triggers of autism.*” IMMUNOe (Denver, CO; Aug 25, 2014)
- 190) 2014 “*Coronary mast cell activation, myocardial infarction and POTS.*” 20th Annual Meeting of the Mastocytosis Society (Rochester, MN; September 17, 2014).
- 191) 2014 “*Synergistic activation of mast cells by the cytokine IL-33 and neuropeptide substance P.*” 20th Annual Meeting of the Mastocytosis Society (Rochester, MN; September 17, 2014).
- 192) 2014 “*Implications of coronary mast cell activation.*” 20th Annual Meeting of the Mastocytosis Society (Rochester, MN; September 17, 2014).
- 193) 2014 “*Elevated serum stress hormone levels in children with autism predict response to treatment.*” Autism Education Summit (Dallas, TX; October 17, 2014).
- 194) 2014 “*Elevated serum stress hormones in children with autism and in “autistic” dogs.*” National Autism Association (St. Petersburg, FL; November 15, 2014).
- 195) 2015 “*Focal brain inflammation in multiple sclerosis and autism.*” First PanHellenic Interscience Congress on for pediatric Multiple Sclerosis (Athens, Greece; January 16-18, 2015).
- 196) 2015 “*Brain inflammation and autism.*” (Melbourne, Australia, April 27, 2015).
- 197) 2015 “*Brain fog and mastocytosis.*” Australasia Mastocytosis Society (Sydney, Australia; May 4, 2015).
- 198) 2015 “*The musical vs. the behavioral brain in autism.*” The Boston Conservatory of Music (Boston, MA; May 8-9, 2015).
- 199) 2015 “*Methoxyluteolin inhibits human mast cells and reduces skin inflammation.*” Annual Congress of the European Academy of Allergy and Clinical Immunology (Barcelona, Spain; June 6-10, 2015).

- 200) 2015 “An overview of mast cell disorders and inflammation.” TMS San Francisco Bay Area Meeting (San Francisco, CA: July 26, 2015).
- 201) 2015 “*Neurocognitive manifestations in mast cell disorders.*” TMS Annual Meeting (Washington, DC; August 14-15, 2015).
- 202) 2015 “*The cross-talk between the nervous system and the immune system.*” IgNS2015 (Washington, DC; September 18-20, 2015).
- 203) 2015 “*Objective biomarkers identify autism subgroup amenable to treatment.*” Autism Education Summit (Dallas, TX; September 26-28, 2015).
- 204) National Autism Association (October 15, 2015; St. Pete, FL)
- 205) Autism Research Institute (December 5, 2015; Boston, MA, 2015)
- 206) Cyprus Pediatric Association (February 14, 2016; Nicosia, CY)
- 207) TARF Think Tank (February 19, 2016; Boston, MA)
- 208) NCIMS (February 27, 2016; Greenboro, NC)
- 209) TACA Massachusetts (March 12, 2016; Watertown MA)
- 210) 11th PanHellenic Conference on Allergy & Clinical Immunology (April 16, 2016; Athens, Greece)
- 211) TACA Webinar (April 25, 2016; 1 pm)
- 212) All Childrens Hospital (April 1, 2016; St. Pete, FL)
- 213) TACA Philadelphia (May 7, 2016; Philadelphia, PA)
- 214) Autism One (May 27, 2016; Chicago, IL)
- 215) Autism One Think Tank (May 28, 2016; Chicago, IL)
- 216) EAAACI (June 7-11, 2017; Vienna, Austria)
- 217) Old North State Medical Society (June 23-25, 2016; Raleigh, NC)
- 218) FASEB Summer Research Conference in the long-running Neuroimmunology series entitled “***Translational Neuroimmunology: From Mechanisms to Therapeutics***” (July 24-29, 2016; Big Sky, MT)
- 219) 11th Annual USAAA World Autism and Asperger Conference (August 29, 2016; Louisville, KY)
- 220) MAPS Conference (September 9, 2016; Atlanta, GA)
- 221) The Mastocytosis Society (September 15-17, 2016; Orlando, FL)
- 222) Autism Education Summit (October 1, 2016; Dallas, TX]
- 223) International College of Geriatric Psychoneuropharmacology (ICGP) (October 6-8, 2016; Athens, Greece)
- 224) TACA National Conference (October 22, 2016; Costa Mesa, CA)

- 225) ILADS Annual meeting (November 3, 2016; Philadelphia, PA)
- 226) Cyprus Pediatric Association Annual Meeting (November 17, 2016; Nicosia, Cyprus)
- 227) 1st International Conference on Autism (November 22, 2016; Paphos, Cyprus)
- 228) Cyprus Pediatric Association (February 14, 2016; Nicosia, CY)
- 229) TARF Think Tank (February 19, 2016; Boston, MA)
- 230) NCIMS (February 27, 2016; Greenboro, NC)
- 231) TACA Massachusetts (March 12, 2016; Watertown MA)
- 232) 11th PanHellenic Conference on Allergy & Clinical Immunology (April 16, 2016; Athens, Greece)
- 233) TACA Webinar (April 25, 2016; 1 pm)
- 234) Johns Hopkins-All Childrens Hospital Grand Rounds (April 1, 2016; St. Pete, FL)
- 235) TACA Philadelphia (May 7, 2016; Philadelphia, PA)
- 236) Autism One (May 27, 2016; Chicago, IL)
- 237) Autism One Think Tank (May 28, 2016; Chicago, IL)
- 238) EAAACI (June 7, 2017; Vienna, Austria)
- 239) FASEB Summer Research Conference in the long-running Neuroimmunology series entitled “*Translational Neuroimmunology: From Mechanisms to Therapeutics*” (July 24-29, 2016; Big Sky, MT)
- 240) 11th Annual USAAA World Autism and Asperger Conference (August 29, 2016; Louisville, KY)
- 241) National Autism Association (September 10, 2016; New Orleans, LA)
- 242) The Mastocytosis Society (September 15-17, 2016; Orlando, FL)
- 243) Autism Education Summit (October 1, 2016; Dallas, TX)
- 244) International College of Geriatric Psychoneuropharmacology (ICGP) (October 6-8, 2016; Athens, Greece)
- 245) TACA National Conference (October 22, 2016; Costa Mesa, CA)
- 246) ILADS Annual meeting (November 3, 2016; Philadelphia, PA)
- 247) Cyprus Pediatric Association Annual Meeting (November 17, 2016; Nicosia, Cyprus)
- 248) 1st International Conference on Autism (November 22, 2016; Paphos, Cyprus)
- 249) Georgia TACA Association (February 24, 2017; Atlanta, GA)
- 250) Cyprus Autism Association (March 6-11, 2017; Nicosia, Cyprus)
- 251) Kansas Mastocytosis Society (April 30, 2017; Kansas City, KS)

- 252) Peru Autism Association (May 27-30, 2017; Lima, Peru)
- 253) Philadelphia TACA Association (May 12, 2017; State College, Philadelphia, PA)
- 254) AutismOne (May 24-27, 2017; Colorado Springs, CO)
- 255) TACA (Talk About Curing Autism) National Conference (October 19, 2017; Costa Mesa, CA)
- 256) UK Autism Society (November 30, 2017; London, UK)
- 257) UK Mastocytosis Society (December 1, 2017; London, UK)
- 258) TARF Think Tank (February 18, 2017; Boston, MA)
- 259) Medical University of Plovdic (March 7, 2018; Plovdic, Bulgaria)
- 260) TACA Regional Conference (Philadelphia, PA; May 11, 2018)
- 261) Autism One (May 26, 2018; Chicago, IL)
- 262) International Conference on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (June 1, 2018; London, UK)
- 263) European Congress on Lyme disease (July 15, 2018; Warsaw, Poland)
- 264) NIH Mast Cell Activation Syndrome Workshop (September 7, 2018; Rockville, MD)
- 265) Canadian Society of Allergy and Clinical Immunology (September 15-16, 2018; Halifax, Canada)
- 266) NorthEast TMS Support Group Meeting (August 18, 2018; Dover, NH)
- 267) Arizona TMS Support Group Meeting (November 3, 2018; Scottsdale, AZ)
- 268) Maryland TMS Support Group Meeting (December 8; Baltimore, MD)
- 269) Floating Hospital for Children-Ground Rounds (January 17; Boston, MA)
- 270) The Forum for Integrative Medicine (March 7-9, 2019; Seattle, WA)
- 271) Pediatric Neurology Grand Rounds-Tufts Medical Center (January 13, 2019)
- 272) TARF (February 21, 2019; Boston, MA)
- 273) TMS 25th Anniversary Conference (May 3, 2019; Palo Alto, CA)
- 274) American Initiative for Mast Cell Diseases sponsored by NIH (May 5, 2019; Stanford, CA)
- 275) International Conference on Fibromyalgia (May 12, 2019; Pescara, Italy)
- 276) MAPS Conference (September 24, 2019; Costa Mesa, CA)

- 277) ILADS Annual meeting (October 15, 2019; Boston, MA)
- 278) Inflammaging and Autoimmunity-A revolution in assessment and treatment (September 11-13, 2020; virtual)
- 279) TACA Annual Conference (October 1-31, 2020; virtual)
<https://tacanow.org/conferences/virtual/>
- 280) ISEAI Conference (October 2-4, 2020; virtual)
<https://www.google.com/search?q=iseai+conference&oq=&aqs=chrome.69i59l8.23002029j0j15&sourceid=chrome&ie=UTF-8>
- 281) WANP conference (October 8-12, 2020; virtual)
<https://wanp.org/event/wanps-annual-virtual-conference-connect-2020/>
- 282) Medical University-Plovdiv Jubilee Scientific Conference on the occasion of its 75th Anniversary-Medicine of the Future (October 29-31, 2020)
<https://mu-plovdiv.bg/en/>
- 283) International Conference on Medical Aspects of Genetics and Comorbidities in Autism (November 7-8; virtual) <https://fb.me/e/1xhzrnSv3>
- 284) ACAM/AAPMD Conference (November 11-14, 2020; virtual)
<https://www.acam.org/mpage/2020AAPMDHome>
- 285) International Oncology Conference (January 23, 2021; virtual)
- 286) R & D and Innovation in Healthcare (February 2, 2021; virtual)
<https://www.rndinnovationconference.gr/>
- 287) Forum for Integrative Medicine (March 5-7, 2021; virtual)
<https://forumforintegrativemedicine.org/conference-schedule/>
- 288) MAPS (March 19-21, 2021; Orlando, FL)
<https://www.medmaps.org/spring2021/>
- 289) European Congress of Rheumatology (June 5-7, 2021; Paris, France)
<https://congress.eular.org/>

ACAM/AAPMD=American College for Advancement in Medicine/American Academy
of Pathological Medicine & Dentistry

EAAACI=European Academy of Allergy and Clinical Immunology

ILADS=International Lyme and Associated Diseases Society

ISEAI=International Society for Environmentally Acquired Illness

MAPS=Medical Academy of Pediatrics Special Needs

NCIMS=North Carolina Integrative Medical Society

TARF=The Autism Research Foundation

TMS=The Mastocytosis Society

TACA=The Autism Community in Acton (formerly Think About Curing Autism)

WANP=Washington Association of Naturopathic Physicians